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Fig.  Figure 
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I. INTRODUCTION 
1. The ATP-Binding Cassette Transporter Family 
ATP-binding cassette (ABC) transporters are archaic proteins found in the three kingdoms of 
life, namely the prokaryotic archaea and bacteria as well as eukaryotes. Among human 
transporters they are the largest subgroup consisting now of 48 functional diverse members 
[1]. Functional ABC transporters normally contain two transmembrane domains (TMD) and 
two nucleotide binding domains (NBD) or ABCs. The ABC domain is determined by two 
short, conserved peptides, called Walker A and Walker B motifs [2]. These motifs are 
common in ATP-binding proteins. According to a signature motif, located between the two 
Walker motifs, ABC-transporters are divided in seven subfamilies (A-G) [3]. Proteins from the 
ABCE and ABCF family, in contrast to all other ABC-transporters, lack the TMD. The TMD 
and ABC domains can be coded on a single polypeptide, like the full-size transporter ABCA1, 
or two polypeptides that need to form homo- or heterodimers, like half-size proteins from the 
ABCG family (Fig. 1 and Table 1). 
 
Figure 1. Diagram depicting domain arrangements of human ABC transporters. The ABC is 
shown as green circle, and the membrane spanning domains are depicted as barrels. (A) The TMD0-
(TMD-ABC)2 structure. In addition to the regular full-size type, containing the (TMD-ABC)2 domain 
arrangement, this type displays additional five TMDs termed TMD0. (B) Prototype ABC transporter 
with the (TMD-ABC)2 structure. (C) Two alternative types of half size molecules, TMD-ABC and ABC-
TMD. Only corresponding half-molecule organizations are able to form heterodimers. (D) The (ABC)2 
type of molecules lacking TMDs is unlikely to function as transporter [*]. 
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Table 1. Overview of human ABC transporters [*]. 
Gene Alternative 
name 
Location Domain structure Lipid 
regulation Known/putative transported molecule 
ABCA1 ABC1 9q31.1 (TMD-ABC)2 + Choline-phospholipids and cholesterol 
ABCA2 ABC2 9q34 (TMD-ABC)2 + Estramustine, steroids 
ABCA3 ABC3 16p13.3 (TMD-ABC)2 + Surfactant phospholipids 
ABCA4 ABCR 1p22.1-p21 (TMD-ABC)2 - N-retinylidene-PE 
ABCA5  17q24 (TMD-ABC)2 +  
ABCA6  17q24 (TMD-ABC)2 + Phospholipids 
ABCA7  19p13.3 (TMD-ABC)2 + Sphingolipids and serine-phospholipids  
ABCA8  17q24 (TMD-ABC)2 -  
ABCA9  17q24 (TMD-ABC)2 +  
ABCA10  17q24 (TMD-ABC)2 -  
ABCA12  2q34 (TMD-ABC)2 -  
ABCA13  7p11-q11 (TMD-ABC)2 -  
ABCB1 MDR1, PGY1 7p21 (TMD-ABC)2 + 
Phospholipids, PAF, aldosterone, 
cholesterol, amphiphiles, 
β-amyloid peptide 
ABCB2 TAP1 6p21 TMD-ABC - Peptides 
ABCB3 TAP2 6p21 TMD-ABC - Peptides 
ABCB4 MDR3 7q21.1 (TMD-ABC)2 + Phosphatidylcholine 
ABCB5  7p14 (TMD-ABC)2 -  
ABCB6 MTABC3 2q36 TMD-ABC + Fe/S clusters 
ABCB7 ABC7 Xq12-q13 TMD-ABC - Fe/S clusters  
ABCB8 MABC1 7q36 TMD-ABC - Fe/S clusters 
ABCB9  12q24 TMD-ABC +  
ABCB10 MTABC3 1q42 TMD-ABC - Fe/S clusters 
ABCB11 BSEP, SPGP 2q24 (TMD-ABC)2 + Monovalent bile salts 
ABCC1 MRP1 16p13.1 TMD0-(TMD-ABC)2 + 
GSH-, glucuronate-, sulfate-conjugates, 
GSSG, sphingolipids, LTC4, PGA1, PGA2, 
17β-glucuronosyl estradiol 
ABCC2 MRP2 10q24 TMD0-(TMD-ABC)2 + 
GSH-, glucuronate-, sulfate-conjugates, 
bilirubin glucuronide, LTC4, 17β-
glucuronosyl estradiol, taurolithocholate 3-
sulfate, anionic drugs 
ABCC3 MRP3 17q21.3 TMD0-(TMD-ABC)2 - 
glucuronate-, sulfate-conjugates, 17β-
glucuronosyl estradiol, taurolithocholate 3-
sulfate 
ABCC4 MRP4 13q32 (TMD-ABC)2 + Xenobiotics, nucleosides 
ABCC5 MRP5 3q27 (TMD-ABC)2 + Xenobiotics, nucleosides 
ABCC6 MRP6 16p13.1 TMD0-(TMD-ABC)2 - Anionic cyclopentapeptides 
ABCC7 CFTR 7q31.2 (TMD-ABC)2 - Chloride ions, ATP 
ABCC8 SUR1 11p15.1 TMD0-(TMD-ABC)2 - Sulfonylureas 
ABCC9 SUR2 12p12.1 TMD0-(TMD-ABC)2 - Sulfonylureas 
ABCC10 MRP7 6p21 TMD0-(TMD-ABC)2 -  
ABCC11 MRP8 16q11-q12 (TMD-ABC)2 -  
ABCC12 MRP9 16q11-q12 (TMD-ABC)2 -  
ABCD1 ALD Xq28 TMD-ABC + Very-long-chain fatty acids 
ABCD2 ALDR 12q11-q12 TMD-ABC + Very-long-chain fatty acids 
ABCD3 PMP70, PXMP1 1p22-p21 TMD-ABC - Very-long-chain fatty acids 
ABCD4 PMP69 14q24.3 TMD-ABC + Very-long-chain fatty acids 
ABCE1 OABP 4q31 (ABC)2 - Oligoadenylate  
ABCF1  6p21.33 (ABC)2 - translation elongation initiation factor 2 
ABCF2  7q36 (ABC)2 -  
ABCF3  3q25 (ABC)2 -  
ABCG1 White 21q22.3 ABC-TMD + Phospholipids, cholesterol 
ABCG2 MXR, BCRP 4q22 ABC-TMD - Drugs 
ABCG4 White2 11q23 ABC-TMD +  
ABCG5 White3 2p21 ABC-TMD + Plant- and shellfish sterols 
ABCG8 White4 2p21 ABC-TMD + Plant- and shellfish sterols  
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ABC-transporters operate in two ways: as active pumps hydrolyzing ATP, like members of 
the ABCB family (MDR/TAP), or as transport-facilitators, like ABCC7 (CFTR) and ABCA1 
that bind ATP, which induces a conformational change, but with a slowly hydrolysis of the 
ATP (Fig. 2). 
 
Figure 2. Structural interpretation of ATP-dependent gating cycle of CFTR. ATP remains tightly 
bound to NBD1 (green) for minutes, during which time many gating cycles occur. Following ATP 
binding to NBD2 (blue) a slow opening step (C2-to-Open) proceeding through a transition state 
(square brackets) in which the intramolecular NBD1–NBD2 heterodimer is formed but the 
transmembrane pore (grey rectangles) has not yet opened. Hydrolysis of ATP bound at the NBD2 
catalytic site and loss of inorganic phosphate (Pi) leads to channel closure (from [4]). 
 
While the majority of full-size transporters act at the plasma membrane, most half-size 
transporters are found in intracellular membrane systems such as mitochondria, 
peroxisomes, the endoplasmatic reticulum (ER) and the Golgi. On the other hand, full-size 
transporters are also located intracellularly as result of vesicular trafficking events, or 
determined by alternative splicing. 
One of the best-characterized ABC-transporters is the gene responsible for cystic fibrosis, a 
lethal inherited disorder that is caused by mutations in ABCC7 (CFTR) [5]. Nowadays various 
ABC-transporters are described in inherited monogenetic diseases (Table 2). 
 
Table 2. Human ABC transporter genes and associated monogenetic disorders (from [6]). 
Gene Monogenetic disorder OMIM no. 
ABCA1 Tangier disease  
Familial hypoapolipoproteinemia 
205400 
604091 
ABCA3 Respiratory distress syndrome (Neonatal surfactant deficiency) 267450 
ABCA4 Stargardt disease 
Retinitis pigmentosa 19 
Cone rod dystrophy 3 
Age-related macular degeneration 
248200 
601718 
604116 
153800 
ABCA12 Lamellar ichthyosis type 2 (Ichthyosis congenital IIB) 
Harlequin ichthyosis (Ichthyosis congenita, Harlequin fetus type) 
601277 
242500 
ABCB4 Progressive familial intrahepatic cholestasis type 3 602347 
ABCB7 X-linked sideroblastosis and anemia 301310 
ABCB11 Progressive familial intrahepatic cholestasis type 2 601847 
ABCC2 Dubin–Johnson Syndrome 237500 
ABCC6 Pseudoxanthoma elasticum (PXE) 264800 
ABCC7 Cystic fibrosis (Mucoviscidosis) 
Congenital bilateral absence of the vas deferens 
219700 
277180 
ABCC8 Familial persistent hyperinsulinemic hypoglycemia of infancy 601820 
ABCD1 Adrenoleukodystrophy 300100 
ABCG5 β-sitosterolemia 210250 
ABCG8 β-sitosterolemia 210250 
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1.1. The ABCA-Subfamily is Involved in Phospholipid- and Cholesterol-
Trafficking 
All members of the ABCA-subfamily are full-size transporters, most of which show a 
ubiquitous expression. Interestingly the ABCA-subgroup is the only one with no homologues 
in yeast, appearing in Caenorhabditis elegans for the first time [7].  
In humans, the 12 ABCAs can be divided in two groups: five genes (ABCA5, ABCA6, 
ABCA8, ABCA9, and ABCA10) are clustered on chromosome 17q24, the remaining seven 
genes are distributed over six chromosomes (Fig. 3). 
 
Figure 3. Phylogenetic consensus tree and chromosomal dispersion of human ABCA-
subfamily transporter genes. Bootstrap values (%) out of 100 iterations are indicated at each branch 
point. The chromosomal loci are schematically shown for each ABC A-subfamily transporter gene 
(arrowheads). Inset: Schematic representation of the structural organization of ABCA transporters 
(from [6]). 
 
An important role for the ABCA subfamily in lipid metabolism is indicated by the finding that 
the transcription of at least six members is regulated by lipids [8-11] (Table 1). The tissue 
distribution of the ABCA transporters is shown in Table 3. 
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Table 3. mRNA Expression of ABCA-class transporters in different human tissues (from [12]). 
Tissue ABCA1 ABCA2 ABCA3 ABCA4 ABCA5 ABCA6 ABCA7 ABCA8 ABCA9 ABCA10 ABCA12 
Brain, whole ● ●●●●● ● ● ● ● ● ● ● ● ● 
Brain, cerebellum ● ●●● ● ● ● ● ● ● ● ● ● 
Heart ● ● ● ● ● ● ● ● ● ● ● 
Skeletal muscle ● ● ● ● ● ● ● ● ● ● ● 
Trachaea ●●● ●●● ● ●●● ●●●●● ●●●●● ●●●●● ●●●● ●●●●● ●●●●● ●●●● 
Lung ●●● ●● ●●●●● ● ● ●● ● ● ● ● ● 
Kidney  ● ● ● ●●● ● ● ● ● ● ● ● 
Liver ●● ● ● ● ● ● ● ● ● ● ● 
Small intestine  ● ● ● ●●● ● ● ● ● ● ● ● 
Colon ● ● ● ● ● ● ● ● ● ● ● 
Salivary gland ● ● ● ● ● ● ●● ● ● ● ● 
Thyroid ● ●●● ● ● ● ● ●● ● ● ● ● 
Adrenal gland ●●●●● ●● ● ● ● ● ● ● ● ● ● 
Testis ●● ● ● ●●●●● ●●● ●● ● ●●●●● ●●●● ●●●● ●●●●● 
Prostate ●● ●● ● ●● ●●●● ● ●●● ●● ●● ●● ●● 
Uterus ●●●●● ●● ● ● ●● ●● ● ●● ●●●● ●●●● ● 
Placenta ●● ● ● ● ● ● ●● ● ● ● ● 
Thymus ●● ● ● ● ● ● ●●●● ● ● ● ● 
Spleen ●●● ●● ● ● ● ● ●●● ● ● ● ● 
Bone marrow ● ● ● ● ● ● ●● ● ● ● ● 
Expression was measured by TaqMan real-time reverse transcription (RT)-PCR. Results were 
converted to a linear scale. Tissues with the highest expression are highlighted (yellow). 
1.1.1. ABCA1 
The human ABCA1 cDNA codes for a 2261 amino acid protein (220 kDa) [13] and is widely 
expressed in tissues with highest expression levels in placenta, liver, lung, adrenal glands 
and fetal tissues [11]. In macrophages, ABCA1 is upregulated by cholesterol loading and 
downregulated by high-density lipoprotein (HDL)3-mediated cholesterol deloading [11]. The 
finding that mutations in ABCA1 cause familial HDL-deficiency syndromes (Tangier disease, 
TD) highlight ABCA1 as a major regulator of HDL metabolism [14-16]. Upregulation of 
ABCA1 expression is associated with increased cholesterol and phospholipid efflux and 
reduced efflux was found in ABCA1 deficient cells [17]. ABCA1 was expected to translocate 
lipids between the inner and outer plasma membrane [18]. In addition, results from 
overexpression of ABCA1 indicated a role in intracellular cholesterol transport [19]. 
Experiments performed in insect Sf9 cells imply that nucleotide binding leads to 
conformational changes of ABCA1 and ATP hydrolysis only takes place at very low rates 
[20]. ATP hydrolysis was also detected in mammalian HEK293 cells [21]. Due to the low ATP 
turnover, ABCA1 is probably a transport-facilitator, not an active transporter. 
Macrophages have an important role in the development and progression of atherosclerotic 
lesions [22]. Upon continuous loading with cholesterol in lesions, they change into foam cells. 
In this process ABCA1 expression is enhanced [11; 17] and ABCA1 is recruited to the 
plasma membrane [17], where it is found in Lubrol-detergent resistant membrane domains 
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[23]. Besides in the plasma membrane, ABCA1 is also found in the Golgi compartment and 
in lysosomes [21; 24], indicating shuttling of ABCA1 between these sites. These data point to 
a function of ABCA1 in foam cell and atherosclerotic lesion development, which is supported 
by findings from chimeric low-density lipoprotein (LDL) receptor (LDLR)−/− mice and 
apolipoprotein E (apoE) null mutant mice [25; 26]. It is of note that the absence of ABCA1 in 
leukocytes had no influence on plasma HDL levels but alters recruitment of inflammatory 
cells [25]. In line with this, overexpression of human ABCA1 in transgenic apoE null mice 
reduced lesion size [27]. These data from in vitro and in vivo experiments emphasize the 
importance of ABCA1 in macrophage lipid homeostasis and its anti-atherogenic potential. 
These features make ABCA1 an interesting target for therapeutic approaches that modulate 
ABCA1 activity. Transcription of ABCA1 is among other factors regulated by zinc finger 
proteins 202 [28], oncostatin M [29], and geranylgeranyl pyrophosphate, which influences the 
nuclear hormone receptor liver X receptor (LXR) [30] (Fig. 4). 
 
Figure 4. Transcriptional regulatory network controlling ABCA1 expression. (A) Mechanisms 
activating the ABCA1 promoter. (B) Repressing factors at the ABCA1 regulatory region (from [31]). 
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LXRα was already shown to be involved in sterol-dependent transactivation of ABCA1 
transcription [32; 33]. In macrophages, ABCA1 expression is induced by the peroxisome 
proliferator activated receptors PPARα and PPARγ agonists [34; 35], supporting the 
influence of nuclear receptors on ABCA1 activity. Further promotion comes from chimeric 
LDLR−/− mice missing PPARγ in their bone marrow-derived cells. This leads to a higher 
prevalence of atherosclerosis in these animals implying that PPARγ-mediated ABCA1 
upregulation in macrophages is atheroprotective in vivo [35]. Noteworthy, the protective 
effect of PPARγ can as well happen without reference to ABCA1, implying possible 
involvement in other antiatherosclerotic pathways [36]. 
Another interesting finding is that unsaturated fatty acids seem to regulate ABCA1 activity. 
They reduce ABCA1 dependent cholesterol/phospholipid efflux from macrophages [37] 
probably due to enhanced degradation of ABCA1 mediated by a phospholipase D2 signaling 
pathway [38]. In addition, polyunsaturated fatty acids (PUFA) likely inhibit ABCA1 expression 
[39]. Furthermore, stearoyl-CoA desaturases decrease ABCA1-mediated cholesterol efflux 
[40]. As systemic fatty acids are increased in type 2 diabetes mellitus, these results may link 
cholesterol metabolism and diabetes. Furthermore, ABCA1 is involved in phosphoinositide 3-
kinase (PI3K)/Akt signaling. Akt is a kinase downstream from PI3K, and PI3K/Akt pathways 
are involved in insulin signaling [41] and the platelet-derived growth factor (PDGF)-
dependent suppression of ABCA1 expression in vascular smooth muscle cells (VSMC) [42]. 
Akt activity is reduced by ABCA1 [43] and HDL-mediated activation of the PI3K/Akt pathways 
results in endothelial nitric oxide synthase (eNOS)-mediated nitric oxide production [44]. The 
PI3K/Akt signaling pathways are moreover involved in apoptosis [45; 46] and autophagy [47]. 
ABCA1 is also expressed in steroidogenic tissues. In mice, mRNA and protein are highly 
expressed in testis and adrenal gland [48], and ABCA1 mRNA was also found in rat ovarian 
theca-interstitial cells albeit with no effect on HDL-supported androgen production [49]. 
1.1.1.1. HDL Deficiency Syndromes 
Loss of functional ABCA1 results in HDL deficiency syndromes [14]. Patients with genetic 
HDL-deficiency suffer from massive accumulation of cholesteryl esters in many tissues and a 
variety of clinical phenotypes like hepatosplenomegaly, atherosclerosis, and peripheral 
neuropathy [50] that are mainly determined by ABCA1, as data from TD patients and ABCA1 
knockout-mice show. TD is a rare autosomal recessive disorder of lipid metabolism marked 
by almost complete absence of plasma HDL and the accumulation of cholesteryl esters in 
the cells of the reticulo-endothelial system leading to splenomegaly and enlargement of 
tonsils and lymph nodes [51]. Coherent with the finding that mutations in ABCA1 cause a 
HDL deficiency phenotype in humans, data from our laboratory show that mice missing 
functional ABCA1 manifest plasma lipid alterations that are consistent with those observed in 
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TD [17]. Female ABCA1-/- mice also suffer from placenta malformation, leading to embryo 
growth retardation, fetal loss, and neonatal death [52]. In male ABCA1-/- mice lipids 
accumulate in Sertoli cells, and Leydig cells reveal a decrease of lipid droplets. In addition, 
those animals have lower intratesticular testosterone levels and sperm count and are less 
fertile compared to wild type animals [53]. 
Up to now, various single-nucleotide polymorphisms (SNPs) have been identified in the 
human ABCA1 gene. Interestingly they appear in clusters located in the C-terminal half of the 
first extracellular domain, the N-terminal ABC and the C-terminus (Fig. 5). The type of clinical 
presentation seems to associate with the localization of the mutation; mutations in the first 
extracellular domain and the C-terminus are frequently associated with a cardiovascular 
phenotype while exchanges in or in the proximity of the N-terminal ABC appear to coincide 
with splenomegaly [6]. 
 
Figure 5. Overview of the published mutations in ABCA1. 
(from http://www.uni-regensburg.de/Fakultaeten/Medizin/Klinische_Chemie/abca1.htm). 
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1.1.1.2. ABCA1 Interacting Proteins 
Several ABCA1 interactive proteins have been described to modulate ABCA1 dependent 
lipid efflux (Fig. 6). 
 
Figure 6. Overview of ABCA1 interaction sites. Sequences represent sites of interaction [*]. 
 
The PSD-95/Dlg/ZO-1 (PDZ) domain proteins α1-syntrophin (SNTA1) and β1-syntrophin 
(SNTB1) enhance lipid efflux by stabilizing ABCA1 [54; 55] and ABCA1 was also reported to 
interact with a β2-syntrophin(SNTB2)/utrophin complex, putatively linking it to the actin 
cytoskeleton [56]. On the other hand, lipid efflux is decreased by the expression of a 
dominant negative form of Fas-associated via death domain (FADD) which also interacts 
with the ABCA1 C-terminus [57]. This might link ABCA1 to apoptosis and host defense, in 
both of which FADD is implied [58; 59]. The small GTPase cdc42 was also shown to interact 
with ABCA1 [60], and overexpression of cdc42 leads to increased lipid efflux [61] while a 
dominant negative mutant substantially reduced apolipoprotein A-I (apoA-I)-induced 
cholesterol efflux [62]. ADP-ribosylation factor-like protein 7 (ARL7), probably in concert with 
ABCA1, may be involved in vesicular transport between a perinuclear compartment and an 
ABCA1-accessible cholesterol pool at the plasma membrane and has also been 
demonstrated to influence lipid efflux [63]. Recently, syntaxin 13 was identified to bind to 
ABCA1, and knock-down of syntaxin 13 reduced ABCA1 protein abundance and lipid efflux. 
Besides disturbed lipid efflux, ABCA1 deficiency is associated with enhanced phagocytic 
uptake. Transfection of functional ABCA1 in Tangier fibroblasts normalized enhanced uptake 
of lipoproteins and phagobeads. These findings suggest involvement of ABCA1 in the 
modulation of phagocytic uptake in type I- and type II phagocytosis [64]. 
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1.1.2. ABCA7 
ABCA7 is localized on chromosome 19 in close proximity to HA-1 [65] (Fig. 7), and, with its 
high homology to ABCA1 (54%), was initially described as a sterol-regulated gene similar to 
ABCA1 [8]. Therefore, it was assumed that ABCA7 might also be involved in lipid 
metabolism. 
 
Figure 7. Structural organization of the ABCA7/HA-1 gene locus. Exons are numbered in 5´ to 3´ 
order and shown as black (ABCA7) or gray boxes (HA-1), respectively. Domains found in HA-1 are 
highlighted (adapted from [65]). 
 
In transfection experiments it was shown that ABCA7 releases phospholipids via an 
apolipoprotein-mediated mechanism [66-71] and that ABCA7 may be a regulator of serine 
phospholipid species transport, including phosphatidylserine and ceramide [72]. Whether 
ABCA7 is involved in the release of cholesterol is unclear [66-68; 70; 71]. Recently two 
isoforms of ABCA7 have been identified, a full-length cDNA named type I and a shorter 
splice variant named type II [68]. Overexpression of ABCA7 type I in HEK293 cells localizes 
ABCA7 to the plasma membrane and mediates apoA-I-dependent release of cholesterol and 
phospholipids. In contrast ABCA7 type II was mainly found in the ER and did not influence 
apoA-I-mediated lipid efflux [68]. In spite these in vitro findings, ABCA7-mediated lipid efflux 
may not significantly influence plasma HDL-levels as data from macrophages and fibroblasts 
treated with ABCA7 small interfering (si)RNA [70; 73], from ABCA7 knockout mice [69], and 
ABCA7 heterozygous mice [70] indicate. More recent data show that ABCA7 is regulated 
inversely to ABCA1 by cholesterol loading through a sterol regulatory element/sterol 
regulatory element-binding protein 2 (SREBP2) dependent mechanism and suggests that 
this regulation of ABCA7 is involved in phagocytosis [73]. The involvement of ABCA7 in 
phagocytosis is supported by the finding that it  has an important role in the removal of 
apoptotic cells and therefore ABCA7, not ABCA1 [74], might be the ortholog of 
Caenorhabditis elegans CED-7 [75]. 
The mRNA tissue distribution of ABCA7 differs from ABCA1, while ABCA1 is ubiquitously 
expressed with a high expression in placenta, liver, lung, adrenal glands and fetal tissues 
[11], ABCA7 is predominantly expressed in lymphohematopoetic tissues [8]. 
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1.2. ABCG1 
ABCG1 is a homodimer forming half-size transporter highly expressed in macrophages. 
Silencing of ABCG1 by siRNA reduced cholesterol and phospholipid efflux to HDL while its 
overexpression enhanced HDL-mediated cholesterol efflux, thereby lowering cellular 
cholesterol mass [76-78]. In contrast to ABCA1, that only poorly interacts with the major HDL 
fractions HDL2 and HDL3 [79; 80] and mediates efflux to lipid-poor apolipoproteins (e.g. 
apoA-I, apoE) [79; 81], ABCG1 uses HDL2 and HDL3 but not lipid-free apoA-I as acceptor 
[77; 78]. It was also reported that ABCG1 transfers cholesterol to LDL particles [78]. ABCG1 
mRNA, similar to ABCA1, is upregulated by LXR agonists and cholesterol loading [77]. 
Interestingly different transcripts of ABCG1 are produced because of alternative promoters 
and alternative splicing [82; 83] (Fig. 8). 
 
 
Figure 8. Genomic organization of the human ABCG1 together with the three putative 
promoters and resulting isoforms. Upper part: Alternative promoters and alternative splicing lead to 
multiple mRNA transcripts. The predicted proteins have the ABC and TM domains in common, but 
differ at the N-terminus. Due to alternative splicing of the exons 1-4 and 6 the N-terminus of hABCG1-
c is even more variable [82]. Arrows indicate translation start (from [84]). Lower part: Putative 
promoters of ABCG1 with transcription factor binding sites [*]. 
 
While ABCA1 is well known to transport phospholipids (reviewed in [85]) ABCG1 appears to 
be less efficient [78]. On the other hand, controversial data on the ability of ABCA1 to 
transport cholesterol directly exist (reviewed in [85]). Recent findings suggest a two-step 
model, in which ABCA1 transfers phospholipids to lipid-poor apoA-I, thereby generating 
acceptor particles for ABCG1-mediated cholesterol efflux [86]. 
hABCG1-c hABCG1-a hABCG1-b 
I. Introduction 
12 
ABCG1-/- mice have defects previously linked to respiratory syndromes [87] (Fig. 9). Under 
normal conditions, phospholipid and cholesterol rich surfactant from the alveolar hypophase 
is cleared by type 2 cells (recycling and degradation) and by macrophages (degradation). In 
ABCG1-/- mice type 2 cells are transformed to hypertrophied pneumocytes, accumulating 
cholesterol crystals (CC) and excess lamellar bodies. In macrophages, a constant supply of 
cholesterol and fatty acids is generated by degrading surfactant. In ABCG1-/- compared to 
wild type macrophages lipid homeostasis is disturbed as upregulation of ABCA1 and 
downregulation of lipid/sterol biosynthesis are not sufficient to balance loss of ABCG1. 
Therefore, enhanced intracellular unesterified cholesterol content is detectable in these cells, 
leading to CC formation or esterification and formation or cholesterol ester (CE)-rich lipid 
droplets. The increased recovery of lipids in bronchioalveolar lavages from ABCG1-/- mice 
might be due to the combined hypertrophy of type 2 cells and a partial defect of both 
pneumocytes and macrophages in surfactant clearance [87]. 
 
Figure 9. ABCG1 controls sterol/lipid homeostasis in type 2 cells and alveolar macrophages. 
For details see text. (from [87]). 
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2. Genes Involved in Lysosome-Related Organelle Synthesis and/or 
Trafficking 
Trafficking of lysosome-related organelles (LROs), like melanosomes, platelet dense 
granules, and lamellar bodies, is accomplished through the endocytic pathway and they are 
characterized by subsets of shared membrane proteins, acidic pH and relatively high calcium 
content [88-90]. Mutations leading to Hermansky-Pudlak Syndrome (HPS) [91-93], Chediak-
Higashi Syndrome [94; 95], and Griscelli Syndrome [96] exposed genes with important 
functions in LRO synthesis and/or trafficking (Table 4). 
 
Table 4. Genes involved in LRO synthesis and/or trafficking. 
Defective gene Defective cells Affected complex Mouse mutant 
Hermansky-Pudlak-Syndromes 
HPS1 Melanocytes and platelets BLOC-4 "Pale ear" 
AP3B1 (HPS2) Immunocytes, melanocytes & platelets AP-3 "Pearl" 
HPS3 Melanocytes and platelets BLOC-2 "Cocoa" 
HPS4 Melanocytes and platelets BLOC-3 "Light ear" 
HPS5 Melanocytes and platelets BLOC-2 "Ruby-Eye2" 
HPS6 Melanocytes and platelets BLOC-2 "Ruby-Eye" 
DTNBP1 (HPS7) Melanocytes and platelets BLOC-1 "Sandy" 
AP3D1 Melanocytes and platelets AP-3 "Mocha" 
RABGGTA Immunocytes, melanocytes & platelets Transient with Rabs "Gunmetal" 
PLDN Melanocytes and platelets BLOC-1 "Pallid" 
MU Melanocytes and platelets BLOC-1 "Muted" 
CNO Melanocytes and platelets BLOC-1 "Cappuccino" 
VPS33A Melanocytes and platelets Unknown "Buff" 
Chediak-Higashi-Syndrome 
LYST Immunocytes and melanocytes Unknown "Beige" 
Griscelli-Syndromes 
MYO V Melanocytes and neurons Rab27a/MyoV/Melanophilin "Dilute" 
RAB27A Immunocytes and melanocytes Rab27a/MyoV/Melanophilin "Ashen" 
MLPH Melanocytes Rab27a/MyoV/Melanophilin "Leaden" 
The defective genes in human diseases impairing secretory lysosomes are shown together with the 
affected cell types, involved complex and their mouse models (from [97]). 
 
For the genetically heterogeneous HPS, 8 and at least 15 responsible genes were identified 
in humans [92; 98] and mice [90], respectively, causing among others hypopigmentation, 
prolonged bleeding, and lung disease. Most murine HPS proteins belong to the three 
Biogenesis of Lysosome- related Organelles Complexes (BLOCs) [90; 99]. Mutations in 
HPS2 (AP3B1, pearl) and AP3D1 (mocha) affect subunits of the Adapter Protein-3 (AP-3) 
complex [100]. A recent study using mutant mice doubly or triply deficient in protein subunits 
of various BLOC complexes and/or AP-3 complex demonstrated extensive, tissue and cell 
type specific interactions among BLOC and AP-3 complexes in LRO synthesis [101]. 
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At least part of cholesterol transport is mediated by vesicular transport, which requires fusion 
of membranes mediated by soluble N-ethylmaleimide-sensitive factor attachment protein 
receptors (SNAREs) [102]. The SNARE protein Syntaxin 13, besides ABCA1 [64], also binds 
to syntaxin 13 binding protein (pallidin) [103], which is a component of BLOC-1 [101], thereby 
linking ABCA1 to LRO and the AP-3 pathway. Furthermore, the Ras-related small regulatory 
GTPases ADP-ribosylation factors control vesicle budding in vesicular transport processes in 
the secretory and endosomal pathway [104] and it is assumed that ADP-ribosylation factor-
like proteins undertake similar functions [105]. Together with the finding that ARL7 influences 
lipid efflux, this suggests ARL7 as part of the AP-3 pathway [63]. Figure 10 presents an 
overview of ABCA1-related AP-3 constituents. 
 
Figure 10. Overview of ABCA1-related AP-3 constituents. For details see text [*]. 
 
Interestingly, data from drosophila also link ABCG1, the human homolog of the drosophila 
white gene product, to the AP-3 pathway, as the garnet (homolog of AP3D1/mocha)/AP-3 
transport system seems to be necessary for correct intracellular localization of the white 
gene product [106]. 
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3. Cholesterol Uptake, Biosynthesis and Transport to Cellular Sites 
of Steroidogenesis 
Cholesterol is vital as it serves as essential component of cell membranes and as precursor 
of steroid hormones and vitamin D that is either derived from nutrition or synthesized in the 
body. The liver removes excess cholesterol, either by conversion to bile acids, or secretion 
together with bile acids into the small intestine. Essential quantities of cholesterol are 
reabsorbed in the small intestine, leading to enterohepatic cholesterol cycling. 
3.1. Uptake and Cellular Processing of Cholesterol 
Cholesterol is found in the intestinal lumen in its free, unesterified form. After absorption, it is 
incorporated together with triglycerides (TG), phospholipids, and apolipoproteins into large 
TG-rich lipoprotein particles called chylomicrons, which are transported from the intestine to 
the liver. There, cholesterol is esterified with CoA-activated fatty acids (mainly oleoyl-CoA) by 
the enzyme Acyl coenzymeA:cholesterol acyltransferase; the same reaction is catalyzed by 
lecithin-cholesterol acyltransferase in the plasma with phosphatidylcholine as fatty acid 
donor. Accordingly, cholesterol is either transported for storage to peripheral tissues or 
transferred via reverse cholesterol transport to the liver for biliary excretion. Albeit most 
tissues are able to synthesize cholesterol the main sites of synthesis include the liver, the 
gut, steroidogenic tissues and the central nervous system. 
 
Figure 11. ABC transporters and dietary cholesterol metabolism. For details see text [*]. 
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A key step in this process is catalyzed by 3-hydroxy-3-methylglutaryl coenzyme A-reductase 
(HMGCR), which can be inhibited by various substances, e.g. statins, which are of 
pharmacological interest in lowering cholesterol levels in the blood. ABC transporters are key 
molecules in these processes. ABCG5/ABCG8 are crucial for hepatobiliary and intestinal 
cholesterol excretion, while ABCA1 is essential for HDL formation and, hence, for inter-organ 
trafficking of the highly water-insoluble cholesterol molecules [107] (Fig. 11). 
3.2. The NPC/Late Endosome Pathway 
After delivery to its destination, cholesterol is taken up by different receptor-mediated 
pathways and processed along the phagosomal/endosomal route (Fig. 12). 
 
Figure 12. Rheostat model for lipid influx, synthesis, storage and efflux. Cholesterol derived from 
phagosomal/endosomal uptake can traffic and regulate several mechanisms in the cell: (a) 
mitochondrial conversion to 27-hydroxycholesterol (27-OH-chol) via CYP27 and direct secretion, (b) 
action as nuclear receptor ligand, (c) storage as CE in lipid droplets, and (d) export via apoA-I 
dependent and independent routes, involving ABC transporters (from [31]). 
 
NPC1 and NPC2 are critically involved in post-endosomal cholesterol traffic. Mutations in 
these genes result in Niemann-Pick type C disease (NPC), an autosomal recessive 
neurovascular lipid storage disorder [108; 109]. On the cellular level this leads to 
accumulation of LDL-derived free cholesterol in late endosomes, lysosomes and the Golgi 
[110; 111]. The intact feedback regulation of cholesterol homeostasis observed by oxysterols 
and de novo synthesized cholesterol in NPC-deficient cells indicates that the transport of 
LDL-cholesterol to regulatory sites is impaired [112]. 
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3.3. SREBP and Sterol Sensing at the ER Level 
Cholesterol also modulates cell-signaling protein complexes and influences development. 
Seven subgroups of proteins, namely HMGCR, SREBP-cleavage-activating protein (SCAP), 
7-dehydrocholesterol reductase, Dispatched/CHE-14, Patched (Ptc), NPC1 and Ptc-related, 
exert important functions in cholesterol homeostasis or cholesterol-mediated signaling and 
are evolutionary conserved (Fig. 13 A). All of them have the phylogenetically conserved 
sterol-sensing domain consisting of approximately 180 amino acids that are organized into 
five consecutive membrane-spanning domains (Fig. 13 B) in common [113]. Originally, this 
domain was identified in HMGCR and SCAP. Both play key roles in cholesterol homeostasis 
[114; 115], measuring cellular cholesterol content. Under low sterol conditions, SCAP 
translocates SREBP from the ER to the Golgi, where it is processed by Site-1 protease 
(S1P) and Site-2 protease (S2P) (Fig. 13 C). This releases the N-terminal basic helix-loop-
helix leucine zipper (bHLH-Zip) domain, which enters the nucleus and activates transcription 
of target genes regulating lipid synthesis and uptake. Under higher sterol conditions, the 
SCAP/SREBP complex is retained in the ER and Golgi-mediated liberation of the bHLH-Zip 
domain is prevented [116]. 
 
Figure 13. Sterol-sensing domain (SSD)-containing proteins and model for the sterol-mediated 
cleavage of membrane-bound SREBP. (A) Evolutional conservation of SSD. (B) Predicted topology 
of all known protein classes carrying SSDs. (C) Model of the sterol-mediated cleavage of membrane-
bound SREBP. Details are found in the text. PTD, Ptc-related Disp-like; Ce, Caenorhabditis elegans; 
Hs, Homo sapiens; Dm, Drosophila melanogaster; Mm, Mus musculus; 7DHCR, 7-dehydrocholesterol 
reductase; Disp, Dispatched; PTR, Ptc-related (from [113] and [116]). 
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3.4. Cholesterol Biosynthesis and Relation to Uptake and ER Cholesterol 
Content 
As mentioned above, under conditions of low cellular cholesterol levels the N-terminal bHLH-
Zip domain of SREBP is released and, after entering the nucleus, activates transcription of 
various target genes. Figure 14 presents a schematic overview of SREBP target genes and 
the main metabolic intermediates in the pathways for synthesis of cholesterol, fatty acids, 
and TG. SREBP-2 mainly enhances transcription of genes influencing cholesterol 
metabolism, among others the LDLR, while SREBP-1c predominantly upregulates genes for 
fatty acid and TG metabolism [117]. 
 
Figure 14. Overview of SREBP target genes and their metabolic function. DHCR, 7-
dehydrocholesterol reductase; FPP, farnesyl diphosphate; GPP, geranylgeranyl pyrophosphate 
synthase; CYP51, lanosterol 14α-demethylase; G6PD, glucose-6-phosphate dehydrogenase; PGDH, 
6-phosphogluconate dehydrogenase; GPAT, glycerol-3-phosphate acyltransferase (from [117]). 
 
Interestingly SREBP-2 is reported to regulate transcription of ABCA1 and ABCA7 in opposite 
directions. While ABCA1 is downregulated, expression of ABCA7 in enhanced [73]. In 
conclusion, SREBP increases cholesterol-uptake and -synthesis, while reducing efflux under 
conditions when cellular cholesterol levels are low. 
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3.5. StAR Function and the START Family 
The steroidogenic acute regulatory protein (StAR)-related lipid transfer (START) domain is 
evolutionary conserved in plants and animals. Fifteen human proteins comprise the START 
domain alone or together with other protein domains (Fig. 15) [118]. Proteins containing this 
domain are involved in lipid trafficking, lipid metabolism and cell signaling. By multiple 
sequence alignment, the 15 human members were divided in 6 subgroups (Fig. 15) [119]. 
StAR, playing a key role in steroidogenesis by transferring cholesterol into mitochondria, and 
metastatic lymph node (MLN)64, related to the NPC-proteins, belong to the STARD1/StAR 
group and their START domains were shown to bind cholesterol (Fig. 15) [120]. 
 
 
Figure 15. Human START-domain proteins. Upper part: Phylogenetic tree and domain 
organizations of the 15 START-domain proteins. Lower part: Characteristics of the START-domain 
proteins. BFIT, brown fat-inducible thioesterase; CAB1, coamplified with erbB2 1; CACH, cytoplasmic 
acetyl-CoA hydrolase; COL4A3BP, collagen  type IV alpha 3 binding protein; DLC-1, deleted in liver 
cancer 1; FFAT, two phenylalanines in an acidic tract motif responsible for ER targeting; GPBP, 
Goodpasture-antigen-binding protein; GTT1, gestational trophoblastic tumor 1; MENTAL, MLN64 N-
terminal domain; MLN64, metastatic lymph node 64; Mt, mitochondrial targeting motif; PCTP, 
phosphatidylcholine transfer protein; PH, pleckstrin homology domain; RHOGAP, Rho-GTPase-
activating-protein domain; SAM, sterile alpha motif; SDCCAG, serologically defined colon cancer 
antigen; StAR, steroidogenic acute  regulatory protein; THEA, thioesterase-adipose-associated 
protein; THIO, acyl-CoA thioesterase domain (adapted from [119]). 
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While the START domain in some proteins eventually just works as a lipid sensor, a common 
function seems to be the transfer of lipids between membranes. Although the mechanism of 
lipid transport is not completely clear, data indicate that StAR acts at the surface of the outer 
mitochondrial membrane [119]. The proposed model for START-mediated translocation of 
lipids is shown in Figure 16. When interacting with the membrane the α4 helix makes the 
lipid-binding pocket accessible. After loading, the pocket closes and the lipid can be 
transferred to its destination membrane. The mechanism underlying targeting to membranes 
are not clear, but in case of StAR and MLN64, both containing membrane-targeting motifs, it 
is speculated that they are directed to specific contact sites by other motifs and/or binding to 
membrane-resident proteins [119]. 
 
Figure 16. Model of the START-mechanism for lipid promotion. In its free form, the START 
domain binds to the membrane by its C-terminal α4 helix, leading to a conformational change making 
the lipid-binding pocket accessible. Loading with the lipid (yellow) closes the lid. Targeting of the 
loaded START protein to an acceptor membrane is necessary for delivery of bound lipids (from [119]). 
3.6. The Adrenal Gland as Steroid Hormone Producing Organ 
The adrenal gland plays a major role in the regulation of stress response by the synthesis of 
corticosteroids and catecholamines, including cortisol and adrenaline. 
An adrenogonadal precursor lineage in the intermediate mesoderm is the common origin of 
the adrenal cortex and steroid-secreting cells of the gonads [121]. The adrenal gland is 
divided into two functional regions, the outer cortex, derived from mesoderm, and the inner 
medulla, derived from the neural crest. While synthesis of steroid hormones occurs in the 
cortex, the catecholamine hormones norepinephrine and epinephrine are produced in the 
medulla. 
The adrenal cortex consists of three zones, namely zona glomerulosa, zona fasciculata, and 
zona reticularis, all of which are involved in steroidogenesis (Fig. 17). 
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Figure 17. Steroid hormone synthesis in the cortex of the adrenal gland. Mitochondria include the 
enzymatic activities of CYP11A1, CYP11B1, and CYP11B2. The ER includes the rest of the enzymatic 
activities. The major inducers of mineralcorticoid secretion are angiotensin II and the serum 
concentration of potassium. Adrenocorticotropic hormone (ACTH) mainly increases the production of 
cortisol and corticosterone; transiently it also increases aldosterone secretion. For details see text. 
DOC = deoxycorticosterone; DHEA = dehydroepiandrosterone. 
 
The synthesis of all steroid hormones starts with the conversion of cholesterol to 
pregnenolone, the rate-limiting and hormonally regulated step in this process carried out by 
the StAR/CYP11A1 system. 
In the conversion process of cholesterol to pregnenolone the cholesterol side chain is 
cleaved by mitochondrial CYP11A1, encoded by a single gene [122; 123] on chromosome 
15q23-q24 [124], mediating three distinct sequential reactions: cholesterol sequentially 
undergoes 20-hydroxylation, 22-hydroxylation, and scission of the 20,22 C-C bond to yield 
prenenolone and isocaproaldehyde (for review see [125]). As CYP11A1 only works in 
mitochondria [126] the transport of cholesterol to the inner mitochondrial membrane by StAR 
is a crucial and quantity regulating step in steroidogenesis. 
Different groups demonstrated that ACTH rapidly enhances adrenal steroidogenesis and that 
this process is hampered by inhibitors of protein synthesis [127-130], suggesting involvement 
of a short-lived protein. Further experiments led to the identification of StAR. Overexpression 
in MA-10 and in COS-1 cotransfected with CYP11A1 increased steroidogenesis [131-133] 
and mutations in StAR were found in congenital lipoid adrenal hyperplasia [132]. 
The pathways in the adrenal cortex have many components in common, like the StAR, 
cholesterol side-chain cleavage enzyme CYP11A1, the type 2 isozyme of 3β-hydroxysteroid 
dehydrogenase (HSD3B2), and CYP21A2, but differ in certain key enzymes catalyzing 
terminal reactions in the steroid biosynthesis (Fig. 17). 
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CYP11B2 is restricted to outer zona glomerulosa, converting corticosterone to aldosterone. 
In the inner zones, CYP17 and the closely related isozyme CYP11B1 are expressed. Both 
participate in the production of cortisol, the predominant glucocorticoid in humans. When 
besides the 17α-hydroxylase activity of CYP17, necessary for the production of C-21 17-
hydroxysteroids such as cortisol, also the 17,20 lyase activities is present, C-19 precursors of 
sex steroids are produced. Therefore, the activities of CYP17 direct pregnenolone towards its 
final metabolic pathway. 
3.6.1. Adrenal Development 
Two discrete proliferative/migratory events are necessary to give rise to the adrenocortical 
cells in human embryos (Fig. 18; reviewed in [134]). 
 
Figure 18. Time line of adrenal development in humans. The major events in adrenal development 
in humans are shown. w, week; p, postnatal; FZ, fetal zone; DZ, definitive zone (from [135]). 
 
Because of the low HSD3B2 activity, the fetal adrenal produces large amounts of 
pregnenolone-, 17-hydroxy-pregnenolone-, and DHEA-sulfates, which cross into the 
placenta. The placenta is rich in sulfatases and HSD3B2 and converts the products to 
progesterone and 17α-hydroxyprogesterone, which are returned to the fetus, enabling the 
formation of aldosterone and cortisol. DHEA is metabolized to 16α-hydroxy-DHEA, the 
substrate for biosynthesis of estriol [136] (Fig. 19). 
 
Figure 19. Steroid biosynthesis in the placental-fetal unit (from [136]). For details see text. 
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Postnatal notable transformation of the adrenal gland takes place: a rudimentary medulla is 
formed, the fetal zone forms back by the third month and the definitive zone of the human 
adrenal cortex forms discrete functional compartments (zona glomerulosa, zona fasciculata, 
zona reticularis) [134]. In the third trimester the zona glomerulosa gains steroidogenic 
capacity and synthesizes aldosterone under control of the renin- angiotensin system. Under 
the regulation of ACTH by 15 weeks of gestation, the zona fasciculata secretes 
glucocorticoids, whereas the zona reticularis in humans secretes dehydroepiandrosterone 
and its sulfates [135]. Along with regression of the fetal zone, levels of these adrenal 
androgens decrease, and increase again during childhood, along with adrenarche. 
Several findings indicate interactions between different transcription factors in adrenal 
development, namely the nuclear receptors steroidogenic factor 1 (Sf1) and DSS-AHC-
critical region on the X chromosome gene 1 (Dax1), and wingless-type MMTV integration site 
family, member 4 (Wnt4) and Dax1. Sf1 was shown to activate the expression of Dax1 [137-
139], in contrast Dax1 inhibits Sf1 [140-142], suggesting a feedback loop maintaining 
expression level of target genes in the adrenal cortex. Impaired Dax1 expression in the 
absence of Wnt4 may contribute to the abnormal sexual differentiation observed [143; 144]. 
Wilms tumor 1 gene (Wt1) is only present in earliest adrenogonadal precursors [145]. Data 
from cell culture models imply that Sf1 and Wt1 directly interact to activate the expression of 
anti-Müllerian hormone [146]. It was suggested that Wt1, like Sf1, activates Dax1 expression 
[147]. Taken together these findings suggest that Sf1 and Wt1 interact at earliest stages of 
adrenogonadal development to permit the survival of cells that ultimately form the adrenal 
cortex. 
3.7. The Gonads as Steroid Hormone Producing Organs 
Besides the adrenal gland, the gonads play an important role in steroid hormone synthesis. 
The adrenal cortex and steroid-secreting cells of the gonads arise from a common 
adrenogonadal precursor lineage in the intermediate mesoderm [121]. 
3.7.1. Gonadal Development 
Testis and ovary arise from the undifferentiated embryonic gonad. Both testis and ovary 
comprise three main cell types, Sertoli cells, Leydig cells, and germ cells in testis, and 
granulosa cells, theca cells, and oocytes in ovary. An overview of genetic pathways implied 
in gonadal development is shown in Figure 20. 
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Figure 20. Genetic pathways involved in gonadal development. The bipotential gonad expresses 
genes such as Wt1, Sf1, Emx2, M33, Lhx9, Pod1, and Dmrt1. Subsequently, expression of the insulin 
receptor family Ir, Irr, and Igf1r; GATA4/Fog2; Wt1; and Sf1 are thought to promote the expression of 
Sry in the male. Sox9 and Sox8 are downstream of Sry. Sf1 regulates AMH activation in Sertoli cells 
and steroidogenesis in Leydig cells. In the male, Dax1 may repress Sf1 in a dose-dependent manner, 
modulating the transactivation of AMH and genes necessary for steroid hormone biosynthesis. Dax1 
also supports the normal formation of testis cords. Additional factors such as Arx, Dhh, Pdgfr, Fgf9, 
and FgfR2 are involved in Leydig and Sertoli cell differentiation. A description of the cellular events 
downstream of Sry and thus specific to male development is outlined in the center box. PGC, 
Primordial germ cell; PTM, peritubular myoid cell. Female differentiation requires the activity of Wnt4a 
and repression of Sox9. Other key factors include Fst, Bmp2, and Dax1 (from [148]). 
 
In males and females, the adrenal gland and kidney ascend toward the abdominal region. 
The final position of the gonad depends on its differentiation into either an ovary or testis, 
and on the gestation of the sex-specific Müllerian or Wolffian ducts. Due to testosterone in 
males, the proximal Wolffian duct is virilized to form the epididymis, vas deferens, and 
seminal vesicle. Anti-Müllerian hormone (AMH) imparts back formation of the distal Müllerian 
duct [149]. Insulin-like 3 (Insl-3) finally is responsible for testicular descent [149; 150]. In the 
absence of testosterone and AMH in females the Wolffian duct regresses and the Müllerian 
duct develops into oviduct, uterus, and upper vagina. After sex determination, steroid 
hormones are crucial for the succeeding phenotypic differentiation. 
Little is known about the function and target genes of the testis-determining gene Sry. On the 
other hand, various cellular and morphological events downstream of Sry are well-
characterized (Fig. 20 and Fig. 21). Following Sry expression proliferation of coelomic 
epithelial cells in XY gonads is notably elevated [151]. Between 11.2 and 12.5 days post 
coitum (dpc) the testis cord is formed by differentiating Sertoli cells that surround germ cells. 
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In parallel, vascular endothelial cells migrate from the mesonephros into the XY gonad giving 
rise to a testis-specific vasculature [152]. The steroidogenic Leydig cells differentiate 
between 12.5 and 13.5 dpc in the interstitial space between cords. 
 
Figure 21. Early murine gonad differentiation. A thickening of the coelomic epithelium of the 
mesonephros (gray) gives raise to the bipotential gonad (yellow). Between 9.5 and 11.5 dpc, 
primordial germ cells (green) migrating from the hindgut into the urogenital ridges populate the 
gonads. Between 10.5 and 12.0 dpc, testis differentiation is triggered by specific expression of the Y-
linked gene Sry in the XY gonads. Development starts with the differentiation of Sertoli cells (purple) 
and the formation of a male-specific vasculature (red). At about 12.5 dpc the differentiation of 
steroidogenic Leydig cells (blue) in the testis interstitium starts. In the XX gonads no marked 
morphological changes are observed until 13.5 to 14.5 dpc, when germ cells enter the prophase of 
meiosis (from [153]). 
 
In contrast, less visible morphological changes take place in XX gonads in this time (Fig. 21). 
Evident aspects of ovarian development start with the entry of the germ cells into the 
prophase of meiosis happening in anterior-to posterior wave between 13.5 and 14.5 dpc 
[154]. The differentiation of granulosa cells and the formation of primordial follicles take place 
close to birth. 
By 13.5 dpc, germ cells in male and female gonads have taken different developmental 
paths. In males, germ cells halt in mitosis as prospermatogonia, in contrast to females where 
they enter prophase of the first meiotic division (Fig. 21). The somatic environment is vital for 
germ cell fate, not their chromosomal sex [155]. Therefore, until now unidentified signals of 
somatic cells seem crucial for differentiation of embryonic germ cells. 
On the other hand, signals from germ cells influence somatic cells in their environment. 
Germ cells in XY but not XX gonads express Prostaglandin D synthase between 11.5 and 
12.5 dpc and prostaglandin D2 leads to partial masculinization of XX gonads. This indicates 
that signals from germ cells might be involved in testis differentiation [155]. Recent data 
demonstrate that meiotic germ cells can block testis cord formation when aggregated with 
XY somatic cells, indicating that XX germ cells determinate to the ovarian pathway 
countering male development [156]. 
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3.7.2. The Role of Leydig Cells in Steroidogenesis 
Sertoli cells and germ cells are found in the seminiferous tubules where spermatogenesis 
occurs. The interstitial compartment is populated by Leydig cells producing testosterone. 
Migration of mesonephric cells into the XY gonad is an early and well-characterized step in 
testis differentiation [157-159]. This step is induced by XY but not XX gonads, and necessary 
for normal testis development as prevention of migration inhibits testis cord formation [157; 
160]. The majority of migrating mesonephric cells are vascular endothelial cells decisive for 
building testis-specific vasculature (Fig. 21) [152; 159]. 
In testicular development, Sf1 is restricted to Leydig cells after 13.5 dpc. Sf1 target genes 
include enzymes necessary for testosterone biosynthesis including StAR, Cyp11A1, Cyp17, 
and HSD3B2. Factor implied in Leydig cell determination and lineage development are not 
well-characterized. In addition, their origin remains ambiguous. Paracrine signal seem to be 
essential for Leydig cell fate. The Sertoli-secreted factor Desert hedgehog (Dhh), which is 
supposed to have an important role in Leydig cell differentiation, binds to the receptor Ptc1 
expressed on Leydig cells and induces CYP11A1 expression [161]. Other factors influencing 
Leydig cell development are PDGF receptor α (PDGFRA) and Aristaless-related homeobox 
(Arx). Genetic analysis placed PDGFRA, inducing mesonephric migration and required for 
full CYP11A1 expression in gonads, upstream of Dhh [162]. Arx on the other hand is 
predominantly expressed in peritubular myoid cells, endothelial cells, and in the epithelium of 
the tunica albuginea [163]. 
In embryonic and adult testis, Leydig cells localize to the interstitial compartment and are 
responsible for the production of androgen (testosterone), which is crucial for the 
development of the male phenotype and spermatogenesis. Anyway, embryonic and adult 
Leydig cells are separate populations. Embryonic Leydig cells appear between 12.5 and 13.5 
dpc and produce testosterone needed to masculinize the internal and external genitalia. After 
birth, they are lost step-by-step. Adult Leydig cells develop during puberty and are held 
through adult life [164; 165]. 
Some data are available on molecular signals that regulate the proliferation, differentiation 
and function of adult Leydig cells [166], but data on origin and differentiation of embryonic 
Leydig population are scarce besides their vital role in male reproductive development. Dhh 
has been shown to be necessary for the differentiation and expansion of fetal Leydig cells. 
Depending on the genetically background different defects in mice deficient for Dhh are 
visible: on a 129/Sv background they have disturbed spermatogenesis [161], on a mixed 
genetic background (129/Sv, C57BL/6 and Swiss Webster) they have defects in 
development of peritubular myoid cells and Leydig cells in the adult testis [167; 168]. 
Analysis of Dhh mutants on mixed background reveal involvement of Dhh in development of 
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fetal Leydig cells. Sertoli cells start secreting Dhh at 11.5 dpc and its receptor Ptc1 follows at 
12 dpc in the interstitial space between testis cords [161]. Gonads mutated in Dhh contain no 
Leydig cells at 13.5 dpc. Later some Leydig cells appear, but their number is eminently 
decreased compared to controls [161]. This finding explains why mutants on this background 
have feminized external genitalia. Data from humans with mutations in Dhh in 46,XY 
individuals leading to partial or complete pure gonadal dysgenesis further support the 
essential role of Dhh in testis development [169; 170]. 
Furthermore, PDGF signaling plays a key role in fetal Leydig cell differentiation. Vascular 
development, testis cord formation, and early Leydig cell differentiation are disturbed in XY 
embryos with mutations in the PDGFRA [162]. CYP11A1 is not detectable in these embryos 
at 12.5 dpc, proofing an impact on Leydig cell differentiation. This might just be a 
downstream effect but the role of PGDFα is stressed by the finding that mutants also have 
defects in the development of adult Leydig cells [171]. Even though effects of PGDFα 
mutations on embryonic Leydig cells have not been analyzed, no abnormalities in 
development of the external genitalia were observed, indicating that embryonic Leydig cells 
are not influenced. This effect might be due to redundancy among different PDGF ligands.  
The very low turnover of Leydig cells in adult testis [172] is maintained by mitosis of the 
persistent small population of progenitor/immature cells. This is supported by experimental 
work that showed development of a new Leydig cell population within months [173; 174] and 
spontaneous recovery of steroidogenesis after elimination of mature adult Leydig cells using 
ethylene dimethanesulfonate [175]. In addition long-term administration of human chorionic 
gonadotropin/ luteinizing hormone leads to elevation in Leydig cell numbers [176-179]. The 
progenitors may be mesenchymal cells whose consecutive differentiation along with 
proliferation finally results in mature Leydig cells [180] or genuine stem cells, which like 
hemopoietic stem cells have side population characteristics [181]. 
In testis the final step in testosterone synthesis, converting androstenedione to testosterone, 
is mediated by 17β-hydroxysteroid dehydrogenase III [182]. In adults, the conversion takes 
place in Leydig cells while in fetal mouse this enzyme localizes to the tubules rather than 
Leydig cells. Hence androstenedione secreted by fetal Leydig cells is modified to 
testosterone in the tubules [183].  
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3.8. Genetic Defects Related to Steroid Hormone Metabolism 
Cholesterol is the obligate precursor for the biosynthesis of steroid hormones, and many 
genes involved in disorders of steroidogenesis are known (Table 5). 
 
Table 5. Mutations affecting the hypothalamic-pituitary-adrenal axis in humans (from [184]). 
 
OMIM = Online mendelian inheritance in man; AR = autosomal recessive; AD = autosomal dominant; 
CPHD = combined pituitary hormone deficiency; GH = growth hormone; ACTH = adrenocorticotropic 
hormone; MC2R/ACTHR = melanocortin-2 receptor/adrenocorticotropin receptor; Sf1 = steroidogenic 
factor-1; ALDP = adrenoleukodystrophy protein; mt = mitochondrial; CTLA-4 = cytotoxic T-lymphocyte-
associated 4; AIRE = autoimmune regulator; APS = autoimmune polyendocrinopathy syndrome; SLO 
= Smith-Lemli-Opitz; StAR = steroidogenic acute regulatory protein. 
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Mutations affecting synthesis, mitochondrial transport and cleavage of cholesterol interfere 
with both adrenal and gonadal steroid synthesis. This results in adrenal insufficiency and 
undervirilization and lack of pubertal development, respectively, in karyotypic (46,XY) males 
and (46,XX) females [185-191]. 
3.8.1. Adrenal Disorders 
3.8.1.1. Adrenocortical Dysplasia  
Adrenocortical dysplasia (acd) is an autosomal recessive disorder caused by mutations in 
the acd gene localized on chromosome 8 [192]. Its phenotypes are small size, 
hyperpigmentation, and premature death. In agreement with the assumption that they died 
from adrenocortical insufficiency, in mice that were assumedly homozygous for the acd 
mutation, low levels of corticosterone and high ACTH levels were detected. This indicates 
that acd mutations disturb cellular proliferation in the adrenal cortex along with secondary 
hypertrophy of cortical cells eventually caused by elevated ACTH levels. 
3.8.1.2. Adrenal Steroid Resistance 
Familial glucocorticoid resistance, caused by mutations in the glucocorticoid receptor, is 
accomplished by symptoms of mineralocorticoid and androgen excess (hypertension, 
hypokalaemia, hirsutism, baldness, oligomenorrhoea) and elevated cortisol and ACTH 
concentrations [193]. The molecular reasons for this are abnormalities in ligand binding, co-
factor interaction, nuclear localization and DNA binding, resulting in changes of the target 
gene transcription [194]. Mutations in the mineralocorticoid receptor lead to aldosterone 
resistance in pseudohypoaldosteronism type I [195], characterized by neonatal salt wasting, 
hyperkalemia and hypotension, with elevated aldosterone and renin activity. In contrast to 
pseudohypoaldosteronism type II, which is caused by mutations in the epithelial sodium 
channel, these symptoms tend to remit with age. 
3.8.1.3. Adrenal Hypoplasia 
Adrenal hypoplasia is characterized by underdevelopment or atrophy of the adrenal glands. 
Reasons are intrinsic defects in adrenal development and function (primary) or disturbed 
ACTH secretion and action (secondary) (Fig. 22) [196]. 
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Figure 22. Overview of the hypothalamic-pituitary (corticotroph)-adrenal axis. Loss-of function 
mutations in the genes listed have been shown to cause single gene disorders in humans. CRF = 
corticotrophin-releasing factor; ACTH = adrenocorticotropic hormone; ATII = angiotensin II; DHEA = 
dehydroepiandrosterone; ALD = adrenoleukodystophy; AIRE = autoimmune regulator; CTLA-4 = 
cytotoxic T-lymphocyte-associated 4 (from [184]). 
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4. Physiology and Pathophysiology of Aldehyde Oxidase 1 
Aldehyde oxidase 1 (AOX1) catalyses the oxidation of aldehydes and nitrogen-containing 
heterocyclic compounds, as well as the reduction of nitro-aromatic compounds, isoxazole, 
and isothiazole ring systems [197]. The physiological function of AOX1 remains largely 
unknown. However data from Tomita et al. indicate that AOX1 (EC 1.2.3.1) is identical to 
retinal oxidase [198], suggesting retinal as physiological substrate of AOX1. AOX1 and 
retinaldehyde dehydrogenase (EC 1.2.1.36) are capable of catalyzing the oxidation of retinal 
to retinoic acid (RA), but require different co-factors [199]. AOX1 has been suggested to be 
involved in ethanol-induced liver injury [200] and the generation of reactive oxygen species 
(ROS) during ethanol metabolism [201; 202]. A comparable two-step process is involved in 
the metabolism of both ethanol and retinol (Fig. 23). 
 
Figure 23. Schematic drawing of possible mechanisms of excessive ethanol effects on retinoid 
metabolism. ADHs, Alcohol dehydrogenases; ALDHs, aldehyde dehydrogenases; ARAT, acyl-
coenzyme A–retinol acyltransferase; CRBP, cellular retinolbindingprotein; CYPs, cytochrome P450 
enzymes; LRAT, lecithin:retinol acyltransferase; RA, retinoic acid; RAL, retinal; RALDHs, 
retinaldehyde dehydrogenases; RBP, plasma retinol-binding protein; RDHs, retinol dehydrogenases; 
REH, retinyl ester hydrolases; REs, retinyl esters;ROH, retinol; and TTR, transthyretin (from [203]). 
 
Both are first oxidized to the aldehyde form, and the aldehyde is subsequently oxidized to the 
acid form [203]. Products of the retinal dehydrogenase and AOX1 metabolic pathway, 9-cis 
RA and all-trans RA (ATRA), modulate retinoic acid receptors (RAR) / retinoid X receptors 
(RXR) target genes and thereby influence ABCA1-mediated HDL maturation [204]. 
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Data from Yang et al. demonstrate that 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) 
significantly reduced hepatic all-trans-retinol level and enhanced hepatic ATRA content, and 
upregulated AOX1 mRNA and enzymatic activities in mice [205]. The transcriptional effect 
was attenuated by supplementation with vitamin A. The observed induction of AOX1 may be 
responsible for the changed all-trans-retinol/ATRA levels due to TCDD and addition of 
vitamin A may weaken the effect of TCDD on AOX1 mRNA [205]. 
4.1. Structure of Aldehyde Oxidase 1 Protein 
The cryptozoic proteins of the mammalian molybdo-flavoenzyme (MFE) group are marked by 
a similar general structure. They are homodimers composed of approx. 150 kDa subunits 
[206-209] with a typical and easily recognized tripartite structure: the N-terminal domain of 
approx. 20 kDa comprising two 2Fe/2S redox centers, a 40 kDa flavin-containing region, and 
a 85 kDa C-terminal domain insisting the MoCo and the substrate-binding sites (Fig. 24). The 
final electron acceptor for xanthine oxidase (XO), AOX1, aldehyde oxidase homolog 1 
(AOH1), and possibly AOH2 and AOH3 is oxygen, producing superoxide oxygen radicals or 
hydrogen peroxide, whereas xanthine dehydrogenase (XD) uses NAD+. 
 
 
 
Figure 24 Structure and reaction scheme of 
MFEs. Upper part: MFEs consist of three 
domains joined by poorly conserved and 
unstructured hinge regions: a 20 kDa N-
terminal domain (light green), the 40 kDa FAD-
binding domain (orange) and a 85 kDa 
domains (blue). In the XD form of XOR, the 
FAD-containing domain binds NAD (NAD+). 
Lower part: The different redox centers of 
MFEs are displayed from top to bottom 
according to their implication in charge 
transfer. Oxidation of the substrate (R-H) takes 
place at the molybdenum centre. The products 
is shown as R-OH. Reducing equivalents are 
passed over flavin, to molecular oxygen 
(NAD+ in the case of the XD form of XOR). 
The Fe/S centers [always shown in their 
reduced (‘red’) state] are thought to mediate 
the transfer of electrons between MoCo and 
the flavin cofactor and to serve as electron 
sinks, storing reducing equivalents during 
catalysis (from [210]). 
 
 
In humans this family consists of xanthine oxidoreductase (XOR) and AOX1 while in mouse 
three homologous of AOX1, named AOH1, AOH2, and AOH3, are present. Sequence 
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homologous of mouse AOH1, AOH2, and AOH3 are also present in humans, but do not 
seem to code for functional MFEs [210]. 
In mice and humans 34 out of 36 junctions are conserved in XOR relative to AOX1, AOH1 or 
AOH2. Protein alignment and gene structure data clearly indicate that all known mammalian 
MFEs have a common origin and have evolved from an ancestral precursor [210]. Human 
AOX1 maps to chromosome 2q32.3-2q33.1 [211]. 
4.1.1 Regulation of AOX1 Expression 
The promoter of AOX1 contains no TATA sequence [212; 213] and the transcription of AOX1 
in human liver starts from a consensus transcriptional initiator for mammalian RNA 
polymerase II [214], common to other TATA less genes [215], 298 bp upstream of the 
translation start site [214]. In HepG2 transcription initiation seems to arise from several sites 
that are located closer to the ATG [212]. Additional analysis revealed a structurally complex 
region upstream of AOX1, containing sequences for a proximal promoter, enhancer sites, 
and a silencer element, indicating the potential for complex regulation of AOX1 expression 
and pointing out the essential role for the transcription factors Sp1 and Sp3 in  
epithelial cells [216]. Up to now very little is known about expression and regulation of AOX1 
and its homologs, AOX1 is regulated in a tissue type specific manner in humans [214], cattle 
[206], rabbits [217], and rats [218], with liver and lung showing highest expression. Besides 
the tissue specific regulation, AOX1 is also regulated in a gender specific way, which was 
shown for murine liver AOX1 and AOH1. Hepatocytes of male animals synthesize by far 
larger amounts than females [208]. This is in good agreement with the finding that chronic 
administration of testosterone to female mice induces both AOX1 and AOH1 [208; 219]. This 
effect is due to elevated mRNA levels, suggesting an influence of testosterone on the 
transcription of both genes [208]. Probably the modulation is indirect, mediated by growth 
hormone and/or somatomedins [220; 221]. No sex-related differences in the expression of 
AOX1 and AOH1 have been found in lung indicating that the effects of testosterone are 
tissue-specific [209]. Interestingly AOX1 is observed in target organs of testosterone, namely 
testis, epididymus, and prostate [222]. 
“Dioxin like” compounds found ubiquitous in the environment are also reported to influence 
AOX1 expression. In the mouse hepatoma cell line Hepa-1, AOX1 mRNA is upregulated by 
dioxin. Data from mutants defective in the key enzymes of the aryl hydrocarbon receptor 
(AHR) pathway, namely AHR and AHR nuclear translocator (ARNT), show that AOX1 mRNA 
expression is only enhanced if both proteins are present [223]. Upon ligand binding the 
cytosolic AHR migrates to the nucleus and forms heterodimers with the nuclear localized 
ARNT [224]. These dimers specifically recognize DNA sequences in the 5´ regulatory region 
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of responsive genes, known as xenobiotic response elements [225], leading to enhanced 
transcription [226]. Furthermore, dioxin increased AOX1 mRNA, protein, and enzymatic 
activity in the liver of C57BL/6 mice. An upregulation of AOX1 mRNA was detectable at 4 h 
after dioxin treatment, peaking at 24 h. Elevated protein levels of AOX1 and AOH1 were 
observed following 3 days of treatment and remained elevated at least to 6 days. Tungstate 
inhibiting AOX1 and eventually AOH1 activity by replacing molybdenum lowered both basal 
and dioxin induced aldehyde oxidase activity [223]. These data show a co-regulation of 
AOX1 and AOH1 in mice. The delay of time between mRNA and protein increase of AOX1 
indicates that dioxin in vivo does not only enhance transcription but also affects other factors 
regulating AOX1 [223]. Taking into account the complex synthesis of catalytically active 
holoenzyme forms of the molybdo-flavoenzymes which is controlled by many genes this 
finding is not surprising [210]. For XOR it was demonstrated that its increase by interferons 
and interferon inducers in vivo is partly regulated at the translational level [227]. 
Recent data report downregulation of AOX1 on mRNA and protein level by the PPARα 
activators adiponectin and fenofibric acid and the PPARα antagonist RU486 blocks this 
effect, thus identifying AOX1 as PPARα target gene [228]. 
4.1.2. Tissue Distribution of AOX1 
AOX1 expression is most prominent in the liver, as was shown for humans [229], rats [218] 
and cattle [206]. Significant but low levels of both mRNA and protein are also present in lung 
and testis [208; 209]. By northern blot analysis of tissues from unstimulated CD1 mice, the 
AOX1 transcript was detected in hepatocytes, cardiocytes, lung, and esophageal epithelial 
cells, with trace amounts in brain, spinal cord, spleen and eye. Nevertheless enzymatic 
activity was only detected in liver, lung and spinal cord [219]. Low expression of AOX1 
mRNA and protein in mouse brain and spinal cord was also described by Bendotti et al. 
[230]. AOX1 is only active in epithelial cells of the choroid plexus, which is involved in the 
secretion and reabsorption of the cephalo-rachidian fluid, as well as in the motor neurons of 
the brain and spinal cord. In mice, AOX1 and AOH1 reveal entirely overlapping tissue 
distribution. In situ hybridization studies suggest that different, although partially 
superimposable, subpopulations of hepatocytes are the sites of AOX1 and AOH1 expression 
[209]. While AOH1 is present in hepatocytes in the final phase of fetal development AOX1 is 
only found in adult animals, implying a role of AOH1 in liver development [209]. 
Immunohistochemical studies demonstrated a common allocation of AOX1 in respiratory 
(epithelial cells from trachea and bronchium, alveolar cells), digestive (surface epithelia of 
small and large intestine, hepatic cells), urogenital (proximal, distal and collecting tubules of 
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the kidney), and endocrine tissues (ductuli epididymidis and glandular epithelia, cortex of 
adrenal gland) [222]. 
The expression of AOH2 is distinct from AOX1 and AOH1, with mRNA and protein being only 
detectable in keratinized epithelia, such as the epidermis and the mucosa of the oral cavity, 
the oesophagus and the first part of the stomach [209]. 
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5. Apoptosis/Autophagy 
It is well known that ABCA1 is upregulated in macrophage foam cells [11; 231]. Based on 
own unpublished observations demonstrating inverse regulation of ABCA1 and ABCA7 
under this conditions and the finding that ABCA1 and ABCA7 are inversely regulated by 
SREBP-2 in a sterol-dependent manner [73] the current working hypothesis is that ABCA1 
and ABCA7 fulfill different functions in the same pathway (Fig. 25). 
 
Figure 25. Model of the postulated functional relation of ABCA1 and ABCA7 [*]. 
 
When cells are loaded with cholesterol, ABCA1 is upregulated to generate acceptor-
molecules for cholesterol efflux, providing the cell with the possibility to get rid of the excess 
cholesterol. ABCA7, on the other hand, is downregulated, and the same is expected for 
autophagy under this conditions. When cells are deloaded ABCA1 is downregulated, to 
prevent excess efflux of cholesterol, ABCA7 and autophagy on the other hand are increased 
to breakdown and recycle components that were needed under excessive cholesterol 
loading, like lipid droplets or mitochondria. The involvement of ABCA7 in 
phagocytic/autophagic processes is further supported by experiments demonstrating that 
knock-down of ABCA7 impairs engulfment of apoptotic cells by macrophages due to 
disturbed ERK signaling [75]. 
Autophagy is an evolutionary conserved mechanism in eukaryotic cells and can be divided in 
several subgroups, like microautophagy, macroautophagy and chaperone-mediated 
autophagy. The vacuolar, self-digesting process mediating removal of long-lived proteins and 
damaged organelles by the lysosome is termed macroautophagy [232]. Key players in 
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autophagy are the Atg genes primary described in yeast [233]. Macroautophagy shows basal 
activity in most cells, presumably liable for its anti-aging role [234; 235]. It enables the cell to 
get rid of damaged mitochondria [236] or functional redundant organelles [237]. Under 
starving conditions, macroautophagy is induced in order to provide the necessary 
components for survival. For example in the liver amino acids are generated and transformed 
into glucose to provide energy for the brain and erythrocytes [232]. Newer findings indicate 
that muscles also contribute amino acids under these conditions [238; 239]. Of note is that in 
cases of prolonged nutrient depletion macroautophagy is downregulated, eventually by 
ketone bodies [232]. Another important function of macroautophagy when nutrients are 
scarce is the generation of oxidizable substrates in neonates, indicated by transient 
upregulation in different tissues of the early neonate [238]. Autophagy is moreover involved 
in different diseases [237] resembling its dual role as cell-protective and –destructive [232]. 
In advanced stages of cancer, macroautophagy may be necessary to supply cells without 
connection to the blood stream in the inner part of solid tumors [240]. In apoptosis, again 
macroautophagy could play a dual role. It is able to protect cells from apoptosis by providing 
sufficient substrates under nutrient depletion [241] or reduced uptake of nutrients in case of a 
miss of growth factor [242]. Autophagy can also cause an apoptosis (Type I programmed cell 
death) independent cell death named autophagic cell death or Type II programmed cell 
death [243].  
Amino acids processed by autophagic break down constitute a potent feedback inhibition of 
autophagic sequestration and moreover the process is inhibited by insulin (in the liver) and 
enhanced by glucagon (reviewed in [244]). Both hormones exert their influence on 
autophagy in the liver at intermediate amino acid concentrations by altering the 
phosphorylation state of ribosomal protein S6 (S6); insulin, like high amino acid 
concentrations alone, increases and glucagon reduces phosphorylation [232]. Rapamycin 
entirely blocks amino acid-mediated S6 phosphorylation, implying mammalian target of 
Rapamycin (mTOR) and p70S6 kinase as members of this pathway and partly reduced 
inhibition of autophagy by amino acids. Furthermore, rapamycin partly reduced protein 
synthesis, suggesting a common regulation of both pathways [245]. Besides activating 
mTOR amino acids seem capable to inhibit autophagy independent of mTOR [246; 247]. 
In addition to rapamycin the PI3K inhibitors wortmannin and LY294002 reduced amino acid 
stimulated S6 phosphorylation. In contrast to rapamycin autophagy was decreased in the 
absence of amino acids [248]. These results were clarified by the finding that the product of 
class-III PI3K is necessary for autophagy and that the products of class-I PI3K display 
inhibitory potentials [47]. As both classes are affected by those PI3K inhibitors, autophagy is 
abolished. The specific autophagy inhibitor 3-methyladenine was identified as PI3K inhibitor, 
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accounting for its effect on autophagy and S6 phosphorylation [47; 248]. A schematic 
drawing of the complex regulation of autophagy is shown in Figure 26. 
 
 
Figure 26. Diagram of autophagy signaling. Detail are found in the text (adapted from [232]). 
5.1. Effects of Atherogenic Lipoproteins on Macrophages 
The recruitment of monocytes to the arterial wall and the enhanced entrapment of LDL in the 
intima are the earliest events in atherogenesis [22]. LDL in the subendothelium is modified to 
an atherogenic particle that is taken up by lesional macrophages and leads to foam cell 
formation [249]. Foam cells have been detected in early and advanced lesions and influence 
plaque rupture eventually leading to myocardial infarction and stroke. The enhanced survival 
and proliferation as well as apoptotic and necrotic cell death of lesional foam cells has been 
reported and contributes to the development of atherosclerotic lesion and the final rupture of 
the plaque [250]. 
The oxidative modification of LDL (Ox-LDL) in the intima is catalyzed by vascular cells and 
generates an atherosclerotic particle. Numerous studies investigated foam cell formation in-
vitro using copper oxidized LDL. Ox-LDL was demonstrated to be cytotoxic and to induce 
apoptotic cell death in macrophages [251]. Apoptosis was shown to depend on p53 and 
superoxide dismutase (MnSOD) in-vitro and in atherosclerotic lesions where MnSOD 
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immunoreactivity correlates to plaque advancement [252]. The expression of the 
proapoptotic Bcl-2 family protein BAX was found induced in lesional macrophages [253]. In 
addition Ox-LDL activates sphingomyelinase and the subsequent rise of intracellular 
ceramide leads to apoptotic cell death [254]. In contrast, lightly oxidized LDL or low amounts 
of Ox-LDL enhance macrophages survival and promote proliferation [255]. The mitogenic 
effect was attributed to lysophospholipids in Ox-LDL and was enhanced by aggregation 
[256]. Current research indicates that besides oxidation partial degradation of LDL by 
enzymes secreted from vascular cells takes place in the subendothelium [257]. Treatment of 
LDL with trypsin and cholesterylesterase generates an atherogenic lipoprotein called 
enzymatically modified LDL (E-LDL), with a similar size as lipoproteins isolated from 
atherosclerotic lesions [257]. Furthermore E-LDL binds C reactive protein and activates 
complement [258]. E-LDL induces foam cell formation more rapidly than Ox-LDL [259] and 
this might explain that E-LDL is a more potent inducer of gene expression as was 
demonstrated for monocyte chemotactic protein 1 [260], early growth response gene-1 [261] 
or adipophilin [262]. These studies indicate that E-LDL and Ox-LDL influence identical target 
genes but with different kinetics. E-LDL was also demonstrated to exert effects not identified 
or opposite of Ox-LDL treated cells. The expression of cathepsin H was induced by E-LDL 
but not Ox-LDL in macrophages and cathepsin H may also contribute to the transformation of 
LDL to an atherogenic moiety [263]. In contrast to Ox-LDL, E-LDL induces foam cell 
formation also in freshly isolated peripheral blood monocytes and cytotoxicity of E-LDL is 
only observed using very high amounts of this modified lipoprotein [259; 260]. 
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II. AIMS OF THE THESIS 
The goals of this thesis were to identify and functionally characterize new and previously 
identified ABCA1 or ABCA7 interacting proteins and genes in the ABCA1-pathway in more 
detail. 
Firstly, yeast two-hybrid screens were performed to identify new putative ABCA1 associated 
proteins and these results were confirmed by independent methods. 
Secondly, the interaction of AOX1 with ABCA1 was verified and the functional relevance of 
this interaction was analyzed, which was the major topic of my thesis. 
Thirdly, syntaxin 13 and Tax1 binding protein 3 (TAX1BP3) associated proteins were 
identified by yeast two-hybrid screens. 
Fourthly, yeast two-hybrid screens were performed to identify putative ABCA7 interacting 
proteins and the regulation of the promoter(s) of ABCA7 was analyzed. 
Fifthly, genes were identified that are regulated by atherogenic lipoproteins in a similar 
manner as ABCA1. 
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III. MATERIAL 
1. Chemicals, Enzymes, Markers, Media and Buffers 
-Leu Dropout (DO) Supplement    Clontech, Palo Alto, CA, USA 
-Leu/-Trp DO Supplement     Clontech, Palo Alto, CA, USA 
-Leu/-Trp/-His DO Supplement    Clontech, Palo Alto, CA, USA 
-Trp DO Supplement     Clontech, Palo Alto, CA, USA 
1 kb plus Ladder, DNA     Gibco BRL, Berlin, Germany 
Agarose       Biozym, Hameln, Germany 
Alkaline Phosphatase, Shrimp    Roche, Mannheim, Germany 
Ampicillin        Roche, Mannheim, Germany 
Apolipoprotein A-I (apoA-I)    Calbiochem, Bad Soden, Germany 
Bovine serum albumin (BSA, Lipid-free)   Sigma, Deisenhofen, Germany 
DMEM with L-Glutamin     Bio WHITTAKER, Walkersville, MD, USA 
EDTA (Di-sodium)     Pharmacia Biotech, Freiburg, Germany 
Eicosapentaenoic acid (EPA)    Calbiochem, Bad Soden, Germany 
Fetal Calf Serum (FCS)     Gibco BRL, Berlin, Germany 
Fluoresbrite microparticles    Polysciences, Eppelheim, Germany 
FuGene 6      Roche, Mannheim, Germany 
Full-Range Rainbow Molecular Weight Markers   Amersham Pharmacia Biotech, Freiburg, Germany 
H2O Nuclease-free     Promega, Madison, AL, USA 
Human recombinant M-CSF    R&D Systems, Wiesbaden-Nordenstadt, Germany 
γ-linolenic acid      Biotrend, Köln, Germany 
Luria Broth Agar  Base     Gibco BRL, Berlin, Germany 
Luria Broth Base      Gibco BRL, Berlin, Germany 
Macrophage serum free medium (SFM)    Gibco BRL, Berlin, Germany 
MEM (Non-essential Amino acid)    Gibco BRL, Berlin, Germany 
Minimal SD Agar Base     Clontech, Palo Alto, CA, USA 
Minimal SD Base      Clontech, Palo Alto, CA, USA 
Complete Mini Protease inhibitor Cocktail   Roche, Mannheim, Germany 
Phosphate Buffered Saline (PBS) w/o Ca+2/Mg+2  Gibco BRL, Berlin, Germany 
Protein A-Dynabeads     Dynal, Hamburg, Germany 
Pwo-DNA-Polymerase     Roche, Mannheim, Germany 
Ready Gels, 4-20%     BioRad, Hercules, CA, USA 
Restrictionendonucleases     Roche, Mannheim, Germany 
RNAiFect      Qiagen, Hilden, Germany 
Taq-DNA-Polymerase     Roche, Mannheim, Germany 
TaqMan PCR Mastermix     Applied Biosystems, Darmstadt, Germany 
T4-DNA-Ligase      Gibco BRL, Berlin, Germany 
Triton X-100       Boehringer, Mannheim, Germany 
Trypsin / EDTA      Sigma, Deisenhofen, Germany 
YEASTMAKER Carrier DNA    Clontech, Palo Alto, CA, USA 
YPD Agar Base      Clontech, Palo Alto, CA, USA 
YPD Base      Clontech, Palo Alto, CA, USA 
All other chemicals and solvents    Sigma, Deisenhofen, Germany 
2. Kit Systems 
BCA Protein Assay Kit     Pierce, Rockford, IL, USA 
BigDye Terminator Cycle Sequencing Kit v.1.1  Applied Biosystems, Darmstadt, Germany 
Cell Death Detection ELISAPLUS    Roche, Penzberg, Germany 
Centrisep spin columns      Princeton Separations, Adelphia, NJ, USA 
ECL+ Western Blotting Analysis System   Amersham Pharmacia Biotech, Freiburg, Germany 
Galactosidase enzyme assay    Promega, Madison, AL, USA 
MATCHMAKER Two-Hybrid System II and III  Clontech, Palo Alto, CA, USA 
MicroSpin GST Purification Module    Amersham Pharmacia Biotech, Freiburg, Germany 
Ni-NTA Spin Kit      Qiagen, Hilden, Germany 
Protein Assay      BioRad, Hercules, CA, USA 
QIAprep Spin Miniprep Kit     Qiagen, Hilden, Germany 
QIAquick Gel Extraction Kit    Qiagen, Hilden, Germany 
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QIAquick PCR Purification Kit    Qiagen, Hilden, Germany 
Reverse Transcription System    Promega, Madison, AL, USA 
RNeasy Mini Kit       Qiagen, Hilden, Germany 
Soluble Fas ELISA     R&D Systems, Wiesbaden-Nordenstadt, Germany 
TNT Quick Coupled Transcription/Translation System Promega, Madison, AL, USA 
YEASTMAKER™ Yeast Plasmid Isolation Kit  Clontech, Palo Alto, CA, USA 
3. Oligonucleotides, AODs, and siRNA 
All sequences are denoted from 5´ to 3´. 
3.1. Oligonucleotides 
Oligonucleotides were ordered from Qiagen/Operon. 
3.1.1. For Cloning 
3.1.1.1. Constructs Related to ABCA7 
Bait-constructs for the yeast two-hybrid screen: 
YTHA7Crev GGA TCC GTC GAC TTA GAG CAC AGT CTC GGC AGT GC 
ABCA7Ctermuni GGG GAA TTC CGC TGC CTG GGC AGC CCG CAA 
ABCA7Ntermrev CCC GGA TCC CCC TAG GCC AGC CAG CGT CCT GTG 
ABCA7Ntermuni GGG GAA TTC GCC TTC TGG ACA CAG CTG ATG CTG 
 
Constructs for the verification of the interaction in yeast: 
CAP37 Fwd_Eco:  GGG GAA TTC ATG ACC CGG CTG ACA GTC CTG 
CAP37 Rev_Bam:  GGG GGA TCC CTA GGC TGG CCC CGG TCC CGG 
FB5_uni_Eco GGG GAA TTC ATG CCA GGA ATA AAA AGG ATA 
FB5_rev_Xho GGG CTC GAG TCA GAA TGG GTA CTG CGA CAC 
GIP2_uni_Bam_ACT2 GGG GGA TCC AA ATG CCC CTG AAG CTG CGG GGG 
GIP2_rev_Xho_ACT2 GGG CTC GAG TCA TAA TCC TCT TCG TTT GGC 
VC_uni_Eco GAG GAA TTC GAG CAT CGC AAG GCG GTG CCA 
VC_rev_Bgl GGG AGA TCT TCA CTC CGG GCA CTG AGT GGT 
MT2_uni_Eco GGG GAA TTC ATG GAT CCC AAC TGC TCC TGC 
MT2_rev_Bgl GGG AGA TCT TCA GGC GCA GCA GCT GCA CTT  
JAM_uni_Mun GGG CAA TTG ATG GGG ACA AAG GCG CAA GTC 
JAM_rev_Bam GGG GGA TCC TCA CAC CAG GAA TGA CGA GGT  
JAB_uni_Eco GGG GAA TTC ATG GCG GCG TCC GGG AGC GGT 
JAB_rev_Bam GGG GGA TCC TTA AGA GAT GTT AAT TTG ATT 
C1Q_uni_Eco GGG GAA TTC ATG GAG GGT CCC CGG GGA TGG 
C1Q_rev_Bam GGG GGA TCC TCA GGC AGA TGG GAA GAT GAG 
Constructs for pull-down assays and coimmunoprecipitation: 
capTOPODIRuni CAC CAT GAC CCG GCT GAC AGT CCT G 
capTOPODIRrev CGG TCC CGG GTT GTT GAG AAC 
capTOPODIRreifuni CAC CAT GAT CGT TGG CGG CCG GAA GGC G 
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JAM_TD_uni CACC ATG GGG ACA AAG GCG CAA GTC 
JAM_TD_rev CAC CAG GAA TGA CGA GGT CTG 
JAB_TD_uni CACC ATG GCG GCG TCC GGG AGC GGT 
JAB_TD_rev AGA GAT GTT AAT TTG ATT AAA CAG 
GIP2_TD_uni CACC ATG CCC CTG AAG CTG CGG GGG 
GIP2_TD_rev TAA TCC TCT TCG TTT GGC ATC ACC 
VC_TD_uni CACC ATG GCG GCG GTG GCT GGA TC 
VC_TD_rev CTC CGG GCA CTG AGT GGT CGG 
VC3uniTD CACC GGA TCC CGT GCC CCT GGC C 
VC3revTD GAA CTC CAC CTT GCA GGC CGG G 
FB_TD_uni CACC ATG CCA GGA ATA AAA AGG ATA C 
FB_TD_rev GAA TGG GTA CTG CGA CAC ATA TAT C 
C1Q_TD_uni CACC ATG GAG GGT CCC CGG GGA TGG 
C1Q_TD_rev GGC AGA TGG GAA GAT GAG GAA GCC 
 
Constructs for promoter-assay: 
(+) 65  CCC AAG CTT GGC TGT CTC CGG CGA TAC ATG 
-1170 CCC AAG CTT CCG AGT CCT TCT CAC CTT CC 
H1 CTC GAG AAT GCG GGG TTG GGG CCG GGA GGG 
B8 CCC ACG CGT ATA GCA GCG TGC AGA GGC AG 
A CCC ACG CGT GGA GCA GGC CAG TGA GTG ACG 
B7 CCC ACG CGT TGA TCC CGT CTC CTC CCT T 
B6 CCC ACG CGT AAG AAA CCC GGC TAG GCG A 
B5 CCC ACG CGT CTA CGG TGA TGC AGC AAG AG 
B4 CCC ACG CGT AAG ACA GCG CAG CCT CGT T 
B3 CCC ACG CGT GTT ATA CAA CGT GGG GAG 
B2 CCC ACG CGT GAA CTC CTG CAA TTC GGA G 
B1 CCC ACG CGT GAG TCT GGA CTA AAC TAG AG 
B CCC ACG CGT GAA CGA ATG ATC TAG TGG AAC CC 
H CCC ACG CGT AGG AGG AGC AAA AGC TGA AGC 
3.1.1.2. Constructs Related to ABCA1 
Bait-constructs for the yeast two-hybrid screen: 
YTHA1Cuni GAA TTC GTC AAT GGA AGG TTC AGG TGC 
YTHA1Crev GGA TCC GTC GAC TCA TAC ATA GCT TTC TTT CAC 
 
Constructs for the verification of the interaction in yeast: 
A1CT2rev GGA TCC TAC ATA GCT TTC TTT CAC TTT C 
A1CTrev3del GGA TCC TCA TTT CAC TTT CTC ATC CTG 
A1CTrev4mut GGA TCC TCA TCC ATA TCT TTC TTT CAC TTT C 
GIPC1 Fwd_Eco:  GGG GAA TTC ATG TTT TGC ACC CTG AAC AC 
GIPC1 Rev_Bam:  GGG GGA TCC CTA GTA GCG GCC GAC CTT GGC 
TIP1 Fwd_Eco:  GGG GAA TTC ATG TCC TAC ATC CCG GGC CAG 
TIP1 Rev_Bam:  GGG GGA TCC CTA GGA CAG CAT GGA CTG CTG 
SDCBP Fwd_Mun:  GGG CAA TTG ATG TCT CTC TAT CCA TCT CTC 
SDCBP Rev_Bam:  GGG GGA TCC TTA AAC CTC AGG AAT GGT GTG 
b2_YTH_ECO GAA TTC CCC GCG GGT GAG GCG GGC 
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b2_YTH_BAM GGA TCC GCG TAG GAT CAA CGT GTT CCT G 
 
Constructs for pull-down assays and coimmunoprecipitation: 
MAGITDuni CAC CAT GTC GAA GAC GCT GAA GAA GAA GAA GCA C 
MAGITDrev ATG TTG CTC GGG TTT CAC GTA GGA G 
GIPC1 Fwd:  CAC CAT GCC GCT GGG ACT GGG GCG 
GIPC1 Rev:  GTA GCG GCC GAC CTT GGC GTC 
TIP1 Fwd:  CAC CAT GTC CTA CAT CCC GGG CCA G 
TIP1 Rev:  GGA CAG CAT GGA CTG CTG CAC 
SDCBP Fwd:  CAC CAT GTC TCT CTA TCC ATC TCT C 
SDCBP Rev:  AAC CTC AGG AAT GGT GTG GTC 
 
Construct for PDZ-Array: 
QE_A1_uni GGA TCC GTC AAT GGA AGG TTC AGG TG 
QE_A1_rev AAG CTT TCA TAC ATA GCT TTC TTT CAC TTT C 
3.1.1.3. Constructs Related to TOSO 
For cloning in the pcDNA3.1D/V5-His-TOPO TOSO was amplified using the primers 
FWD:  CAC CAT GGA CCT CTG GCT TTG GCC ACT TTA 
REV:  GGC AGG AAC ATT GAT GTA GTC ATC TGA ATC AC 
The TOSO probe for northern blots was generated using the primers  
FWD:  TGA GGA TCC TCC CAG AAG TA 
REV:  CCT CCC AGA CTG TGA GCC AT 
3.1.2. For Sequencing 
capTDsequni CCC CGG GGT TAG CAC CGT GG 
capTDseqrev GCC ACT CGG GTG AAG AAG TC 
FBTDuni CTC CAG GCC TCT TAT ATG CC 
FBTDrev GAT AAG GCT CCT CAC AGC GG 
JABTDseq GCA TAT GAA TAC ATG GCT GC 
pACT2Seqrev GCA CGA TGC ACA GTT GAA GTG 
SeqFBuni GTG CAA CAG ATT CCC ACC AG 
SeqFBrev AGA TAA GGC TCC TCA CAG CG 
SeqJAMuni ACC ATT GGG AAC CGG GCA GTG 
SeqGIP2uni AAA GAT GGT GGT GTT ATT GAC 
YTH_VER_UNI GAG CGC CGC CAT GGA GTA C 
YTH_VER_REV CAG TTG AAG TGA ACT TGC GG 
TD_UNI CTC ACT ATA GGG AGA CCC AAG 
TD_REV CCT CTA GAC TCG AGC GGC C 
A1_CT_sequin TGC TAC AAT ACC AGC TTC 
A1_CT-seqrev TGT CTG AGA AAC AGA GTA G 
pAS2-1rev CGT TTT AAA ACC TAA GAG TCA C 
PAS2-1uni TCA TCG GAA GAG AGT AG 
GADT7uni CTA TTC GAT GAT GAA GAT ACC CCA CCA AAC CC 
GADT7rev GCG GGG TTT TTC AGT ATC TAC GAT TCA TCT GC 
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INSERTuni CAG TGA ATT CCA CCC AAG C 
INSERTrev CCC GTA TCG ATG CCC ACC C 
pACT2_Seq_uni GCT TAC CCA TAC GAT GTT CCA G 
pUCuni GTA AAA CGA CGG CCA GT 
pUCrev CAG GAA ACA GCT ATG AC 
MAG340 CGG CAT TAC CTA AGT CTT CAG 
MAG640 CAA GTC CTC TTT GAT AAT GAG 
MAG940 CAC TGA CAC AGG GAT GAT C 
MAG1240 GGT GTC CTT GTT CGA GCA TC 
MAG1540 CAG TGA AGA TCC TGT TGT GG 
MAG1840 GTG TCA AGG CCT TCA GAA AGG  
MAG2140 GGA TCC CCA AAA TTG GAT CC 
MAG2440 ACG GAA GAT CTT CTA TGG AG 
MAG2740 CAT TGT TGA ACT GTC TCA TG 
MAG3040 CCA GTA GAG CTG GAG AGA GG 
MAG3220 GAA CCT ACA CAA GGA ATC AC 
GIP360 CAC TTG GTC TCA CCA TTA CAG 
VC325 CCT GCC TCT CAC AAG CTA CTG 
VC640 GGA GTA CGT GGC TGA GTC TC 
VC940 GCG CTC CGA GGT GGC TGC TG 
VC1240 CTC TGT GTG CGC CCT GCT GG 
VC1540 CAC GCA AGA CTG AGA AAG AAG 
VC1840 CCT GGA GCT GGG GCC GAT C 
VC2140 CAC CAG TGA GGC TGG GCT GAG 
QE uni CGG ATA ACA ATT TCA CAC AG 
QE rev GTT CTG AGG TCA TTA CTG G 
QE prom CCC GAA AAG TGC CAC CTG 
3.2. TaqMan-Assays 
3.2.1. Gene Expression Assays 
Assays on Demand (AOD) were purchased from Applied Biosystems. 
Gene Assay ID 
ABCA1 Hs00194045_m1 
SNTA1 Hs00162045_m1 
SNTB1 Hs00221412_m1 
SNTB2 Hs00198844_m1 
GIPC1 Hs00194807_m1 
TIP1 Hs00205924_m1 
Scribble Hs00363005_m1 
MAGI3 Hs00326365_m1 
GIPC2 Hs00214273_m1 
AOX1 Hs01565229_m1 
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Primers and Probes. 
The mRNA sequences for ABCA7 type I and type II, TOSO and SDCBP were derived from 
GenBank and primers and TaqMan probes were designed using the PrimerExpressSoftware 
v2.0 (Applied Biosystems). Primers for ABCA7 and SDCBP and 6-carboxyfluoresceine 
(FAM)-labeled probes, quenched by a non-fluorescent quencher (TAMRA) at its 3´ end, were 
obtained from Applied Biosystems. Primers for TOSO were obtained from MWG-Biotech 
(Ebersberg, Germany). 
 
ABCA7 type I: 
FWD  TCT TCA TCC TGG TGG CTG TTC 
Probe  CCA CTC CCA CCC GCC CCT G 
REV  ACC ATG AAT GCC ACT TCC CA 
 
ABCA7 type II: 
FWD  GGA CCC CTA GTG AGT GTT CAA AA 
Probe  CAT TGT CCC CCT TGT GGT CTT TCT CCC 
REV  AGG AAT CCC TGG GGT TGG 
 
TOSO: 
FWD  TGG TGC CAA GGA GTC TCA TCT 
Probe  TCT GCT GAT GTC CAA TAC CTG CTT CAT GTG 
REV  GGG AAT GAT GAG GGC TCT GA 
 
SDCBP: 
FWD  GCT CAA ACT GCT TTT TCT GCA A 
Probe  CCC TGC CAA TCC AGC AAT TTT GTC A 
REV  TGA GGG ATA GGA GCA GAA GCT T 
3.2.2. SNP Genotyping Assay 
SNP Genotyping assays located in or near AOX1 (Assay IDs: C____144529_1_, 
C____144530_10, C___8130525_10, C__25473600_20, C__27967310_10, 
C__29454081_20, C__30787305_10) were purchased from Applied Biosystems. 
3.3. siRNA 
siRNAs were supplied by Ambion, Austin, TX, USA. 
Aldehyde Oxidase 1 (AOX1, NM_001159): 
Sense:   GCC AAU GCC UGU CUG AUU Ctt 
Antisense:  GAA UCA GAC AGG CAU UGG Ctg 
Silencer Negative Control #1 siRNA 
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4. Antibodies 
Antigen Host Clonality Provider 
ABCA1 (AB.H10) mouse monoclonal Abcam, Cambridge, UK 
AOX1 mouse monoclonal BD Biosciences, Erembodegem, Belgium 
β-Actin  mouse monoclonal Sigma, Deisenhofen, Germany 
Caspase-8 mouse monoclonal BD Biosciences, Erembodegem, Belgium 
CD95 (DX2) mouse monoclonal Calbiochem, Bad Soden, Germany 
CD95L mouse monoclonal Santa Cruz, Heidelberg, Germany 
FADD mouse monoclonal BD Biosciences, Erembodegem, Belgium 
FLIPL rabbit polyclonal Chemicon, Hampshire, UK 
GST goat polyclonal Abcam, Cambridge, UK 
HA mouse monoclonal Clontech, Palo Alto, CA, USA 
Mouse goat polyclonal Jackson ImmunoResearch, Suffolk, UK 
Rabbit goat polyclonal BD Biosciences, Erembodegem, Belgium 
V5 mouse monoclonal Invitrogen, Carlsbad, CA, USA 
5. Radioactive Materials 
[3H]Choline phospholipid   Amersham Pharmacia Biotech, Freiburg, Germany 
[14C]Cholesterol    Amersham Pharmacia Biotech, Freiburg, Germany 
[α32P]dCTP      Amersham Pharmacia Biotech, Freiburg, Germany 
6. Films and Membranes 
ECL Hyperfilm     Amersham Pharmacia Biotech, Freiburg, Germany 
Fluorotrans Membrane (PVDF)   Pall Filtron GmbH, Dreieich, Germany 
Genescreen membrane    NEN Life Science, Boston, MA, USA) 
Instant Picture Film Typ 667   Polaroid, Offenbach, Germany 
X-Ray Films Biomax    Kodak, Rochester, NY, USA 
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7. Organisms and Plasmids 
Organisms Characteristics Reference 
Monocytes Primary human-derived monocytes this work 
COS-7 African green monkey kidney fibroblast-like cells [264] 
HepG2 Human hepatoblastoma cells [265] 
HL-60 Human acute myeloid leukemia [266] 
Jurkat Human T cell leukemia [267] 
S. cerevisiae 
Y187 
MATα, ura3-52, his3-200, ade2-101, trp1-901, leu2-3, 112, 
gal4∆, met-, gal80∆, URA3::GAL1UAS-GAL1TATA-lacZ 
Clontech, Palo Alto, CA, USA 
S. cerevisiae 
PJ69-2A 
AH109 
MATa, trp1-901, leu2-3, 112, ura3-52, his3-200, gal4∆, 
gal80∆, LYS2::GAL1UAS-GAL1TATA-HIS3, GAL2UAS-GAL2TATA-
ADE2, ura3::MEL1UAS-MEL1TATA-lacZ 
Clontech, Palo Alto, CA, USA 
E. coli BL21-Gold F-, ompT, hsdS (rB-, mB-), dcm+, Tetr, gal, endA, Hte Stratagene, La Jolla, CA, USA 
E. coli TOP10 
           GC10 
F-, mcrA, ∆(mrr-hsdRMS-mcrBC), Φ80lacZ∆M15, ∆lacX74, 
deoR, recA1, araD139, ∆(ara-leu)7697, galU, galK, 
rpsL(StrR), endA1, nupG 
Invitrogen, Carlsbad, CA, USA 
Biomol, Hamburg, Germany 
E. coli TOP10F´ F´{lacIq, Tn10(TetR)}, mcrA, ∆(mrr-hsdRMS-mcrBC), 
Φ80lacZ∆M15, ∆lacX74, deoR, recA1, araD139, ∆(ara-
leu)7697, galU, galK, rpsL(StrR), endA1, nupG 
Invitrogen, Carlsbad, CA, USA 
 
Plasmid Marker Reference 
pGEX-5X-1 Ampr Amersham Pharmacia Biotech 
constructs based on pGEX-5X-1 Ampr this work 
pQE30 Ampr Qiagen, Hilden, Germany 
pQE30-ABCA1-CT Ampr this work 
pAS2-1 Ampr, TRP1 Clontech, Palo Alto, CA, USA 
constructs based on pAS2-1 Ampr, TRP1 this work 
pACT2 Ampr, LEU2 Clontech, Palo Alto, CA, USA 
constructs based on pACT2 Ampr, LEU2 this work 
pGADT7 Ampr, LEU2 Clontech, Palo Alto, CA, USA 
constructs based on pGADT7 Ampr, LEU2 this work 
Human Matchmaker cDNA-Libraries Ampr, LEU2 Clontech, Palo Alto, CA, USA 
pCR2.1-TOPO Ampr, Kanr, lacZ Invitrogen, Carlsbad, CA, USA 
pCRII-TOPO Ampr, Kanr, lacZ Invitrogen, Carlsbad, CA, USA 
pcDNA3.1D/V5-His-TOPO Ampr, Neor Invitrogen, Carlsbad, CA, USA 
constructs based on pcDNA3.1D/V5-His-TOPO Ampr, Neor this work 
pcDNA3.1D/V5-His-lacZ Ampr, Neor Invitrogen, Carlsbad, CA, USA 
pGL3-Basic Ampr Promega, Madison, AL, USA 
constructs based on pGL3-Basic Ampr this work 
pSV-β-Galactosidase Control Vector Ampr Promega, Madison, AL, USA 
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8. Technical Equipment 
2100 Bioanalyzer, Caliper     Agilent, Palo Alto, CA, USA 
Autoclave Steam Sterilizer Type 24    Melag, Berlin, Germany 
Automatic Gamma Counter 1470 WIZARD   Berthold, München, Germany 
Biofuge 15R      Heraeus, Hanau, Germany 
Cell culture Incubator 6000     Heraeus, Hanau, Germany 
ELISA-reader       Tecan, Stuttgart, Germany 
FACScan      BD, Heidelberg, Germany 
GeneQuant pro RNA/DNA Calculator    Amersham Pharmacia Biotech, Freiburg, Germany 
GeneChip Fluidics Station 450    Affymetrix, Santa Clara, CA, USA 
GeneChip Scanner 3000     Affymetrix, Santa Clara, CA, USA 
Horizontal Shaker GFL-3016    GFL, Großburgwedel, Germany 
Hybridization Oven 640     Affymetrix, Santa Clara, CA, USA 
Incubator B 6120      Heraeus, Hanau, Germany 
Instant Camera MP4     Polaroid, Offenbach, Germany 
Kodak X-Omat 2000 processor    Kodak, Rochester, NY, USA 
LaminAir Hood       Heraeus, Hanau, Germany 
Liquid Scintillation Counter Wallac 1410   Berthold, München, Germany 
Lumi Imager F1      Boehringer, Mannheim, Germany 
LUMAT LB9501       Berthold, München, Germany 
Megafuge 1.0 R      Heraeus, Hanau, Germany 
Microscope (Visible) Leitz Laborlux S    Leitz GmbH, Wetzlar, Germany 
Milli-Q UF Plus System     Millipore, Bradford, VT, USA 
MiniSpin Plus Centrifuge     Eppendorf, Hamburg, Germany 
Mini Transblot Cell     BioRad, München, Germany 
Mini Protean-3 Electrophoresis Cell    BioRad, München, Germany 
Mini-Sub Cell GT Electrophoresis     BioRad, München, Germany 
pH-Meter pH537      WTW, Weilheim, Germany 
Precision Balance Sartorius MD BA 200   Sartorius, Göttingen, Germany 
Power Supply PAC 300     BioRad, München, Germany 
Princeton MicroMax CCD-1317-K/1     Roper Scientific, Trenton, NJ, USA 
Shaking Incubator GFL-3032    GFL, Großburgwedel, Germany 
Shaking Water Bath Julabo SW-20C    Julabo, Seelbach, Germany 
Spectrophotometer UV/VIS Lambda 2   Perkin Elmer, Überlingen, Germany 
Stirrer with Heating Surface IKAMAG    Labor Center, Nürnberg, Germany 
SpeedVaq Alpha RVC     Christ, Osterode, Germany 
Sysmex Micro-Cell Counter F-300    Digitana AG, Hamburg, Germany 
Thermocycler Gene Amp PCR System 9600   Perkin Elmer, Uberlingen, Germany 
Thermomixer Comfort     Eppendorf, Hamburg, Germany 
Ultrasonic Disintegrator Soniprep 150   MSE, Watford Herts, United Kingdom 
Ultracentrifuge (fixed angle) J2-21 M/E   Beckman, München, Germany 
Ultracentrifuge L-70      Beckman, München, Germany 
Ultracentrifuge Optima TLX     Beckman, München, Germany 
Vortex-Mixer REAX 2000     Heidolph, Kelheim, Germany 
Zeiss Axiovert S-100 Spectral Microscope    Carl Ze
III. Material 
50 
9. Preparation of Solutions 
PBS-Tween 
10 l PBS 
100 ml 10% Tween 
 
Transfer-buffer (western blot) 
1 l Methanol 
30.3 g TRIS 
144 g Glycine 
Ad 10 l H2O 
 
5x SDS-Gel running buffer (western blot) 
75 g TRIS 
360 g Glycine 
250 ml 10% SDS 
Ad 5 l H2O 
 
5x sample loading buffer (Laemmli dye - western blot) 
5 ml Glycerol  
1 g SDS  
2.56 ml ß-Mercapto-Ethanol  
2.13 ml 0.5M TrisHCl pH 6.8+ 0.4% SDS   
Bromphenolblue Traces 
 
5x TBE-buffer (DNA) 
54 g Tris 
27.5 g Boric acid 
20 ml 0.5 M EDTA (pH 8.0) 
Ad 1 l H2O  
 
6x Sample buffer (DNA) 
0.25 % (w/v) Bromphenolblue 
0.25% (w/v) Xylencyanol 
15% (w/v) Ficoll 400 in H2O  
 
Ethidiumbromid stock solution (DNA – RNA) 
10 mg/ml ethidium bromide in H2O  
 
E. coli and yeast media 
were prepared according to the manufacturers´ instructions. 
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IV. METHODS 
1. Cell Culture Techniques 
1.1. Elutriation of Human Monocytes 
Suspensions enriched in human peripheral blood leukocytes were isolated by leukapheresis 
in a Spectra cell-separator (Gambro BCT), supplemented with the anticoagulant ADCA and 
diluted with an equal volume of PBS (w/o Ca2+, Mg2+). The diluted apheresate was 
subjected to counterflow centrifugation (J2-MC centrifuge with JE- 6B Rotor, Beckmann) 
using buffers and centrifuge adjustment as follows: 
 
Running buffer: 
PBS (w/o Ca2+, Mg2+) 
1.0 % (v/v) penicillin / streptomycin-solution 
0.5 % (w/v) BSA 
0.1 % (w/v) Glucose 
 
Rotation: 2040 rpm 
Rotor temperature: 15°C 
 Flow rate (ml/min) Volume of fraction (ml) 
Loading 7 - 
Pre-run 9 150 
Fractions 1 - 4 12 50 
Fractions 5 - 8 15 50 
Fractions 9 - 12 18 50 
Fractions 13 - 16 20 50 
Fractions 17 - 19 22 50 
Fractions 20 - 22 24 50 
 
The monocyte content of each fraction was determined using flow cytometry based on the 
different scatter properties of lymphocytes, granulocytes and monocytes. Fractions that were 
devoid of granulocytes with a monocyte content of at least 95% of leukocytes were pooled, 
washed with PBS (w/o Ca2+, Mg2+) and resuspended in culture medium. The concentration 
of the suspension was determined with a Sysmex micro-cell counter F-300. 
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1.2. Cultivation of Cells and Cell Lines 
Monocytes were isolated from blood donors 25 to 45 years of age with normal lipid status by 
counterflow elutriation. Cells were cultivated in macrophage serum free medium (SFM) with 
M-CSF for 4 d on plastic dishes (106 cells/ml) to induce phagocytic differentiation as 
described [268]. Incubation with atherogenic LDL (E-LDL, Ox-LDL) for 24 h was as 
previously described [262]. For deloading with HDL3 the medium was removed, cells were 
washed with macrophage SFM and incubated in macrophage SFM with M-CSF 
supplemented with 100 µg HDL3 for 24 h. 
COS-7 cells were obtained from LGC Promochem (Wesel, Germany), all other cell lines 
were obtained from DSMZ (Braunschweig, Germany). Cells were cultivated according to the 
providers’ recommendations in an incubator at 37°C (95 % humidity, 10 % CO2). 
1.3. Incubation of Monocytes with Fatty Acids 
For stimulation of monocytes with long-chain, free PUFA, 4 mM PUFA were complexed to 
BSA by incubation with 6% lipid-free BSA in PBS for 10 min. Complexed PUFA were 
subsequently used for stimulation at the indicated final concentrations. Lipid-free BSA at the 
same concentration was used for control incubations. 
1.4. Phagocytic Activity 
Phagocytic capacity was determined by flow cytometry. HepG2 and COS-7 cells were 
incubated with fluoresbrite yellow green microspheres (0.75 µm, Polysciences Europe 
GmbH) for one, or two, and four h, respectively (pulse). Following two washes with PBS 
fresh medium was added and cells were incubated for additional two h (chase). After 
washing with PBS fluorescence intensity of cells was determined by a FACSCalibur flow 
cytometer (BD Biosciences). 
1.5. Assessment of ApoA-I-mediated Radioactive Lipid Efflux 
Cells were labeled with [3H]choline and [14C]cholesterol (Amersham Pharmacia Biotech) for 
31 hrs, and subsequently incubated in the presence of BSA or BSA plus apoA-I for 17 hrs 
and processed as described previously [269] according to the method of Bligh and Dyer 
[270]. Lipid efflux was calculated by subtracting the radioactivity secreted in the supernatant 
from total radioactivity. Specific lipid efflux was determined as lipid efflux in the presence of 
apoA-I subtracted by the efflux in the presence of a nonspecific acceptor (BSA). 
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1.6. Transfections of Cell Lines 
1.6.1. Knock-down of Expression 
RNA interference is based on the observation that the presence of double stranded (ds)RNA 
in a cell eliminates the expression of a gene having the same sequence, whereas 
expressions of other genes are unaffected. dsRNA is recognized and bound within the cell by 
the Dicer-RDE-1 (RNAi deficient-1) protein complex. This protein complex cleaves long 
dsRNA into 19-22 bp siRNA oligonucleotides. The antisense strand of the siRNA is used by 
an RNA-induced silencing complex (RISC) to guide mRNA cleavage, thus promoting mRNA 
degradation.  
Knock-down of Aldehyde Oxidase 1 (AOX1) expression was achieved by transfection of cells 
with siRNA. The siRNA was designed and supplied by Ambion. A sequence of 19 
nucleotides of AOX1 (EMBL-GenBank, Accession No. NM_001159; bp 312-330; see III.3.3.) 
was targeted. HepG2 cells were seeded in a 12-well plate at a density of 106 cells/well. 24 h 
after seeding AOX1 or non-silencing control siRNA were added using RNAifect (Qiagen) and 
the method was optimized according to the manufacturer’s instructions. Functional studies 
were started 24 h (lipid efflux studies) or 48 h (phagocytic activity) after transfection. 
1.6.2. Recombinant Expression 
COS-7 cells were transfected with the recombinant plasmids containing the complete cDNA 
of TOSO using FuGene 6 (Roche) following the manufacturers instructions and stable cells 
were selected by G418. 
1.7. Luciferase Reporter Assays 
HepG2 or Jurkat cells were transiently transfected with FuGene reagent (Roche) as 
described by the manufacturer. Two µg of the respective reporter gene constructs were 
cotransfected with 1 µg of the pSV-galactosidase vector (Promega). A promoterless pGL3-
basic vector served as control. Cells were lysed in reporter lysis buffer (Promega), and after 
centrifugation, luciferase assay reagent with luciferyl-CoA (Promega) was added to the 
supernatant as recommended by the manufacturer. Luciferase activity was finally determined 
in a LUMAT LB9501 (Berthold). All data were normalized for protein concentrations (BioRad 
protein assay) and -galactosidase activity (Promega -galactosidase enzyme assay). Each 
experiment was repeated three times, and measurements were performed in triplicate. 
Results are expressed as multiples in comparison to promoterless pGL3-basic vector activity. 
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2. Isolation of Lipoproteins 
Lipoproteins and lipoprotein-deficient serum were prepared from human plasma or serum by 
sequential preparative ultracentrifugation in potassium bromide gradients followed by 
extensive dialysis and filter sterilization. All lipoprotein concentrations mentioned are protein 
concentrations determined by Lowry’s method [271]. Lipoprotein fractions were stored at 4°C 
and used within two weeks from end of dialysis. 
2.1. Enzymatic and Oxidative Modifications of LDL 
Enzymatic degradation of native LDL was performed as described previously [260] with the 
following modifications. LDL was diluted to 2 mg/ml in 20 mM 4-(2-hydroxyethyl)-1-piperazine 
ethan-sulfonic acid (HEPES), 150 mM NaCl, 2 mM CaCl2, pH 7.0 and treated with trypsin 
(6.6 mg/ml, Sigma) and cholesterol esterase (40 mg/ml, Roche) for 24 h at 37oC. 
Subsequently, trypsin inhibitor (Sigma) was added and the pH was adjusted to 5.0 by 
morpholinoethane sulfonic acid buffer. Ox-LDL was prepared as recently described [272]. 
During LDL preparation and subsequent modification, general precautions were taken to 
avoid lipopolysaccharide contamination. The latter was excluded by Limulus endotoxin assay 
(Sigma) [273]. 
3. Protein Methods 
3.1. Protein Isolation 
Cells were harvested, washed 3 times with PBS, collected by centrifugation for 7 min. at 
400 g. Afterwards, cells were resuspended in lysis buffer (normally PBS, 1% Triton X-100 
with protease inhibitor (Roche)) and left on ice for 20 min. After an additional incubation for 
15 min at room temperature, cell debris was separated by centrifugation at 14,000g at 4°C 
for 10 min and samples were stored at -20°C until u se. 
3.2. Recombinant Expression and Purification of the ABCA1 C-terminus 
ABCA1 C-terminus was cloned from bp 6,352 to 6,786 (EMBL-GenBank, Accession No. 
AB055982) in fusion with gluthation S-transferase (GST) in pGEX-5X-1, and expressed in  
E. coli BL21-Gold (Stratagene) according to the manufacturer’s instructions (Amersham 
Pharmacia Biotech). The fusion protein was purified with glutathione sepharose 4B beads in 
a batch procedure following manufacturer’s instructions (Amersham Pharmacia Biotech). 
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For expression of ABCA1 with an N-terminal His-tag ABCA1 was cloned in pQE30 (Qiagen) 
and expressed in E. coli as suggested by the manufacturer. The fusion protein was purified 
under denaturating conditions using the Ni-NTA Spin Kit (Qiagen) according to the 
manufacturer’s instructions. 
3.3. Determination of Protein Concentration 
For protein quantification, the bicinchonic acid (BCA) protein assay kit (Pierce) was used. 
The method is based on the reduction of Cu2+-ions to Cu+-ions in alkaline environment 
(Biuret reaction). The Cu+-ions form a complex with BCA, a purpled colored complex with 
peak absorption at 562 nm. The absorption is linear in a range of 20 – 2000 µg/ml and is 
proportional to the protein concentration. 
BCA reagent was freshly prepared by adding 4% CuSO4 to the protein solution at a ratio of 
1:50. 25 µl of the sample or the standard were added to a microtiter plate and mixed with 
200 µl of the prepared BCA solution. After incubation at 37°C for 30 min the extinction was 
measured in an ELISA-reader and the protein concentration was calculated. 
3.4. Pull-down Assays 
In-vitro translation was performed according to the manufacturer’s protocol (Promega). Equal 
amounts of GST or GST-ABCA1 were incubated with the in-vitro translated proteins 
overnight at 4°C while shaking in a total volume of  500 µl of the denoted buffer. The 
reactions were cleaned up with the GST Micro Spin Purification Module (Amersham 
Pharmacia Biotech) following the manufacturer’s instructions. Washing was carried out in the 
same buffer as overnight incubation. Bound proteins were eluted by boiling in Laemmli buffer 
and analyzed by immunoblot. 
3.5. Coimmunoprecipitation 
HepG2 cells were lysed in PBS with protease inhibitor mixture (Roche Molecular 
Biochemicals), 0.5% Triton X-100 as described above (IV.3.1.). Three µg of the supernatant 
were incubated with magnetobeads coupled with Protein-A (Dynal) linked to monoclonal anti-
AOX1 antibody overnight at 4°C while shaking. Washi ng was performed in PBS with 
protease inhibitor mixture (Roche Molecular Biochemicals), and 0.5% Triton X-100. Bound 
proteins were eluted by boiling in Laemmli buffer and analyzed by immunoblot. 
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3.6. SDS-PAGE and Immunoblot 
Proteins are separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis 
(PAGE) according to their size. For gel electrophoresis, pre-cast gradient gels (BioRad) were 
used. Protein samples were diluted in 5x Laemmli dye and incubated at 65°C for 5 min. The 
samples were loaded on the gel and separated in a BioRad apparatus (25 milliampere per 
gel, 90 min at room temperature). 
After electrophoresis, the gel was transferred to a polyvinylidene fluoride fluotrans transfer 
membrane using a Mini Trans-Blot electrophoretic transfer cell (BioRad). The transfer 
conditions were 4°C, 350 milliampere for 1.5 h. 
For the immunoblot of AOX1 in different human tissues, a commercial blot from Imgenex 
(San Diego, CA, USA) was used according to the manufacturer’s instructions. 
After blotting, the membrane was blocked using 5% nonfat dry milk in PBS-Tween 0.1% at 
room temperature for 30 min. Afterwards, primary antibodies were applied for 1 h at room 
temperature or overnight at 4°C. After washing 3 ti mes with PBS-Tween 0.1%, the secondary 
peroxidase-conjugated antibody was diluted 1:5000 and incubated at room temperature for 
1 h. Detection of the immune complexes was carried out with the ECL Western blot detection 
system (Amersham Pharmacia Biotech) according to manufacturer’s instruction. 
4. Nucleic Acid Methods 
4.1. Sequencing 
Cycle sequencing was performed in a Gene Amp PCR System 9600 (Perkin Elmer) using 
the BigDye Terminator Cycle Sequencing Ready Reaction Kit v.1.1 (Applied Biosystems) 
according to the manufacturer’s instructions. 
After purification of the sequencing reaction using Centrisept Spin Colums (Princeton 
Separations) 4 µl of the sample were mixed with 21 µl HighDye Formamid (Applied 
Biosystems) in 96-well plates (Applied Biosystems). Signal detection was carried out on an 
ABI PRISM 3130xl Genetic Analyser equipped with Data Collection Software v3.0 (both 
Applied Biosystems). 
4.2. Polymerase Chain Reaction 
By polymerase chain reaction (PCR), specific nucleotide sequences can in vitro be amplified 
exponentially. The PCR reaction consists of the three steps denaturation (segregation of the 
doublestrands of the template), annealing (hybridization of the specific oligonucleotides to 
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the singlestranded template), and elongation (polymerization, resulting in doublestrands). 
According to the requirements Pwo- or Taq-DNA polymerase were used following the 
manufacturer’s protocols. Pwo-polymerase leads to blunt-end PCR products used for CACC-
cloning (IV.4.9.); Taq-polymerase due to its terminal transferase activity adds a single 
deoxyadenosine to the 3´end of PCR products, making it usable for TA-cloning (IV.4.8.). 
Thermocycling was performed in a Gene Amp PCR System 9600 (Perkin Elmer). Initially the 
template was denatured for 2 min at 95°C. Following  35 cycles of: 
Denaturation:       15 sec, 94 °C 
Annealing:  15-60 sec, 40-70 °C 
Elongation:             30-240 sec, 72 °C 
Elongation was completed by incubation for 7 min at 72°C and the reaction was cooled to 
4°C. Afterwards the whole sample was loaded on an a garose gel and following gel 
electrophoresis (IV.4.3.) the PCR product was purified (IV.4.4.2.). 
4.3. DNA Gel Electrophoresis 
Different length DNA-molecules can be separated in agarose gels according to their mobility 
and the negative total charge of the DNA-double helix. 
The electrophoretic mobility of the DNA is inversely proportional to the logarithm of base 
pairs. Polyacrylamid gels are capable of separating DNA fragments up to 1 kb of size, 
whereas agarose gels separate fragments up to 20 kb. In order to achieve a maximum of 
separation capacity gels are cast in following concentrations: 
 
DNA fragment size < 1 kb               1.5% - 4% gel 
DNA fragment size 1 – 10 kb         0.7% - 1% gel 
DNA fragment size > 10 kb             0.5% gel 
 
The applied voltage varied between 80 – 100 volt. To visualize the DNA in the gel, ethidium 
bromide was incorporated in the gel, and this mutagen substance binds to the DNA double 
helix, staining it with an orange colored fluorescent light when observed under UV (365 nm). 
The gel was photographed with a MP-4 camera (Polaroid) or scanned with a Lumi-imager 
(Boehringer-Mannheim). 
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4.4. DNA-Purification 
4.4.1. Plasmid Purification 
For plasmid purification, the QIAprep Spin Miniprep Kit (Qiagen) was used due to the 
manufacturer’s instructions. Shortly overnight cultures of E. coli were collected, and 
resuspended in resuspension buffer. After lysis and neutralization, the debris including the 
genomic DNA was separated and the supernatant was loaded on columns containing a 
silica-matrix. At high salt concentrations DNA binds to this matrix and is after washing eluted 
in water. 
4.4.2. From Agarose Gels and Solutions 
DNA-fragments were purified from agarose gels or solution using the respective Qiagen Kit 
(QIAquick Gel Extraction Kit or PCR Purification Kit) according to the manufacturer’s 
instructions. In brief DNA is mixed with the respective binding buffer (Gel Extraction: QG; 
PCR Purification: PB), bound to a silica-matrix at a high salt concentration and after washing 
then eluted in water (30 – 50 µl). 
4.5. Enzymatic cleavage  
The restriction digest can either be performed analytically to analyze the DNA or preparative 
to prepare DNA for further cloning. The incubation is performed with buffers obtained from 
Roche (10x buffers: A, B, L, M, H) for up to 2 h at the according temperature in a thermo 
block. 
For the analytical approach, one µg DNA was digested with 10 units of restriction enzyme in 
20 µl total volume. For preparative digestions the following mixture was used: 
Vector DNA    50 ng 
Restriktionsendonuclease  1.0 µl (3 U) 
Buffer      0.7 µl 
H2O     ad 7.0 µl 
Samples were incubated for 10 min at 37°C and after wards the reaction was stopped by 
incubating for 15 min at 65°C. 
 
 
 
IV. Methods 
59 
4.6. Dephosphorylation of Plasmid-DNA 
To prevent re-ligation of cohesive ends dephosphorylation was carried out. Shrimp alcaline 
phosphatase (SAP) was added to remove the 5´-phosphate. 
To the reaction prepared for digestion (IV.4.5.) 0.9 µl 10x dephosphorylationbuffer and 1 µl (1 
U) SAP were added. The reaction was incubated for 10 min at 37°C, followed by heat–
inactivation of the SAP for 15 min at 65 °C. The sa mple can directly be used for ligation. 
4.7. Ligation 
In the presence of ATP and Mg2+-ions T4-DNA-ligase is able to covalently join blunt- or 
cohesive ends by a phosphodiester bridge between a 5´phosphate and a 3´OH group. For 
ligation the dephosphorylation reaction (IV.4.6.) was supplemented as follows: 
 Insert-DNA    150 ng 
 T4 DNA ligase    1.0 µl 
 5x T4 DNA ligase-buffer   4.0 µl 
 H2O     variable 
 total     20 µL 
The mixture was incubated overnight at 14°C or 25 m in at room temperature and 
subsequently used for transformation of E. coli. 
4.8. TA-Cloning 
TA cloning is based on the terminal transferase activity of different thermophile polymerases 
(e.g. Taq-polymerase). Due to this activity during the PCR reaction, an additional, 
overhanging adenosine is added to the 3´ ends of the product. TopoTA-vectors (pCR2.1-
TOPO, pCRII-TOPO) are linearized and posses a 3´overhangig thymine allowing direct 
ligation of the PCR product. In addition, the vector binds topoisomerase I, an enzyme 
keeping the vector in its relaxed state.  
For the ligation 4 µl purified PCR-product (10-100 ng), 1 µl salt-solution and 1 µl TopoTA 
vector were mixed and incubated for 15 min at room temperature. The mixture afterwards is 
placed on ice and used for the transformation of E. coli. 
4.9. CACC-Cloning 
For the generation of expression constructs for eukaryotic cells or in vitro translation 
pcDNA3.1D/V5-His-Topo vector was chosen. This vector allows the direct ligation of blunt-
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ended PCR-products. Oligonucleotides were designed to amplify the complete coding 
sequence without the stop-codon. 5´before the ATG CACC was added for directional cloning 
of the fragment. For the ligation 4 µl purified PCR-product (10-100 ng), 1 µl salt-solution and 
1 µl TopoD vector were mixed and incubated for 15 min at room temperature. The mixture 
afterwards is placed on ice and used for the transformation of E. coli. 
4.10. Transformation and Cultivation of E. coli Cells 
50 µl of competent cells were thawed on ice, mixed by pipetting with the ligation mixture (5 – 
20 µl) and placed on ice for 15 min. In case of ampicillin selection cells were than directly 
plated on pre-warmed LB-selection plates (37°C) and  placed overnight in an incubator at 
37°C. 
E. coli were cultivated either on agar plates or in liquid medium over night at 37°C in an 
incubator. Cultures were obtained by inoculating a single colony or suspension of bacteria 
from a glycerol culture into LB-medium. Liquid cultures are incubated in a shaker at 37°C and 
240 rpm over night. It is necessary to add an appropriate antibiotic (Ampicillin) to select a 
specific plasmid. E. coli cultures were permanently stored in glycerol, to achieve this 500 µl 
liquid culture was mixed with 500 µl sterile glycerol (30%) in a cryotube and were shock 
frozen in liquid nitrogen and stored at -80°C. 
4.11. RNA-Isolation 
Harvesting of cells and RNA extraction was carried out according to the manufacturer’s 
instructions using the TRIzol reagent or the RNeasy Mini Kit (Qiagen, Hilden, Germany). For 
Northern blot, the RNA was isolated by the guanidine isothiocyanate-cesium chloride 
technique. 
Purity and integrity of the RNA was assessed on the Agilent 2100 Bioanalyzer with the RNA 
6000 Nano LabChip reagent set (Agilent Technologies). The RNA was quantified 
spectrophotometrically at 260 nm and then stored at -80°C. The concentration is calculated 
according to the following formula: 
C µg/ml = E260 * k / d  
k= 40 for RNA, k = 20 for ss DNA, k = 50 for ds DNA 
d = Path length of cuvette [cm] 
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4.12. cDNA Synthesis 
First strand cDNA synthesis was performed with the Reverse Transcription System from 
Promega. For 2 µg of total RNA (final RNA concentration: 50 ng/µl) the following reaction 
mixture was prepared: 
MgCl2      8 µl 
RT-buffer     4 µl 
dNTP mix     4 µl 
RNAsin     1 µl 
AMV reverse transcriptase   1.5 µl 
Random Hexamers    4 µl 
RNA + H2O     17.5 µl 
The mix was added and the cup was incubated at 42°C  for 60 min. After heat-inactivation at 
95°C, the reaction was placed on ice and diluted 1: 5 (final concentration: 10 ng/µl). For 
longtime storage, samples were put to -20°C. 
4.13. Northern Blot Analysis 
10 µg of total RNA were separated through a 1.2% agarose gel containing 6% formaldehyde 
after the secondary structure of RNA has been denaturated at 56°C; the formaldehyde keeps 
the RNA from renaturating. Following blot onto nylon membranes and crosslinking by UV-
irradiation (Stratalinker model 1800, Stratagene), the membranes were hybridized with a 
cDNA probe amplified with TOSO specific primers. The blots were stripped and subsequently 
hybridized with a human GAPDH probe (Clontech). The probes were radiolabeled with [α-
32P]dCTP using the Oligolabeling kit from Amersham Pharmacia. Hybridization and washing 
conditions were performed as recommended by the manufacturer of the membrane. 
4.14. Gene Chip Expression Analysis 
RNA was isolated from 5 d M-CSF cultivated macrophages and macrophages incubated for 
4 d with M-CSF and subsequently with 40 µg/ml E-LDL for 24 h. The HgU133A chips from 
Affymetrix were hybridized starting with 10 µg of total RNA according to the instructions of 
the manufacturer. Data analysis was performed using the Affymetrix Microarray Suite 
Version 5.0. 
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4.15. Real-Time PCR 
In conventional PCR, quantification either requires multiple samples or several aliquots must 
be taken from a single sample at certain intervals. The accuracy of this method is limited 
because the amplification product has to be detected by ethidium bromide staining, a 
procedure which lacks sensitivity and specificity and is time consuming. These drawbacks 
can be eliminated by using a novel method, which uses online-detection of fluorescence as a 
marker for the ongoing PCR. Two different methods are used in Real-Time-PCR, both of 
which can be practiced either on the LightCycler system (Roche) or on the ABI Prism 7900 
HT Sequence Detection System (Perkin Elmer). One method is based on the fluorescent dye 
SYBR-Green I, that binds to the minor groove of the DNA double helix. In solution, the 
unbound dye exhibits very little fluorescence, this is greatly enhanced upon DNA-binding. 
The second method is based on hydrolysis (TaqMan) probes and is the method of choice at 
our institute. 
4.15.1. Gene Expression Monitoring with Hydrolysis Probes 
The hybridization probe format is used for DNA detection and quantification and provides a 
maximal specificity for product identification. In addition to the reaction components used for 
conventional PCR, a specially designed, sequence specific oligonucleotide is applied in this 
detection method. This oligonucleotide is called TaqMan probe, it is labeled with two 
fluorescent dyes: one is the emitting fluorescent dye (FAM, VIC) and the other is either a 
fluorescent (TAMRA) or a non-fluorescent quencher. As long as the two dyes are in close 
proximity, the light emitted from the first dye, is quenched by the other, but as elongation 
occurs, the probe is hydrolyzed and the two dyes are separated from each other allowing a 
fluorescence emission. The increasing amount of measured fluorescence is proportional to 
the increasing amount of DNA generated during the ongoing PCR process. 
Per well a reaction is composed of: 
Template cDNA 25 ng 
TaqMan Mastermix 5 µl 
Assay on Demand 0.5 µl 
H2O, nuclease-free 2.5 µl 
Reaction conditions are initial denaturation for 10 min at 95°C, after that 15 sec 95°C and  
1 min 60°C for 45 cycles. 
Relative quantification was carried out as described earlier [12]. 
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4.15.2. SNP Analyses with Hydrolysis Probes 
This is a common approach to detect SNP following the principle mentioned above 
(IV.4.15.1.). In contrast to gene expression monitoring, for this application two differently 
labeled (e.g. one VIC and one FAM) TaqMan probes are used, one for each allele. 
Hydrolysis of the probe by the 5'-3' endonuclease reaction is greatly impaired when it 
mismatches its target sequence by even a single nucleotide. According to the resulting 
fluorescence the analyzed DNA can be discriminated in homozygous (for allele A or B) and 
heterozygous. 
5. The Yeast Two-Hybrid System 
The MATCHMAKER Two-Hybrid System is a GAL4-based system providing a transcriptional 
assay for the identification of protein interaction in vivo in yeast. A short overview is shown in 
Figure 27. In principle a bait gene is expressed in fusion with the GAL4 DNA-binding domain 
(BD), while the library-inserts are expressed in fusion with the GAL4 activation domain (AD) 
[274; 275]. In case of an interaction between bait and library fusion proteins BD and AD are 
brought in proximity, thereby activating transcription of the reporter genes and enabling 
growth on selection media. 
 
Figure 27. Principle of the yeast two-hydrid screen. Details are found in the text. 
 
Screenings were performed according to the manufacturer’s instructions and as previously 
described [56]. 
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6. Flow Cytometry 
The cellular light-scatter signals and three fluorescence signals of 20,000 cells per sample 
were analyzed in list mode at a channel resolution of 1024 with forward scatter as the trigger 
parameter on FACSCalibur flow cytometer (Becton Dickinson). The photomultiplier gains 
were calibrated with polychromatic fluorescent reference beads (Polysciences Europe 
GmbH). Compensation was adjusted with FITC- and R-PE–coated microbeads (Becton 
Dickinson). Gating of cells was based on forward- and side-scatter dot plots. Mean 
fluorescence values were corrected for background by subtraction of cellular 
autofluorescence in case of fluorochrome-conjugated primary antibodies or fluorescent 
beads and in case of fluorchrome-conjugated secondary antibodies by subtraction of the 
mean fluorescence of cells that were incubated with the secondary antibody, but without the 
primary antibody. For analysis of the list files the CellQuest 2.0 software (Becton Dickinson) 
was used on a Macintosh G3. 
7. Immunohistochemistry 
Rudolph Jung performed immunohistochemistry (IHC) and Prof. Dr. Arndt Hartmann 
evaluated the slides (both from the Institute of Pathology, University of Regensburg). 
Immunohistochemical studies for the expression of ABCA1 and AOX1 utilized an avidin-
biotin peroxidase method with a 3,3‘-diaminobenzidine (DAB) chromatogen. Four µm 
sections were cut from formalin-fixed and paraffin wax-embedded tissues. After 
deparaffinization for 10 min in xylol, tissue sections were rehydrated in descencing ethanol 
series. After antigen retrieval (microwave oven for 10 min at 250 W in citrate buffer (pH 7.1)) 
IHC was carried out in a NEXES immunostainer (Ventana, Tucson, AZ) following 
manufacturer’s instructions. The following primary antibodies were used: anti-ABCA1 
(dilution 1:10), and anti-AOX1 (dilution 1:50). For target proteins the ChemMate detection kit 
(DAKO, Glostrup, Denmark) was used, and finally the slides were counterstained with 
haematoxylin for 1 min. Incubation with the primary and secondary antibody was performed 
according to the manufacturer’s protocol. Normal hepatocytes were chosen as internal 
positive control for ABCA1 and AOX1 IHC. A surgical pathologist (A.H.) performed a blinded 
evaluation of the slides without knowledge of clinical data. Causes of non-interpretable 
results included lack of tumor tissue and presence of necrosis or crush artefact. Cytoplasmic 
ABCA1 and AOX1 staining intensity was estimated using a semiquantitative four-step 
scoring system (0-3+): 0, negative; 1+, weak positive; 2+, moderate positive; 3+, strong 
positive. 
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7.1. Tissue Microarray 
ABCA1 and AOX1 protein expression in hepatocellular and renal carcinomas was assessed 
using tissue microarrays (TMAs). Commercially available liver (LV801) and kidney (KD801) 
tumor TMAs were obtained from BioCat (Heidelberg, Germany). Additionally, a 
hepatocellular carcinoma (HCC) TMA from the Institute of Pathology, University of Basel, 
Switzerland and a renal tumor TMA from the Department of Urology, University of 
Regensburg were used. The hepatocellular TMA contained a consecutive series of 233 non-
selected, formalin-fixed, paraffin-embedded primary HCC, 119 specimens with liver cirrhosis, 
and 18 normal liver samples. The kidney TMA contained a consecutive series of 90 non-
selected, formalin-fixed, paraffin-embedded primary renal cell carcinomas (RCC) (stage I - 
IV) and 16 oncocytomas. Before construction of the TMAs, an experienced surgical 
pathologist evaluated haematoxilin-eosin-stained slides of all specimens to identify 
representative areas. In the process of histological review all carcinomas were graded using 
a three-tired nuclear grading system (G1-3) according to WHO criteria (2000).  
8. Statistical Analysis 
Data are given as mean value ± standard deviation. Significance was calculated using two-
tailed Students t-test and p < 0.05 was regarded as significant. 
8.1. Tissue Microarray Data 
Dr. Peter J. Wild performed analyses of TMA data (from the Institute of Pathology, University 
Hospital Zürich, Switzerland). 
Statistical analyses were performed completed using SPSS version 13.0 (SPSS, Chicago, IL, 
USA). Differences were considered statistically significant when P values were <0.05. 
Contingency table analysis and two-sided Fisher’s exact tests were used to study the 
statistical association between clinicopathologic and immunohistochemical parameters. 
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V. RESULTS 
The identification and characterization of proteins involved in lipid metabolism is in the main 
focus of the institute. Two different approaches were chosen, the first was to identify ABCA1 
or ABCA7 related proteins by yeast two-hybrid screen, the other was to search for genes that 
reveal “ABCA1-like” regulation in response to lipid loading.  
1. Constructs for the Yeast Two-Hybrid screens 
For the yeast two-hybrid approaches five bait constructs were created. The denoted regions 
of ABCA1, ABCA7, TAX1BP3 and syntaxin 13 were cloned in pAS2-1 and the indicated 
Matchmaker Libraries (Clontech) were screened for putative interaction partners (Table 6). 
 
Table 6. Bait constructs and Libraries used in this work for the yeast two-hybrid screens. 
Gene Construct Region Amino Acids Accession No.§ Library 
ABCA1 pAS-A1-CT C-terminus (144 aa) 2118-2261 NP_005493 Placenta 
ABCA7 pAS-A7-NT N-terminus (144 aa) 1-144 NP_061985 Bone marrow 
ABCA7 pAS-A7-CT C-terminus* (144 aa) 1865-2008 
2003-2146 
NP_150651 
NP_061985 
Bone marrow 
Spleen 
TAX1BP3 pAS-TAX1BP3 full-length (124 aa) 1-124 NP_055419 Placenta 
Syntaxin 13 pAS-STX13 full-length (276 aa) 1-276 NP_803173 Placenta 
§
 EMBL-GenBank 
* The C-terminal 144 amino acids are identical in both isoforms. 
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2. ABCA1 C-terminal Interactive Proteins 
In order to identify new ABCA1 C-terminus interacting proteins a yeast two-hybrid screen 
was performed. Furthermore the interaction of AOX1 and ABCA1 was confirmed and 
characterized in more detail. 
2.1. ABCA1 Interacting PDZ Proteins 
Screening with pAS-A1-CT (Table 6) identified 5 putative ABCA1 C-terminus interacting PDZ 
proteins. Those are shown together with the structure of SNTB2 in Figure 28. SNTB2 is also 
a PDZ protein shown to bind the ABCA1 C-terminus in our laboratory recently and therefore 
is also indicated here. 
 
Short Full name OMIM/Accession No.§ 
GIPC1 GAIP C-terminus-interacting protein1 *605072 
TAX1BP3 Tax1 (human T-cell leukemia virus type I) binding protein 3 NM_ 014604 
SDCBP Syndecan-binding protein *602217 
Scribble Scribble, drosophila, homolog of *607733 
MAGI3 Membrane associated guanylate kinase, WW and PDZ domain containing 3 NM_020965 (variant 1) 
NM_152900 (variant 2) 
§
 EMBL-GenBank 
 
 
Figure 28. ABCA1 C-terminus interacting PDZ candidates. Upper panel: names and OMIM entries 
of the PDZ proteins found in the yeast two-hybrid screen. Lower panel: Structure of the identified PDZ 
proteins together with SNTB2. MAGI3 variant 1 and variant 2 differ by a region of 25 amino acids 
located between the WW-domain and PDZ domain 1, that is absent in variant 2. Grey bars indicate 
the regions found in the yeast two-hybrid screen. aa, amino acid; COOH, C-terminus; GH, GIPC1 
homology domain; LAPSD, LRR and PDZ-specific domain; LRR, Leucin-rich Repeat domain; NH2, N-
terminus; PDZ, PSD95/Discs-large/ZO-1 domain; PH, pleckstrin homology domain; SU, syntrophin-
unique domain. 
 
The first aim was to confirm the interaction of ABCA1 protein with these candidates. 
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2.1.1. Verification of the Interaction of PDZ Proteins with ABCA1 by                
Co-Transformation in Yeast 
To reconfirm the binding of the ABCA1 C-terminus to the putative PDZ-interaction partners in 
yeast a yeast cotransformation was performed. The complete coding sequence of the 
candidate genes was cloned in a yeast two-hybrid prey vector (GIPC1 in pAS2-1, all other in 
pGADT7) to get fusion proteins with the activation domain of the GAL4 transcription factor, 
suitable for a cotransformation according to the yeast two-hybrid principle. The PDZ protein 
GIPC2 initially identified as putative ABCA7 interaction partner was also included. Besides, 
different ABCA1-GAL4-BD constructs were created to proof the specific PDZ interaction, 
which is based on an intact PDZ binding sequence of ABCA1 (ESYV, class I, consensus: X-
S/T-X-V/L; X: any amino acid, S: serine, T: threonine, V: valine, L: leuzine) and a free C-
terminus. 
1  wt       EKVKESYV Stop 
2  deletion of the stop codon    EKVKESYVGSVDLQPS Stop 
3  deletion of the PDZ binding sequence   EKVK Stop 
4  mutation of the PDZ binding sequence  EKVKERYG Stop 
GAL4-BD-construct 1 is wild type, and should enable yeast to grow on plates selecting on 
interaction when cotransformed with the candidate genes. In the other three constructs the 
PDZ binding sequence was modified by attaching additional amino acids (construct 2), 
deletion (construct 3) or mutation of the key amino acids (construct 4). All modifications 
should abolish interaction thereby preventing growth on plates selecting for interaction. 
Figure 29 shows that, as expected for a specific PDZ interaction, only cotransformants 
containing construct 1 and one of the candidate prey constructs are able to grow under 
conditions selecting for interaction. 
 
 
Figure 29. Verification of the specific PDZ interaction of ABCA1 C-terminus and PDZ 
candidates. Left: Selection medium lacking trp and leu, allowing growth of yeast containing prey and 
bait construct. Right: Selection medium lacking trp, leu and his, selecting for interaction of prey and 
bait construct. 
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2.1.2. Verification of the Interaction In Vitro 
To validate the interaction of ABCA1 with PDZ proteins by coimmunoprecipitations 
expression-constructs were generated. ABCA1 C-terminus was cloned in the pGEX5X-1 
vector, and expressed in E. coli as an N-terminal GST fusion protein. The N-terminal fusion 
was important to prevent blocking of the C-terminal PDZ binding sequence of ABCA1. The 
coding sequence of the candidate genes was cloned in pcDNA3.1D/V5-His-TOPO vector 
and used for in vitro translations, resulting in fusion proteins with C-terminal V5-tags. GST-
ABCA1 and GST (control) were purified using the GST-epitope and incubated together with 
the products from the in vitro translation using different incubation conditions (PBS, PBS 
containing 0.1, 0.5, 1 % Triton X-100 or NP40). After immunoblot, detection was performed 
with a monoclonal anti-V5 antibody. This confirmed the specific binding of TAX1BP3 (in PBS) 
and GIPC1 (in PBS containing 1% Triton X-100) with the ABCA1 C-terminus (Fig. 30 A). 
To proof this finding with full-length ABCA1 HepG2 lysate (PBS containing 0.5 % Triton X-
100) was incubated with in vitro translated, V5-tagged TAX1BP3 and GIPC1, respectively, 
and precipitated with a mouse monoclonal anti-V5-antibody (control mouse monoclonal anti-
MYC-antibody). Detection was done with the monoclonal anti-ABCA1 antibody. Both 
TAX1BP3 and GIPC1, specifically bind ABCA1 under this conditions (Fig. 30 B). 
 
Figure 30. Specific binding of TAX1BP3 and GIPC1 to the ABCA1 C-terminus. (A) In vitro 
translated TAX1BP3 and GIPC1, respectively, was incubated with GST-ABCA1-C-terminus or GST 
alone. (B) HepG2 lysate was incubated with in vitro translated, V5-tagged TAX1BP3 and GIPC1, 
respectively, and precipitated with a mouse monoclonal anti-V5-antibody. 
 
To further confirm the interaction of ABCA1 with MAGI3, Scribble and TAX1BP3, and to 
identify new ABCA1 interacting PDZ proteins a PDZ-array was screened using HIS-tagged 
ABCA1 C-terminus as probe. ABCA1 C-terminus was cloned in the pQE30 vector and 
expressed in E. coli, leading to a fusion protein with an N-terminal HIS-tag. The PDZ-array 
consists of single PDZ domains, enabling to specify the interaction of ABCA1 and PDZ 
domain proteins containing more than one PDZ domain in more detail. As shown in 
Figure 31 ABCA1 C-terminus strongly binds to the PDZ domain of TAX1BP3, PDZ domain 2 
of MAGI3, PDZ domain 1 of Scribble and in addition to PDZ domain 3 of MAGI2. This further 
affirmed the direct interaction of ABCA1 with TAX1BP3, MAGI3 and Scribble and identified 
MAGI2 as putative new ABCA1 interaction partner. 
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Figure 31. Screening of a PDZ-array with 
the His-tagged C-terminal 144 amino 
acids of ABCA1. 
 
 
2.1.3. Co-Expression Analysis of ABCA1 and Interacting Proteins 
To get more insight in the role of the PDZ-interaction with ABCA1 the co-expression of the 
putative ABCA1-interacting PDZ proteins with ABCA1 and the already published interaction 
partners SNTA1, SNTB1, and SNTB2 was analyzed in different tissues by TaqMan real-time 
RT-PCR. The results are presented in a linear scale, reaching from 1 (weak expression) to 5 
(strong expression) dots (Table 7).  
 
Table 7. mRNA Expression of ABCA1 and selected PDZ proteins in human tissues. 
Tissue ABCA1 SNTA1 SNTB1 SNTB2 GIPC1 GIPC2 TAX1BP3 SDCBP MAGI3 Scribble 
Brain, whole ● ●●●●● ● ● ●● ● ●● ●●● ●●● ●● 
Brain, cerebellum ● ●● ● ● ●● ● ● ●● ● ●● 
Spinal Cord ●●●● ●●● ● ● ●●● ● ●●●● ●●●● ●●●● ●●● 
Heart ● ●●●● ● ● ● ● ●● ● ● ● 
Skeletal Muscle ● ●●●● ● ● ● ● ● ● ● ● 
Lung ●●●● ● ●● ● ● ●● ●●●● ● ● ●● 
Kidney ●●●● ●●●● ●● ●●●●● ●● ●●●●●* ● ●●●● ●●●●● ●● 
Liver ●● ● ● ● ● ● ● ● ● ● 
Stomach ●● ● ●● ● ●● ● ●●●●● ●●● ●●● ●● 
Small Intestine ●● ● ● ● ●● ●●●●● ●●●● ●● ●●● ●● 
Colon ●● ● ● ● ●●●●● ●● ●●●●● ● ●● ●●●●● 
Salivary Gland ● ● ●● ● ● ● ● ● ● ● 
Thyroid ●●●  ●●● ●●●●● ●●● ●● ● ●● ●●● ●●●●● ● 
Adrenal Gland ●●●●● ● ●●● ● ● ●● ●●● ● ● ● 
Testis ●● ●● ● ●●●●● ● ● ● ●● ●●● ●● 
Prostate ●● ● ● ●●● ● ● ● ● ● ● 
Uterus ●●●  ● ● ●●● ● ● ● ●●● ●● ●● 
Placenta ●●●● ● ● ● ● ● ●●● ●●●●● ●● ●● 
Thymus ●●● ● ● ●● ● ● ●● ● ● ● 
Spleen ●●● ● ● ● ● ●●● ●● ●●● ● ● 
Bone Marrow ● ● ●●● ● ● ● ● ●●●●● ● ● 
Experiments were performed in triplicate and results were converted to a linear scale (●●●●●: 81-
100% of highest expression; ●●●●: 61-80%; ●●●: 41-60%; ●●: 21-40%; ●:>0-20%;* very high 
expression). Tissues with the highest expression are highlighted (yellow). 
 
ABCA1, SNTA1, SNTB2, GIPC2, SDCBP and MAGI3 are highly expressed in kidney; 
ABCA1, TAX1BP3, SDCBP, and MAGI3 are highly expressed in spinal cord. In general, the 
proteins display a different tissue expression, though mRNA expression is not necessarily 
identical to protein expression. 
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2.2. Verification and Characterization of the Interaction of AOX1 and 
ABCA1 
2.2.1. AOX1 is an ABCA1 Interacting Protein 
In a previous yeast two-hybrid screen of a human liver library fourteen AOX1 clones 
(common region: amino acids 972 to 1338 (EMBL-GenBank, Accession No. NP_001150)) 
were found to interact with the ABCA1 C-terminus [56]. 
The interaction of AOX1 with ABCA1 was confirmed by a pull-down assay using a 
recombinant GST-fusion protein of the ABCA1-C-terminus (GST-ABCA1) and an in vitro 
translated human AOX1-fragment (amino acids 972 - 1338) found in the yeast two-hybrid 
screen. Equal amounts of purified GST-ABCA1 protein or GST alone were immobilized on 
glutathione sepharose beads and incubated with HA-tagged AOX1. Binding of AOX1 was 
investigated by immunoblot using a monoclonal anti-HA-Tag antibody. As shown in 
Figure 32A GST-ABCA1 binds significant amounts of AOX1, in contrast to GST alone. This 
indicates a direct interaction of ABCA1 and AOX1 in vitro. 
 
Figure 32. Confirmation of the interaction of 
AOX1 with ABCA1 and expression of AOX1 in 
human cell lines. (A) Interaction of AOX1 and 
ABCA1 demonstrated by pull-down assay. In vitro 
translated AOX1 fragment (aa 972-1338) with an N-
terminal HA-Tag was precipitated by ABCA1 C-
terminus with an N-terminal GST fusion or GST 
alone. Precipitates were analyzed on immunoblots 
using an anti-HA antibody. (B) Immunoblot showing 
the abundance of AOX1 in different human cell lines. 
(C) Interaction of AOX1 with ABCA1 demonstrated 
by coimmunoprecipitation. AOX1 antibody was 
linked to magnetic beads and incubated with lysate 
from HepG2 cells. Precipitates were analyzed on 
immunoblots for AOX1 and ABCA1 using the 
respective antibodies. 
 
 
Different human adenocarcinoma cell lines (MCF-7 breast, PC3 lung, CaCo-2 colon, HT-29 
colon), carcinoma cells (T84 colorectal, HepG2 hepatocellular, HeLa cervix) together with the 
placental choriocarcinoma BeWo cell line were analyzed by immunoblot for the expression of 
AOX1. Only HepG2 cells showed clearly detectable levels of AOX1 proteins (Fig. 32 B), and 
therefore HepG2 cells were chosen for further analysis of the AOX1/ABCA1 interaction. 
ABCA1 could be precipitated from HepG2 cell lysates using a monoclonal anti-AOX1-
antibody, indicating that ABCA1 also interacts with AOX1 in vivo (Fig. 32 C). 
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2.2.2. Knock-down of AOX1 Expression by siRNA Reduces ABCA1-related 
Cellular Functions 
The physiological role of the AOX1-ABCA1 interaction was further elucidated in HepG2 cells 
by an AOX1 siRNA approach. Indeed, AOX1 siRNA, but not the non-silencing RNA, 
significantly decreased AOX1 mRNA and protein levels at 100 nM (Fig. 33 A and B). Higher 
concentrations of siRNA (up to 300 nM) resulted in no further decrease of protein (data not 
shown). The decrease of AOX1 protein was detectable between 24 and 72 hrs after siRNA 
transfection by immunoblots. ABCA1 mRNA and protein levels were unaffected in response 
to AOX1 siRNA treatment, indicating that knock-down of AOX1 does not affect ABCA1 
mRNA or protein abundance (Fig. 33 A and B). 
 
Figure 33. Effect of AOX1 siRNA on AOX1 and ABCA1 mRNA and protein level. (A) Immunoblot 
showing the abundance of AOX1 and ABCA1 in HepG2 cells treated with AOX1- or non silencing 
control-siRNA. Lysates were analyzed by immunoblot for AOX1 and ABCA1 using the respective 
antibodies. β-Actin is shown as loading control. (B) mRNA expression of AOX1 and ABCA1 in HepG2 
cells treated with AOX1- or non silencing control-siRNA. Expression was analyzed using TaqMan real-
time RT-PCR. Compared to control AOX1 siRNA reduced AOX1 mRNA by 50 ± 10% while ABCA1 
levels were not changed. 
 
Regarding the crucial role that ABCA1 plays in apoA-I-dependent cellular 
cholinephospholipid- and cholesterol-efflux, the effect of AOX1 knock-down on lipid efflux 
was determined. HepG2 cells treated with AOX1 siRNA showed a significantly reduced efflux 
for cholinephospholipids (66 ± 27 %) and cholesterol (51 ± 31 %) as compared to controls 
(Fig. 34 A). These results indicate that AOX1 not only interacts with ABCA1 but also 
enhances the functional activity of ABCA1 by a yet unknown mechanism. 
Recent findings linked ABCA1 function to the phagocytic compartment [64] and hepatocytes 
have been described to be able to engulf apoptotic bodies [276]. Therefore, we analyzed the 
effect of AOX1 knock-down on phagocytic activity of HepG2 cells. Cells treated with AOX1 
siRNA show enhanced uptake of fluorescence-labeled phagobeads (50 ± 6 %, Fig. 34 B), as 
compared to cells treated with non silencing siRNA. These data further emphasize the 
influence of AOX1 on ABCA1 function. 
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Figure 34. Analysis of lipid efflux and phagocytic activity in HepG2 cells treated with AOX1 or 
non-silencing control siRNA. Experiments were performed three times in triplicate and cells treated 
with non-silencing siRNA were set to 100%. (A) apoA-I-specific cholinephospholipid- and cholesterol-
efflux. Bars represent non-silencing siRNA treated cells (grey) and AOX1 siRNA treated cells (light 
gray). (B) Phagocytic activity. Cells were loaded with fluoresbrite yellow green microspheres and 
analyzed by flow cytometry. ** p < 0.001; * p< 0.01. 
2.2.3. Expression pattern of AOX1 in Human Tissues 
As a next step, the mRNA expression of AOX1 in different human tissue samples was 
analyzed. AOX1 mRNA was significantly expressed in liver, kidney, testis, ovary, and adrenal 
gland. All other tissues analyzed showed relative low AOX1 mRNA levels when compared to 
adrenal gland (Table 8). 
 
Table 8. Relative mRNA expression of AOX1 and ABCA1 in human tissues. 
Tissue ABCA1 AOX1 
Brain, whole ● ● 
Brain, cerebellum ● ● 
Spinal Cord ●●●● ● 
Heart ● ● 
Skeletal Muscle ● ● 
Lung ●●●● ● 
Kidney ●●●● ●●● 
Liver ●● ●● 
Stomach ●● ● 
Small Intestine ●● ● 
Colon ●● ● 
Salivary Gland ● ● 
Thyroid ●●● ● 
Pancreas ● ● 
Adrenal Gland ●●●●● ●●●●● 
Testis ●● ●● 
Ovary ●● ●● 
Prostate ●● ● 
Mammary ● ● 
Uterus ●●● ● 
Placenta ●●●● ● 
Thymus ●●● ● 
Spleen ●●● ● 
Bone marrow ● ● 
 
Experiments were performed in triplicate and results were converted to a linear scale (●●●●●: 81-
100% of highest expression; ●●●●: 61-80%; ●●●: 41-60%; ●●: 21-40%; ●:>0-20%). Tissues with the 
highest expression are highlighted (yellow). 
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AOX1 protein was also determined in different human tissues and the highest expression 
was found in the liver, followed by kidney, ovary and testis. Weak expression was detected in 
the heart, lung, brain, stomach and spleen, while no AOX1 protein could be observed in 
skeletal muscle and small intestine (Fig. 35). 
 
 
 
 
Figure 35. Immunoblot showing the abundance of 
AOX1 in different human tissues. Two exposure 
times (10 sec and 5 min) are shown because of the 
big difference of AOX1 expression in different tissues. 
 
 
 
 
In order to assess the cellular distribution of AOX1 and ABCA1 proteins, 
immunohistochemistry for both proteins was performed on human tissue sections from 
organs with the highest AOX1 expression as detected by immunoblots. This work was 
performed by Rudolph Jung and evaluated by Prof. Dr. Arndt Hartmann from the Institute of 
Pathology, University of Regensburg. ABCA1 expression showed a broad cellular distribution 
in liver, kidney, adrenal, testicular and ovarian tissues. Expression of AOX1 was confined to 
hepatocytes, proximal tubular epithelial cells of the kidney, cortical but not medullary cells of 
the adrenal gland, testicular Leydig cells, and theca externa cells in ovaries (Fig. 36). 
2.2.4. In Silico Promoter Analysis of AOX1 
To gain more insight in the regulation of AOX1 an in silico promoter analysis was performed. 
The genomic regions 773 bp upstream of the translation start of human, chimpanzee, and 
rhesus monkey was compared using Transfac (http://www.biobase.de/cgi-
bin/biobase/transfac) and Genomatix MatInspector (http://www.genomatix.de). Specific 
transcription factors found in all three species with both tools are shown in Figure 37. 
 
Figure 37. Putative transcription factors influencing AOX1 transcription. TFs are shown together 
with their localization, sequence and similarity scores. 
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Figure 36. Immunohistochemistry of AOX1 and ABCA1 in different human tissues. 
Immunohistochemical analysis showed that AOX1 and ABCA1 are coexpressed in hepatocytes, 
kidney proximal tubules, adrenal gland cortical cells, and Leydig cells in testis. ABCA1 and AOX1 
were stained utilized an avidin-biotin peroxidase method with a DAB chromatogen. Nuclei were 
counterstained with haematoxylin. Magnification 100 fold. 
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2.2.5. Analyses of ABCA1 and AOX1 in Tissue Microarrays 
In order to elucidate in more detail the potential role of the AOX1/ABCA1 interaction we 
analyzed the protein expression of both genes by immunohistochemistry in tumors of kidney 
(RCC), liver (HCC), and testicular Leydig cells (Leydig cell tumor, LCT). Staining was 
performed by Rudolph Jung and Prof. Dr. Arndt Hartmann evaluated the results (both from 
the Institute of Pathology, University of Regensburg). Statistical analysis of the data was 
performed by Dr. Peter J. Wild (Institute of Pathology, University Hospital Zürich, 
Switzerland). 
2.2.5.1. Expression in Normal Kidney and RCC 
Expression of ABCA1 and AOX1 was investigated by immunohistochemistry using a 
commercial kidney TMA. In normal human kidney 100% (35/35) of controls were found 
positive for ABCA1 and 97% (34/35) for AOX1. In contrast, 54% (21/39) and 15% (6/39) of 
the samples from RCC were ABCA1 and AOX1 positive, indicating reduced AOX1 and 
ABCA1 expression. This finding was supported by a second independent TMA with RCC and 
onkozytomas (Table 9).  
 
Table 9. ABCA1 and AOX1 protein expression in RCC and oncocytomas in relation to clinico-
pathologic parameters and results of immunohistochemistry. 
 
* only RCC were included. 
† Fisher's exact test (2-sided); bold face representing significant data 
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Investigation of immunohistochemical ABCA1 and AOX1 expression in renal tumors was 
informative in 84.9% (90/106) and 85.8% (91/106) of cases, respectively. Cytoplasmic 
ABCA1 and AOX1 protein expression of any intensity (score 1+-3+) was detected in 58.9% 
(53/90) and 12.1% (11/91) of informative cases. No significant association between ABCA1 
and AOX1 immunoreactivity could be found (data not shown). Clinicopathologic and 
immunohistochemical characteristics were associated with ABCA1 and AOX1 IHC for 
descriptive data analysis. ABCA1 immunoreactivity was significantly lost in RCCs compared 
to oncocytomas (p=0.005). In the subgroup of RCCs, no significantly different ABCA1 
(p=0.382) and AOX1 (p=0.160) expression between clear cell, papillary and chromophobe 
carcinomas was found. ABCA1 and AOX1 staining was significantly associated with positive 
nodal status (p=0,029 and p=0,001). 
2.2.5.2. Expression in Normal Liver and HCC 
Expression of ABCA1 and AOX1 was investigated by immunohistochemistry using a 
commercial liver TMA. In normal human liver 62% (24/39) of controls were found positive for 
ABCA1 and 100% (39/39) for AOX1. In contrast, 68% (28/41) and 59% (24/41) of the 
samples from HCC were ABCA1 and AOX1 positive, indicating reduced AOX1 and 
enhanced ABCA1 expression, respectively. This finding was supported by a second 
independent TMA with HCC, normal and cirrhotic liver specimens (Table 10). AOX1 and 
ABCA1 protein expression of any intensity (score 1+-3+) was detected in 77.5% (134/173) 
and 89.0% (146/164) of HCC, respectively. Again, AOX1 expression was significantly 
reduced from normal liver (100% expression) to cirrhosis (92.5%) to HCC (77.5%). 
Accordingly, expression of ABCA1 significantly increased from normal liver (56.3%) to 
cirrhosis (87.3%) to HCC (89.0%). AOX1 and ABCA1 immunoreactivity (intensity score 1+-
3+) co-associated significantly in 69.5% of cases (107/154), whereas simultaneous negative 
AOX1 and ABCA1 expression (score 0) was found only in 6.8% (8/154) of cases (P=0.032). 
For descriptive data analysis, clinico-pathologic characteristics of HCC were associated with 
AOX1 and ABCA1 IHC (Table 10). Loss of AOX1 staining was significantly associated with 
higher tumor stages (P=0.008), positive nodal status (P=0.005), and occurrence of distant 
metastases (P=0.037). Loss of ABCA1 expression was associated with positive nodal status 
(P=0.021) and occurrence of distant metastases (P=0.014). In general, loss of AOX1 and 
ABCA1 expression was associated with negative pathologic parameters in HCC. 
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Table 10. ABCA1 and AOX1 protein expression in HCC in relation to clinico-pathologic 
parameters and results of immunohistochemistry 
 
* only HCC were included 
† Fisher's exact test (2-sided); bold face representing significant data 
‡ Pearson Chi-Square test (2-sided); bold face representing significant data 
2.2.5.3. Expression in Leydig Cell Tumors 
As already shown in Figure 36 (IHC Tissues) AOX1 in the testis is restricted to Leydig cells. 
24 different LCT were analyzed and AOX1 was expressed in 100% of samples. Furthermore 
it was found to retain its specific expression in the Leydig cell population (Fig. 38), 
recommending AOX1 as possible LCT marker. In contrast, ABCA1 was broadly expressed in 
tumor areas and adjacent tissues (Fig. 38). 
 
 
Figure 38. Immunohistochemistry of AOX1 and ABCA1 in Leydig cell tumors. For details see 
text. ABCA1 and AOX1 were stained utilized an avidin-biotin peroxidase method with a 3,3‘-
diaminobenzidine (DAB) chromatogen. Nuclei were counterstained with haematoxylin. Magnification 
100 fold. 
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2.2.6. SNP analysis of AOX1 
The role of AOX1 in acetaldehyde/acetate conversion during alcohol metabolism and ROS-
dependent alcohol-mediated tissue damage is not completely solved, but AOX1 has been 
suggested to be involved in ethanol-induced liver injury [200] and the generation of ROS 
during ethanol metabolism [201; 202]. To gain further insight in this point 7 SNPs found in the 
database that either lead to an amino acid exchange in AOX1 or are located close to its 
putative promoter region were analyzed. A control collective of healthy blood donors was 
compared with alcoholics with or without cirrhosis. 
The two assay detecting amino acid exchanges gave no evaluable results. 
The other 5 assay could be evaluated and the results are shown in Table 11. 
 
Table 11. Genotype- and allele frequencies of selected AOX1 SNPs. 
 
 
The biggest differences were visible for SNP C___8130525_10. Genotype frequencies and 
allele frequencies in controls and cirrhosis samples are almost identical, but a shift is 
detectable in samples from alcoholics without cirrhosis (Table 11, p-Values: genotype 
frequency: control vs. NO cirrhosis p=0.18; allele frequency: control vs. NO cirrhosis p=0.19). 
However, more samples have to be analyzed to reveal if these changes are significant and 
additional experiments are necessary to proof the biological relevance. 
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3. TAX1BP3 or Syntaxin 13 Interacting Proteins 
In cooperation with Tamas Köbling we performed yeast two-hybrid screens to identify new 
TAX1BP3 and STX13 interacting proteins. Screenings were performed using pAS-TAX1BP3 
and pAS-STX13, respectively (Table 6). Eight putative TAX1BP3 interacting proteins and six 
putative STX13 interacting proteins were identified (Table 12). 
 
Table 12. Putative TAX1BP3 interacting proteins and putative STX13 interacting proteins. 
 
A. Candidates from the TAX1BP3 yeast two-hybrid screen. 
Short Full name OMIM 
CTNNB1 Catenin, beta 1 *116806 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase *138400 
GDF15 Growth/differentiation factor-15 *605312 
PFKL Phosphofructokinase, liver type *171860 
PLOD1 Procollagen-lysine, 2-oxoglutarate 5-dioxygenase *153454 
PLXNB2 Plexin B2 *604293 
PRDX5 Peroxiredoxin 5 *606583 
TFAP2A Transcrip factor AP2-alpha *107580 
 
B. Candidates from the STX13 yeast two-hybrid screen. 
Short Full name OMIM 
NAPA N-ethylmaleimide-sensitive factor attachment protein alpha *603215 
SLC3A2 Solute carrier family 3, member 2 *158070 
SNAP29 Synaptosomal-associated protein, 29kDa *604202 
STXBP5 Syntaxin binding protein 5 *604586 
TBK1 TANK-binding kinase 1 *604834 
VAT1 Vesicle amine transport protein 1 *604631 
 
Further experiments in order to confirm these results were performed by Tamas Köbling. 
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4. ABCA7 Interacting Proteins and Regulation 
To get more insight into ABCA7 function two different approaches were chosen. Yeast two-
hybrid screens were performed to identify ABCA7 C-terminal interacting proteins and the 
regulation of both isoforms was analyzed. 
4.1. ABCA7 Interacting Proteins 
Screening with pAS-A7-CT (Table 6) identified 8 putative interacting proteins that are shown 
together with the corresponding OMIM entry in Table 13. 
 
Table 13. Identified putative ABCA7 C-terminus binding candidates. 
Short Full name OMIM/ Accession No§ 
GIPC2 GIPC1 PDZ domain containing family, member 2 NM_017655 
BPY2IP1 BPY2-interacting protein 1 *607573 
C1QA Complement component 1, q subcomponent, alpha polypeptide *120550 
COPS5 Cop9, subunit 5 *604850 
FBLN5 Fibulin 5 *604580 
JAM1 Junction adhesion molecule 1 *605721 
MT2A Metallothionein 2A *156360 
NAZC Neutrophil azurocidin *162815 
§
 EMBL-GenBank  
 
In the screening with pAS-A7-NT (Table 6) no candidates have been found. 
In a next step, the interaction of ABCA7 with these candidates had to be verified. 
4.1.1. Verification of the Interaction by Co-Transformation in Yeast 
To confirm the interaction of the candidates identified in the yeast–two-hybrid screens the 
complete coding sequence of the candidates was cloned in pGADT7. This resulted in AD-
fusion constructs, which were cotransfected together with pAS-A7-CT or a control plasmid in 
yeast. In case of interaction, yeast cells should be able to grow on selection media. No 
growth could be detected, indicating a false positive result of the yeast two-hybrid screen or 
that the full length constructs fold different from the fragments found in the screen, thereby 
inhibiting interaction. 
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4.1.2. Verification of the Interaction In Vitro 
As an independent second approach to confirm the interaction, recombinant ABCA7 C-
terminus with an N-terminal GST fusion was used. ABCA7 C-terminus was cloned in the 
pGEX-5X-1 vector in fusion with an N-terminal GST-tag and expressed in E. coli. The N-
terminal fusion was chosen to keep the putative C-terminal PDZ-binding-sequence (ETVL, 
class I, consensus X-S/T-X-V/L) free. The coding sequences of the candidate genes were 
cloned in pcDNA3.1D/V5-His-TOPO and used for in vitro translations, resulting in fusion 
proteins with C-terminal V5- and His-tags. 
GST-ABCA7 and GST (control), respectively, were purified using the GST-epitope and 
incubated together with the products from the in vitro translation using different incubation 
conditions (PBS, PBS containing 0.1, 0.5, 1 % Triton X-100 or NP40). After immunoblot, 
detection was performed with a monoclonal anti-V5 antibody. 
Under conditions tested here, no specific interaction between ABCA7 C-terminus and the 
candidates from the yeast two-hybrid screen could be confirmed. 
In summary, the interaction of ABCA7 with the candidates could not be confirmed by two 
independent methods suggesting that the use of the ABCA7 C-terminus in the yeast two-
hybrid led to false positive results. 
4.2. Transcriptional Regulation of ABCA7 
In cooperation with Louay Jouma we performed expression analyses of both isoforms in 
different human tissues and cell lines and analyzed the putative promoter region for 
transcriptional activity and possible transcription factors involved in ABCA7 regulation. 
4.2.1. Expression of the two ABCA7 Isoforms 
To get more insight in the function of the two published ABCA7 isoforms their mRNA 
expression in different human tissues was analyzed. TaqMan-Assays specifically recognizing 
ABCA7 Type I and Type II, respectively, were designed. The tissue distribution of both 
isoforms is quite similar, revealing very high expression in thymus and bone marrow and high 
expression in whole brain and mammary (Table 14). 
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Table 14. mRNA Expression of ABCA7 Type I and Type II in different human tissues. 
Tissue type I type II 
Brain, whole ●●●●● ●●●●● 
Spinal Cord ●● ●● 
Heart ● ● 
Lung ●● ● 
Kidney ●●● ●● 
Liver ● ● 
Stomach ●●●● ●●● 
Small intestine ●●● ●●● 
Colon ●●● ●●● 
Salivary Gland ●●●● ● 
Thyroid ●●● ●● 
Pancreas ● ● 
Adrenal Gland ●● ● 
Ovary ● ● 
Mammary ●●●● ●●●● 
Uterus ● ● 
Placenta ●● ●● 
Thymus ●●●●●* ●●●●●* 
Spleen ●●●● ●●● 
Bone marrow ●●●●●* ●●●●●* 
Results were converted to a linear scale (●●●●●: 81-100% of highest expression; ●●●●: 61-80%; ●●●: 
41-60%; ●●: 21-40%; ●:>0-20%; * very high expression). Tissues with the highest expression are 
highlighted (yellow). 
 
Furthermore, we determined the change of expression in HL-60 cells stimulated with 
vitamin D, ATRA or N-butyrate dissolved in ethanol to induce monocytic, granulocytic or 
eosinophilic differentiation. Ethanol and dimethylsulfoxide (DMSO) were included as solvent-
controls. First results imply upregulation of both isoforms during eosinophlic and granulocytic 
differentiation and upon DMSO treatment, but to a different extent. Interestingly the ABCA7 
type II isoform is strongly upregulated during monocytic differentiation (Fig. 39). 
 
 
 
 
Figure 39. mRNA expression of ABCA7 type I and 
type II in differentiated HL-60 cells. Differentiation is 
induced by vitamin D (monocytic), ATRA (granulocytic) 
or N-butyrate (eosinophilic) dissolved in ethanol. 
Ethanol and DMSO were included as solvent-controls. 
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Therefore, we analyzed the expression of both isoforms during differentiation from 
monocytes to macrophages and under lipid loading (E-LDL/Ox-LDL) and deloading (HDL3) 
conditions. Interestingly in this system, ABCA7 type I is significantly upregulated during 
differentiation from monocytes to macrophages (p<0.05) while type II is slightly but not 
significantly decreased (p=0.08) (Fig. 40). Upregulation of ABCA7 Type I under HDL3-
deloading is not significant because of the large inter-individual differences in the three 
donors. 
 
 
Figure 40. mRNA expression of 
ABCA7 type I and type II in 
monocytes and macrophages. 
Monocytes from 3 different donors 
were differentiated to 
macrophages, loaded with E-LDL 
or Ox-LDL and subsequently 
deloaded with HDL3. Average 
expression levels are displayed 
together with their standard 
deviation relative to the 
corresponding controls 
(Monocytes d1 for differentiation; 
Macrophages d6 for loading; 
Macrophages d7 for deloading). * 
p<0.05. 
 
 
 
As ABCA7 was shown to be involved in keratinocyte differentiation [72], we also analyzed 
the expression of both isoforms under these conditions. While ABCA7 type I was 
downregulated during differentiation type II mRNA was found initially reduced and increased 
at day 10 (Fig. 41). In summary, the two isoforms of ABCA7 were similarly expressed in 
human tissues but display different regulation in initial differentiation experiments of HL-60 
cells, monocytes/macrophages and keratinocytes. 
 
 
 
 
 
Figure 41. mRNA expression of ABCA7 
type I and type II during keratinocyte 
differentiation. 
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4.2.2. Analysis of the ABCA7 Promoter(s)  
To characterize the putative ABCA7 isoform1 promoter in more detail we cloned different 
constructs of the putative promoter area in pGL3 basic to assess their transcriptional activity 
in a luciferase-assay. The assay was performed in HepG2 and Jurkat cells, both expressing 
ABCA7. The different fragments together with their activity are shown in Figure 42. These 
results indicate that the ABCA7 core-promoter is localized between the base +144 and -47, 
the shortest fragment with significant promoter activity. Afterwards an in-silico analysis of the 
putative promoter was performed using Genomatix. The putative transcription factor binding 
sites are also displayed in Figure 42. 
 
Figure 42. Promoter activity of several ABCA7 promoter fragments in HepG2 (grey bar) and 
Jurkat cells (white bar) with the predicted transcription factor binding sites. TSS, transcription 
start site; ATG, translation start; Promoter activity is calculated as luciferase activity / β galactosidase 
x protein concentration. 
 
While this work was performed a competitive paper appeared, supporting our data and in 
addition demonstrating regulation of ABCA7 by SREBP-2 [73]. Therefore, we focused on the 
putative alternative promoter of ABCA7.  
 
 
 
 
V. Results 
86 
In silico analysis of this promoter revealed additional binding sites for transcription factors 
different from promoter one (Fig. 43). This supports the data indicating different regulation of 
both isoforms. 
 
Figure 43. The putative second promoter of ABCA7. The promoter fragments for the luciferase 
assay and corresponding transcription factor binding sites are shown. 
 
Detailed analysis of the second promoter is currently performed in our group. 
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5. Genes Regulated by Modified Lipoproteins 
To study the role of cholesterol flux on ABCA1/ABCA7 and autophagy/apoptosis, loading (E-
LDL, Ox-LDL) and HDL3-deloading experiments were performed in cooperation with PD Dr. 
Büchler to search for apoptosis-related genes. 
5.1. Identification of Apoptosis Related Genes Differentially Expressed in 
E-LDL Treated Macrophages 
Total RNA from 5 d M-CSF differentiated macrophages and macrophages cultivated for 4 d 
with M-CSF and subsequently with E-LDL for 24 h was prepared and used to hybridize the 
HgU133A GeneChip from Affymetrix. Three independent experiments with monocytes from 3 
different donors were performed and genes that were either induced or repressed in all 
experiments are listed in Table 15.  
 
Table 15 Apoptosis related genes differentially regulated by E-LDL in macrophages. 
 
A: Induced by E-LDL 
Short name Full name Control signal D-C Unigene C-C 
TOSO Regulator of Fas-induced apoptosis TOSO 170 P Hs.58831 I 
HSPA9B Heat shock 70 kDa protein 9B  428 P Hs.184233 I 
BCL2A1 BCL2-related protein A1  488 P Hs.227817 I 
BCL2L1 BCL2-like 1 106 P Hs.516966 I 
PDCD8 Programmed cell death 8  182 P Hs.424932 I 
 
B: Suppressed by E-LDL 
Short name Full name Control signal D-C Unigene C-C 
CARD8 Caspase recruitment domain family, member 8 163 P Hs.446146 D 
CFLAR CASP8 and FADD-like apoptosis regulator 124 P Hs.390736 D 
Casp1 Caspase 1 142 P Hs.2490 D 
Casp6 Caspase 6 68 P Hs.389452 D 
BNIP3L BCL2/adenovirus interacting protein 3-like 686 P Hs.131226 D 
SOD2 Superoxide dismutase 2, mitochondrial 443 P Hs.487046 D 
STK17B serine/threonine kinase 17b 60 P Hs.88297 D 
TNFSF10 TRAIL, APO2 Ligand (APO2L) 49 P Hs.478275 D 
IER3 Immediate early response 3 613 P Hs.591785 D 
Control signal is the value for the expression of the gene in differentiated cells, D-C is the Detection 
Call (Present = P) and C-C the Change Call (Increase = I, Decrease = D) calculated by the software. 
 
Several genes related to apoptosis were identified to be differentially expressed (Table 15A 
and B). The antiapoptotic gene BCL2A1 and BCL2L1 were found induced, like programmed 
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cell death 8 (Table 15A). TOSO, a cell surface protein and inhibitor of apoptosis, was also 
found upregulated in E-LDL treated cells. CARD8, an antagonist of caspase 9, CFLAR a 
caspase 8 like apoptosis regulator, caspase 1 and 6 and the anti-death protein IER3 were 
found downregulated (Table 15B). The proapoptotic gene BNIP3L was also reduced. 
5.2. E-LDL Promotes the Survival of Freshly Isolated Monocytes and 
Predifferentiated Macrophages 
These GeneChip data indicate that antiapoptotic genes are induced by E-LDL that may 
protect the cells from apoptosis. To test this hypothesis purified monocytes were cultivated in 
serum-free macrophage medium supplemented with M-CSF. E-LDL (40 µg/ml) was added 
for 24 h immediately after purification. The supernatants were used to detect histone-
associated DNA-fragments with the Cell Death Detection ELISA. The amount of 
nucleosomes released from monocytes cultivated with M-CSF only or M-CSF and enzyme 
cocktail (EC, used to prepare E-LDL) as control was nearly 3-fold higher (absorbance: 1.12 ± 
0.56) than from monocytes incubated with E-LDL (absorbance: 0.38 ± 0.32). These 
experiments were performed with monocytes from 8 different donors and the difference is 
statistically significant with p < 0.003. We received similar results with the supernatant from 4 
d predifferentiated macrophages in serum-free macrophage medium supplemented with M-
CSF and then treated with E-LDL (40 µg/ml) for 24 h. 4 d differentiated macrophages were 
furthermore incubated with Ox-LDL (100 µg/ml) but apoptotic cell death was comparable to 
control cells (not shown). 
In addition, the cells were stained with Trypan blue. 8 to 10% of monocytes/macrophages 
cultivated in the presence of M-CSF or Ox-LDL were dead, whereas in E-LDL treated dishes 
only 1 to 3% of the cells stained blue. 
5.3. TOSO mRNA is Strongly Induced in E-LDL but not Ox-LDL Generated 
Foam Cells 
TOSO mRNA is hardly detectable by Northern blot analysis in freshly isolated monocytes 
and in vitro differentiated macrophages (Fig. 44 A and B). However, in monocytes incubated 
with E-LDL TOSO mRNA was found strongly induced after 24 h (Fig. 44 A). Enzyme cocktail 
and native LDL were used as controls and did not induce TOSO mRNA. The Northern blot 
was stripped and subsequently hybridized with a CD36 probe recently identified to be 
induced by native LDL and E-LDL. GAPDH was used as a loading control.  
In a second experiment 4 d predifferentiated macrophages were loaded with E-LDL (40 
µg/ml) or Ox-LDL (100 µg/ml) for 24 h. TOSO mRNA was only found upregulated in E-LDL 
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treated cells. The Northern blot was subsequently hybridized with an adipophilin probe, a 
sensitive marker of lipid loading in monocytes and macrophages, and the expression of 
adipophilin was strongly upregulated in Ox-LDL and E-LDL treated macrophages (Fig. 44 B).  
To obtain more quantitative experimental data on TOSO gene expression a TaqMan assay 
was established. Relative TOSO mRNA expression is 0.9 ± 0.4 in M-CSF differentiated cells 
and Ox-LDL and EC did not alter TOSO mRNA with a relative value of 1.5 ± 0.2 and 1.6 ± 
0.3, respectively. In E-LDL treated cells TOSO mRNA expression is 7.1 ± 3.9 (p = 0.007). 
HDL3-treatment subsequent to E-LDL loading reduced TOSO mRNA to 3.4 ± 3.2, however 
this was not a significant effect (Fig. 44 C). 
 
 
 
Figure 44. TOSO mRNA expression in 
macrophage foam cells. (A) TOSO mRNA 
expression in primary macrophages cultivated 
in M-CSF alone for 5 d (M-CSF) or M-CSF for 
4d and additional 2 h, 4 h or 24 h with either 
100 µg/ml LDL, EC or E-LDL was analyzed by 
Northern blot. Expression of CD36 mRNA and 
GAPDH was also determined. (B) TOSO 
mRNA expression in primary human 
macrophages cultivated in M-CSF alone for 5 
d or M-CSF for 4 d and additional 24 h with 
either 100 µg/ml Ox-LDL, EC or E-LDL was 
analyzed by Northern blot. Adipophilin and 
GAPDH were determined in the identical 
mRNA samples. (C). TOSO mRNA was 
determined by real-time RT-PCR in primary 
human macrophages cultivated in M-CSF 
alone for 5 d or M-CSF for 4 d and additional 
24 h with either EC, 100 µg/ml Ox-LDL or 40 
µg/ml E-LDL. 100 µg/ml HDL were added after 
E-LDL loading for 24 h and TOSO mRNA was 
analyzed. TOSO mRNA expression was 
normalized to GAPDH and the mean values ± 
std dev from three independent experiments 
are shown. 
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5.4. Surface Expression of CD95 and CD95L During Differentiation and 
Upon E-LDL Loading 
TOSO was initially described to inhibit CD95 induced apoptosis. However, the abundance of 
CD95 and CD95L on E-LDL generated foam cells has not been investigated so far. The 
surface levels of CD95 and CD95L were determined during differentiation and foam cell 
formation. Monocytes isolated from 7 different donors were cultivated for 3 days and the 
expression of CD95 and CD95L was found significantly upregulated during  
differentiation (Fig. 45). 
 
Figure 45. CD95 and CD95L surface expression in E-LDL incubated primary macrophages. 
Primary human macrophages were incubated with E-LDL (dashed line) or EC (solid line) as control for 
1 d, 2 d or 3 d. CD95 and CD95L were measured by flow cytometry. 
 
The mean fluorescence signal for CD95 rose from 180 ± 32 in freshly isolated cells to 416 ± 
162 in 3 d macrophages, CD95L was 23 ± 12 in freshly isolated monocytes and 892 ± 587 in 
3 d differentiated cells. The surface expression of CD95 and CD95L was also measured in 
cells treated with E-LDL for 24 h and 72 h. The 24 h incubation did not influence the 
expression of CD95 and CD95L. CD95 was found slightly reduced with a mean fluorescence 
of 337 ± 112 in macrophages incubated with E-LDL for 3 d whereas CD95L expression was 
not altered. The soluble form of CD95 (sCD95) has been shown to be an inhibitor of 
apoptosis and therefore was determined in the supernatants by ELISA. sCD95 in controls 
was 113 ± 29 pg/ml, in EC treated cells 110 ± 35 pg/ml and 105 ± 36 pg/ml in E-LDL 
generated foam cells. Therefore, we can exclude that the enhanced survival of foam cells 
observed after 24 h incubation is caused by a downregulation of CD95 or CD95L or induction 
of sCD95. 
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5.5. Expression of FLIPL and FADD 
It was suggested that TOSO blocks apoptosis by enhancing FLICE-like inhibitory protein long 
form (FLIPL) abundance. FLIPL was determined in E-LDL and Ox-LDL loaded macrophages 
by immunoblot. Neither FLIPL nor FADD or CD163 expression, used as a loading control, 
were influenced by lipid loading (Fig. 46 A). Furthermore, recombinant TOSO was expressed 
in COS-7 cells with a C-terminal V5-tag. Production of the recombinant protein was 
confirmed by immunoblot using the anti-V5 antibody. The level of FLIPL or FADD was not 
influenced by the expression of recombinant TOSO (Fig. 46 B). 
Figure 46. FLIPL and FADD in foam cells and COS-7 
cells expressing recombinant TOSO. (A) FLIPL and 
FADD were determined in primary human macrophages 
cultivated in M-CSF alone for 5 d or M-CSF for 4 d and 
additional 24 h with either E-LDL or Ox-LDL by 
immunoblot. (B) COS-7 cells stably expressing 
recombinant TOSO with a V5-tag or rezepin with a V5-tag 
as control were analyzed for the abundance of V5, FADD 
and FLIPL by immunoblot. 
5.6. TOSO mRNA is Strongly Induced in Macrophages After 
Phagocytosis 
E-LDL contains large amounts of free fatty acids and is most likely taken up by phagocytosis. 
The influence of free fatty acids on TOSO mRNA expression was analyzed by TaqMan real-
time RT-PCR. Human blood monocytes were incubated with γ-linolenic acid (50 µM and 100 
µM) or eicosapentaenoic acid (EPA) (50 µM and 100 µM) complexed to BSA for 24 h in 
serum free medium supplemented with M-CSF. Control cells were cultivated in the same 
medium with lipid-free BSA. A slight but significant (p = 0.02) increase of TOSO mRNA was 
observed in macrophages treated with 100 µM EPA with a relative expression of 4.4 ± 0.3 
when compared to controls with 2.7 ± 1 (Fig. 47 A). 
TOSO mRNA was also determined in macrophages incubated with Bluebeads that are taken 
up by phagocytosis. The relative expression of TOSO mRNA in controls was 2.2 ± 0.4, in E-
LDL incubated macrophages 4.0 ± 0.6 (p = 0.009 vs. control) and in macrophages with 
Bluebeads 6.2 ± 0.5 (p = 0.003 vs. control, p = 0.01 vs. E-LDL) (Fig. 47 B). 
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Figure 47. TOSO mRNA expression in macrophages incubated with free fatty acids or 
Bluebeads and in different cells and tissues. (A) TOSO mRNA expression in primary macrophages 
cultivated in M-CSF alone for 4 d and additional 24 h with either BSA, eicosapentaenoic acid (EPA) or 
γ-linolenic acid (γ-LA). TOSO mRNA expression was normalized to GAPDH and the mean values ± std 
dev from three independent experiments are shown. (B) TOSO mRNA was determined by real-time 
RT-PCR in primary human macrophages cultivated in M-CSF alone for 5 d or M-CSF for 4 d and 
additional 24 h with either E-LDL or Bluebeads.  
5.7. Recombinant Expression of TOSO 
The complete cDNA of TOSO was amplified by RT-PCR using RNA isolated from lipid-laden 
macrophages, cloned in pcDNA3.1D/V5-His-TOPO (Invitrogen) and sequenced. 
5.8. Phagocytic Activity of COS-7 Cells Expressing TOSO 
Uptake of Fluoresbrite Yellow Green Microspheres was measured in COS-7 cells either 
expressing recombinant TOSO or recepin as a control protein after 1 h or 2 h incubation. 
Four independent experiments were performed and indicate that phagocytic activity is not 
elevated in COS-7 cells with recombinant TOSO (not shown). 
5.9. TOSO mRNA Expression in Different Human Tissues 
The TOSO cDNA fragment was used to hybridize a human multiple tissue blot. TOSO mRNA 
was most abundant in lymph nodes followed by the spleen, the appendix, the thymus and 
peripheral blood leukocytes. TOSO mRNA was also detected in the bowel. Expression was 
similar in fetal and adult tissues (Fig. 48). 
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Figure 48. TOSO mRNA expression in different cells and tissues. TOSO mRNA was analyzed in 
different tissues and cell lines. A normalized dot blot containing mRNAs of different human tissues and 
cell lines was hybridized with a radioactively labeled TOSO cDNA probe and signals were analyzed 
using a phosphoimager. The relative tissue expression of TOSO mRNA is shown. 
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VI. DISCUSSION 
1. ABCA1 Interacting PDZ Proteins 
Different ABCA1 interacting PDZ proteins are published in the literature. PDZ proteins 
normally function as molecular scaffolds by mediating protein-protein interactions through 
multiple interaction modules, thereby clustering membrane proteins, cytoskeletal elements, 
trafficking machinery, and signal transduction molecules into multimeric complexes at distinct 
membrane domains [277; 278]. 
The importance of the PDZ interaction for ABCA1 function is not clear so far. The 
interactions with SNTA1 and SNTB1 were reported to stabilize ABCA1 and thereby enhance 
ABCA1-mediated lipid efflux [54; 55], indicating that the SNTB2, also shown to interact with 
ABCA1 [56], might do the same. On the other hand, Lin7 was also shown to interact with 
ABCA1, but with no influence on ABCA1 half-life [54]. As the PDZ interaction relies on a free, 
intact C-terminal PDZ binding motif ([54], this work) the class I motif of ABCA1 (ESYV) would 
play an important role in the association with PDZ proteins. In contrast, data from 
experiments with different C-terminal deletion constructs of ABCA1 only show moderate 
influence of the PDZ motif on lipid efflux. Furthermore chimeric constructs, in which the 
ABCA1 C-terminus is substituted by either the ABCA4 or ABCA7 C-terminus, show that 
ABCA1 could stimulate efflux without a PDZ-binding motif, but requires a motif more 
upstream which is also present in ABCA4 [279]. Most of the data are generated in HEK293 
cells, besides the influence of SNTB1 on lipid efflux that was also shown in primary skin 
fibroblasts and bone marrow-derived macrophages. 
In this work, additional PDZ proteins that in vitro are able to bind to the ABCA1 C-terminus 
were identified (Fig. 49). The interaction of ABCA1 with TAX1BP3, GIPC1, Scribble and 
MAGI3 observed in the yeast two-hybrid screen was confirmed by different methods and the 
interaction was shown to depend on a free, intact C-terminus. For Scribble and MAGI3, both 
containing more than one PDZ domain, the interaction was mapped to PDZ domain 1, 
nevertheless it is possible that also other domains interact with ABCA1 as not all individual 
domains were included on the PDZ-array. As PDZ domain 1 of Scribble was not fully 
included on the clone isolated from the yeast two-hybrid screen this may indicate that either 
this part of domain 1 was sufficient to interact with ABCA1 in yeast or that PDZ domain 3 is 
also involved in this association. 
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Figure 49. ABCA1 interacting PDZ proteins identified in this work. The C-terminal part of ABCA1 
from the last TMD to the C-terminal PDZ binding motif is shown together with the structure of the 
identified PDZ proteins and their chromosomal location. The PDZ binding motif and the interacting 
PDZ domains are displayed in red. aa, amino acid; COOH, C-terminus; GH, GIPC1 homology domain; 
LAPSD, LRR and PDZ-specific domain; LRR, Leucin-rich Repeat domain; NH2, N-terminus; PDZ, 
PSD95/Discs-large/ZO-1 domain. 
 
TAX1BP3 is a 124 amino acid protein containing no additional interaction motifs besides the 
PDZ domain. Recent data suggest that it may act as negative regulator of PDZ-based 
scaffolding by blocking the PDZ binding sequence and preventing complex formation [280]. 
Furthermore TAX1BP3 was shown to interact with the human T-lymphotropic virus Tax 
oncoprotein and the high risk human papilloma virus (HPV) 16 E6 oncoprotein [281; 282] and 
is suggested to alter RhoA signaling to the c-fos serum response element [283]. In addition, it 
was described to interact with L-glutaminase [284] and to modulate the Wnt/β-catenin 
pathway by interacting with β-catenin [285]. 
GIPC1 is one of the three members of the human GIPC family [286] that is able to interact 
with various proteins including G protein coupled receptors (GPCRs), tyrosine kinase 
receptors and membrane proteins, pointing to a function of GIPC1 in GPCR signaling.  The 
regulator of G protein signaling (RGS) 19, which is mainly found in clathrin-coated vesicles, 
forms a complex with GIPC1. This suggests a function for the GIPC1/RGS19 complex in 
vesicular trafficking and endocytosis (reviewed in [287]). 
Scribble is a leucine-rich (LRR) and PDZ (LAP) protein that is known to regulate apical-basal 
polarity in epithelia of Drosophila [288]. Human Scribble was reported to be a functional 
homolog of this tumor suppressor [289]. In humans and Drosophila it was also shown to 
influence cell-cycle [290; 291]. Data from mice indicate an important role for Scribble in 
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development and planar cell polarity [292; 293]. In addition, Scribble was demonstrated to be 
involved in recycling and signaling of the GPCR thyrotropin (TSH) receptor (TSHR) [294]. 
Scribble is reported to be degraded upon interaction with the HPV 16 and 18 E6 oncoprotein, 
in contrast to TAX1BP3 that seems to be a gain of function for HPV 16 E6 and is not 
degraded [282].  
MAGI3 comprises five PDZ domains, 2 WW domains and a guanylate kinase domain, 
enabling various protein interactions. These includes phosphatase and tensin homolog 
(PTEN), receptor tyrosine phosphatase-β, frizzled, transforming growth factor α precursor, 
and the GPCRs β1-adrenergic receptor and lysophosphatidic acid (LPA) receptor LPA2 [295-
300]. Furthermore, it is targeted by the HPV 16 and 18 E6 proteins for degradation and also 
interacts with HTVL-1 Tax [301; 302]. 
Notably GIPC1, Scribble and MAGI3 are related to GPCR signaling. This may indicate that 
these PDZ proteins cluster ABCA1 together with GPCRs or bind to either ABCA1 or GPCRs. 
It was already demonstrated that PDZ proteins retain GPCRs at the plasma membrane [294; 
303-305]. Therefore, it is possible that these PDZ interactions retains the putative 
ABCA1/GPCR-complex or, according to the cell type or stimulus, ABCA1 or GPCRs at the 
cell surface. TAX1BP3, Scribble, and MAGI3 are altered by viral oncoproteins and therefore 
another interesting question would be to determine if viral oncoproteins are able to influence 
ABCA1 activity by modifying its PDZ interactions. 
Taking into account the tissue distribution of the PDZ proteins analyzed in this work 
ABCA1/PDZ protein interaction may be highly cell type or compartment specific and the 
situation in other cell types than HEK293 may be different. For example, scavenger receptor 
class B type I (SR-BI) was shown to be regulated by PDZK1, a multi-PDZ domain containing 
adaptor protein, in a tissue-specific and post-transcriptional manner. PDZK1 knock-out mice 
reveal 95% and 50% reduced SR-BI expression in liver and proximal intestine, respectively. 
In contrast, expression in steroidogenic tissues (adrenal, ovary, and testis) was unchanged. 
The situation for ABCA1 might be similar and additional experiments are needed to clarify 
the role of the ABCA1/PDZ interaction. 
2. AOX1 Interacts with ABCA1 and Influences ABCA1-related 
Functions 
In this work, AOX1 was demonstrated to associate with and influence ABCA1-mediated 
functions. Knock-down of AOX1 expression leads to decreased lipid efflux and enhanced 
phagocytic activity in HepG2 cells, supporting the involvement of ABCA1 in the modulation of 
phagocytic uptake in type I- and type II phagocytosis [64]. These cellular phenotypes are 
comparable to the phenotype of ABCA1-deficient monocytes and/or fibroblasts, that also 
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show enhanced phagocytic activity and defective apoA-I-dependent cholesterol  
efflux [306; 307]. 
The physiological function of AOX1 is not yet fully characterized. Although AOX1 is well-
described as a xenobiotic metabolizing enzyme its physiological substrates and functions are 
poorly understood. AOX1 derived ROS are directly implicated in free radical damage in liver 
and brain during ethanol metabolism [201; 308-311]. Alcohol dehydrogenase produces 
acetaldehyde and NADH from ethanol. Both are substrates for AOX1 and could lead to the 
formation of ROS in certain tissues [216; 312; 313]. Alcohol-mediated ROS injury of the liver 
was shown to operate directly through the combined activities of AOX1 and its close 
homolog xanthine oxidoreductase (XOR) [201; 309; 310; 312] by an iron-dependent process, 
suggesting involvement of hydroxyl radicals in tissue damage [309; 311; 312]. In alcoholics 
without cirrhosis a SNP in the first intron of AOX1 is in direction changed compared to 
controls and alcoholics with cirrhosis. This SNP may alter AOX1 transcription by influencing 
AOX1 promoter activity or may be linked to a yet unknown SNP that affects AOX1 
transcription or activity. Further experiments are required to determine its relevance and 
function. Recently AOX1 was shown to be regulated in a NAD(P)H oxidase-mediated 
manner in VSMC and this regulation was induced by thrombin [314]. NAD(P)H oxidase 
generated ROS is implied in several signal transduction pathways in VSMC [315], in host 
defense in professional phagocytes [316], and contributes to M-CSF induced 
monocyte/macrophage survival via regulation of Akt and p38 MAPK [317]. Akt is a kinase 
downstream from PI3K, and PI3K/Akt pathways are involved in various biological processes, 
including the PDGF-dependent suppression of ABCA1 expression in VSMC [42]. Akt activity 
is reduced by ABCA1 [43] and HDL-mediated activation of the PI3K/Akt pathways results in 
eNOS-mediated nitric oxide production [44]. These data support a complex regulatory 
network of AOX1, ABCA1, HDL, NAD(P)H oxidase, PI3K/Akt, and ROS formation that might 
influence various biological processes including insulin signaling, atherosclerosis and 
phagocytosis. 
Moderate alcohol consumption is associated with a decreased risk of cardiovascular 
diseases [318] and more than 50% of this effect is due to an increase in HDL-cholesterol 
[319; 320]. Moreover, moderate alcohol consumption increases the capacity of serum to 
induce cholesterol efflux from J774 mouse macrophages, which might be mediated by 
ABCA1 [321]. Taken together, these data and our recent results suggest that (i) AOX1 itself 
by direct interaction, and/or (ii) AOX1-derived ROS could influence ABCA1 activity. 
Nevertheless, the role of AOX1 in alcohol metabolism is controversially discussed. Recent 
data from Castro et al. suggest that XOR and not AOX1 itself contributes to the bioactivation 
of ethanol to acetaldehyde [322]. In this scenario, the function of AOX1 and its homologs has 
to be explored in more detail. 
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On the other hand alcohol and retinol were supposed to be metabolized in part by the same 
enzymes [203], and AOX1 was suggested to be identical to retinal oxidase [198], thus being 
involved in the biogenesis of RA. 9-cis RA and all-trans RA (ATRA) are both transcriptional 
modulators for RAR/RXR target genes, and thereby induce ABCA1 and HDL maturation 
[204], which is under strong transcriptional control through LXR/RXR. In rabbit liver two 
pathways for RA biosynthesis exist. One of them involves the cryptozoic NAD+-dependent 
retinal dehydrogenase and the other the oxygen-dependent retinal oxidase (=AOX1). Both 
catalyze the same reaction with an activity ratio of 59% and 41% under experimental 
conditions [199]. While the metabolic significance is unclear, it is possible that NAD+/NADH 
tissue levels affect the rate of retinal oxidation. Retinal dehydrogenase may be more effective 
under conditions with high NAD+ levels while retinal oxidase may maintain basic RA level in 
liver and circulation [199]. The involvement of AOX1 in retinoid metabolism is further 
supported by chicken AOX1, which also posses retinaldehyde oxidase activity [323]. Recent 
data from our laboratory [204] demonstrate the effect of retinoids on lipid efflux in 
macrophages. A strong up-regulation of genes involved in cellular cholesterol homeostasis, 
including ABCA1, was observed. Considering that AOX1 might be involved in retinoid 
metabolism and ABCA1 is a retinoid responsive gene, we expected that AOX1 might 
influence ABCA1 on the transcriptional level. Surprisingly our findings indicate that the effect 
of AOX1 knock-down on ABCA1 activity is not due to changes in mRNA or protein 
expression of ABCA1. 
AOX1 was also reported to catalyzes the predominant reductive pathway of ziprasidone 
(Geodon, Zeldox), an atypical antipsychotic agent for the treatment of schizophrenia [324]. 
Interestingly ziprasidone was reported to have favorable effects on total cholesterol, LDL, 
and HDL levels in patients [325], which may be due to altered ABCA1 activity. On the other 
hand, AOX1 was shown to be a dioxin inducible gene [205]. This effect may be due to AHR-
mediated downregulation of PPARα [326], as AOX1 mRNA and protein expression were 
recently shown do be suppressed by PPARα agonists [228]. TCDD is a persistent 
environmental pollutant accumulating in fat. Intoxication in humans often leads to elevated 
plasma total cholesterol and TG levels [327; 328] and long-term effects in addition to 
hyperlipidaemia include chloracne, psychic disorders, and/or nervous system lesions [328]. 
As only total cholesterol was measured in these studies this could also mean that TCDD 
increases HDL, but as TG are elevated, too, and atherosclerotic plaques, increased intima-
thickness and ischaemic heart disease are common in these patients this can be ruled out. 
The observed hyperlipidaemia in TCDD patients and the inverse regulation of ABCA1 and 
AOX1 by PPARα [34; 228] are not consistent with our model that AOX1 positively influences 
ABCA1 activity that is supported by our data and the influence of ziprasidone on plasma 
lipids. Further experiments are necessary to clarify this point. 
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Immunohistochemical data show a cell-specific expression of AOX1 in different human 
tissues (liver, kidney, adrenal gland, testis, ovary), which differ at least in part from previous 
results [222]. Interestingly, the cell types that express high amounts of AOX1 also express 
high levels of ABCA1. This further underlines the physiological association of ABCA1 and 
AOX1 at the cellular level.  
The impact of hepatic ABCA1 on plasma HDL levels is well described (reviewed in [329]) and 
as the liver is important for detoxification the presence of AOX1 as xenobiotic-metabolising 
enzyme [197] makes sense. Taken together these data suggest a role for the ABCA1/AOX1 
complex in detoxification, even it has to be clarified in detail. In contrast, the roles of ABCA1 
and AOX1 in kidney, adrenal gland and Leydig cells are less clear. While in kidney it may be 
similar to the liver, the co-expression of AOX1 and ABCA1 in steroidogenic tissue suggests 
another function. Data from ABCA1-/- mice showed impaired fertility due to reduced sperm 
count, reduced intratesticular testosterone levels and reduction of Leydig cells lipid droplets 
in these animals [53]. In males, testosterone is primary secreted by Leydig cells and to a 
lesser extent by the adrenal cortex, both expressing high levels of AOX1 that is coexpressed 
with ABCA1. Taken together these data may imply involvement of the AOX1/ABCA1-
complex in steroid hormone metabolism. It will be interesting to find out if the dual roles of 
the AOX1/ABCA1-complex in detoxification and steroid hormone metabolism underlie a 
common mechanism. 
Analysis of the expression of AOX1 and ABCA1 in normal liver compared to HCC indicates a 
reduced expression of AOX1 in cancer cells, while ABCA1 expression is increased. In RCC 
the expression of both proteins compared to normal kidney is reduced. In addition our results 
in HCC show a direct correlation of AOX1 and ABCA1 expression, which is not found in 
RCC. These findings suggest that in cancer the interaction of AOX1 and ABCA1 may be 
disturbed, which in context with the possible involvement of AOX1 in retinoid-metabolism 
could influence cell differentiation/proliferation. Intriguingly both AOX1 and ABCA1 are 
significantly correlated with positive nodal status in renal cell and hepatocellular carcinomas 
(RCC: AOX1: p=0,001; ABCA1: p=0,029 and HCC: AOX1: p=0,005; ABCA1: p=0,021). In 
HCC also a significant correlation with metastatic status (AOX1: p=0,037; ABCA1: p=0,014) 
is detectable. Interestingly, in contrast to HCC and RCC, AOX1 expression was maintained 
in LCT and specific for the Leydig cell population. These findings indicate that AOX1, 
depending on the type of cancer and eventually in combination with ABCA1, might be useful 
as a histopathologic tumor-marker. Our findings are consistent with recent observations 
[330], who reported strong expression of AOX1 in pancreatic acinar cells, reduced 
expression in chronic pancreatitis, and loss of AOX1 in malignant pancreatic 
adenocarcinoma cells. 
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In conclusion, we have demonstrated that AOX1 associates with and modulates ABCA1 
function. The molecular mechanism and a putative complex regulatory network of AOX1, 
ABCA1, HDL, NAD(P)H oxidase, PI3K/Akt, ROS formation and retinoids has still to be 
clarified and is subject of our ongoing work. 
3. ABCA7 Regulation and Function 
Yeast two-hybrid screens were performed to identify ABCA7 C-terminal interacting proteins 
and the expression and regulation of the two isoforms of ABCA7, namely type I and type II, 
was analyzed in different human tissues and during differentiation in different cell types. 
Although eight candidates were identified in the yeast two-hybrid screen, none of them could 
be confirmed in neither yeast or in pull-down assays. This indicates that they were false 
positive interaction partners. 
Recent data concerning the two ABCA7 isoforms indicate that in HEK293 type I was 
localized to the plasma membrane, while type II was mainly found in the ER [68]. Although 
both isoforms display quite similar tissue expression they seem to be regulated in 
differentiation in different manners. This could be the result of isoform-specific promoters, 
sharing common factors for basal transcription and specific factors activated during 
differentiation. Therefore, analysis of the promoter of ABCA7 type I was performed, but in the 
meantime a competitive paper appeared, supporting our data and in addition demonstrating 
regulation of ABCA7 by SREBP-2 [73]. Therefore, we focused on the putative alternative 
promoter of ABCA7. In silico analysis of both promoters resulted in various potential 
transcription factors that might regulate ABCA7 transcription. Experiments to verify the 
transcriptional activity of the second promoter and to evaluate the biological relevance of 
these transcription factors are currently performed and the comparison of both promoters 
may give further clues about the regulation of both isoforms. 
Interestingly our data indicate that DMSO upregulates both ABCA7 isoforms, but mainly type 
II in HL-60 cells. This is of particular interest as the tumor suppressor PTEN is also 
upregulated in DMSO treated HL-60 cells [331]. PTEN is a PI3K antagonist, influencing 
PI3K/Akt signaling, which in HL-60 cells controls progression of cell cycle [332; 333]. 
Moreover PI3K and PTEN were shown to be involved in autophagy [47; 334]. Further data 
possibly linking ABCA7 to autophagy are based on keratinocytes. ABCA7 was reported to be 
upregulated during terminal keratinocyte differentiation [72] and autophagy was also reported 
to be implied in this process [335]. More detailed analysis of the ABCA7 expression under 
this conditions revealed upregulation of ABCA7 isoform II, while isoform I is downregulated.  
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The recent findings that ABCA7 is involved in phagocytosis [73; 75] are in agreement with 
our data demonstrating upregulation of ABCA7 isoform I during monocytes to macrophages 
differentiation, as macrophages are professional phagocytes. 
Considering these data, we would suggest different functions for the two isoforms of ABCA7. 
Isoform I localizes to the plasma membrane and is upregulated during monocyte to 
macrophage differentiation, indicating an involvement in phagocytic processes. In contrast, 
isoform II localizes to intracellular membranes and is upregulated together with PTEN in HL-
60 cells and during terminal keratinocyte differentiation, pointing to a function in the 
autophagic pathway. This further supports our current model of the dual mechanism of 
ABCA1/ABCA7 in lipid-efflux/apoptosis/autophagy. Further experiments are necessary to 
confirm this hypothesis. 
4. Identification of TOSO as Lipid-sensitive Gene 
Numerous studies demonstrate that macrophages in atherosclerotic lesions undergo 
apoptosis and thereby contribute to plaque rupture [250]. Macrophages incubated with Ox-
LDL in vitro transform to foam cells and undergo apoptotic stress supporting the established 
in vivo observations [254]. However, cholesterol loading and apoptosis alone do not explain 
the accumulation of monocytes/macrophages in early atherosclerotic lesions, which may be 
caused by enhanced recruitment of monocytes into the arterial wall. Atherogenic lipoproteins 
were shown to induce the release of monocyte chemotactic protein 1 (MCP-1) from 
macrophages that may attract monocytes to cross the endothelium [260]. Alternatively, the 
increased number of monocytes/macrophages may be also the result of a prolonged life 
span of monocytes/macrophages. This idea is supported by in vitro experiments using lower 
amounts [255], less oxidized [336] or aggregated [256] Ox-LDL preparations. These authors 
describe a prolonged survival of cultivated macrophages and even a proliferative response of 
these cells. In the current study, we demonstrate that E-LDL promotes the survival of 
monocytes and macrophages cultivated in serum-free medium supplemented with M-CSF. 
E-LDL is used at low concentrations and E-LDL is much more effective in foam cell formation 
when compared to Ox-LDL or acetylated LDL [259]. The in vivo relevance of E-LDL was 
demonstrated by immunohistochemistry and is further supported by the ability of E-LDL to 
activate complement [337]. Spontaneous cell death of monocytes/macrophages is mediated 
in vivo and in vitro by apoptosis and CD95/CD95L is at least partly involved [338]. In the 
current work, we demonstrate an enhanced survival of E-LDL loaded macrophages indicated 
by a reduced release of histone associated DNA and a higher number of viable cells. 
Reduction of CD95, CD95L or upregulation of sCD95, that may explain survival,  
were ruled out. 
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GeneChip experiments revealed the upregulation of antiapoptotic genes and the suppression 
of proapoptotic genes in E-LDL treated cells. The upregulation of TOSO by E-LDL was 
confirmed by Northern blot analysis and Real-time RT-PCR. TOSO was recently identified as 
a cell surface inhibitor of Fas-, tumor necrosis factor- and FADD- induced apoptosis in T cells 
[339]. Mechanistically, TOSO was suggested to inhibit apoptosis by reducing caspase 8 
processing through the induction of FLIPL expression [339]. Whereas reduced caspase 8 
activity was also found in E-LDL generated foam cells (not shown) expression of FLIPL was 
not altered. A second study shows that TOSO directly binds FADD and this may disrupt the 
formation of the death-inducing signaling complex [340]. Cholesterol- and 
cholinephospholipid-efflux catalyzed by the ABCA1, that is induced in foam cells upon Ox-
LDL and E-LDL loading, may also depend on FADD binding to the C-terminus of ABCA1 
[57]. ABCA1 was also suggested to be a phosphatidylserine translocase that facilitates 
phosphatidylserine exofacial flipping, an early event in apoptotic cells [341]. Therefore, 
association of FADD with different surface receptors or with ABCA1 may be a central 
mechanism that connects lipid metabolism, proliferation and apoptosis. 
This is the first study that demonstrates an induction of TOSO in foam cells indicative for a 
function of TOSO in the development of atherosclerotic lesions and plaque rupture. TOSO 
was found induced in E-LDL generated foam cells and the use of Ox-LDL in concentrations 
that were recently shown to be toxic to monocytes/macrophages [251] do not induce TOSO 
mRNA. However, Ox-LDL, especially aggregated Ox-LDL, has also been published to 
prolong the survival of monocytes/macrophages [255]. Therefore it may be speculated that 
this effect is due to lipoprotein aggregation and a switch of the uptake pathway from 
scavenger receptors (e.g. CD36; LOX-1) [342] to phagocytic pathways (e.g. Fcγ-receptors), 
as aggregated lipoproteins are taken up by monocytes via phagocytosis [343]. This 
hypothesis is supported by the finding that the uptake of phagobeads also induces TOSO 
mRNA. E-LDL particles are preferentially internalized via non-specific and specific opsonin-
receptor-mediated type I and type II phagocytosis that implies complement and Fcγ-receptors 
and may in part depend on ABCA1 [64; 259; 344]. Therefore, it is concluded together with 
the data shown here, that the type of atherogenic lipoprotein and the mode of its uptake may 
decide about prolonged survival or apoptosis of macrophages in the atherosclerotic lesion. 
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VII. SUMMARY 
The ATP-binding cassette transporters A1 (ABCA1) and A7 (ABCA7) are inversely regulated 
under loading and deloading conditions and we were interested in protein/protein interactions 
of these transporters. The main topic was to identify, verify and characterize these 
interactions. 
In case of ABCA7, the yeast two-hybrid approach led to false positive results, and therefore 
we focused on the expression and regulation of the two published isoforms. Albeit having 
similar tissue distribution, the two isoforms show different regulation by stimulation, indicating 
the use of alternative promoters. This caused us to analyze the promoter of the long isoform 
in more detail and we were able to map the core promoter region. Analyzes of the putative 
alternative promoter might enable us to understand the regulatory differences between both 
isoforms. Due to our initial experiments and data from the literature, we would suggest 
different functions for the two isoforms of ABCA7. Isoform I localizes to the plasma 
membrane and is upregulated during monocyte to macrophage differentiation, indicating 
involvment in phagocytic processes. In contrast, isoform II localizes to intracellular 
membranes and is upregulated together with phosphatase and tensin homolog in HL-60 cells 
and during terminal keratinocyte differentiation, pointing to a function in the autophagic 
pathway. Further experiments are necessary to confirm this hypothesis. 
ABCA1 regulates plasma high-density lipoprotein levels and its cellular function is mediated 
through various protein interactions. One aim was to identify and confirm new ABCA1 C-
terminus interacting PDZ proteins. By different methods seven new PDZ candidates were 
identified, and four of them, namely GAIP C-terminus-interacting protein1 (GIPC1), Tax1 
(human T-cell leukemia virus type I) binding protein 3 (TAX1BP3), Scribble, and Membrane 
associated guanylate kinase, WW and PDZ domain containing 3 (MAGI3) were confirmed to 
bind to ABCA1 by different methods. Together with the known ABCA1 interacting PDZ 
proteins and their different tissue expression this may indicate that PDZ proteins are able to 
regulate ABCA1 trafficking and/or function in a tissue or even cell compartment specific 
manner. 
The cytosolic molybdo-flavoenzyme aldehyde oxidase 1 (AOX1), known as xenobiotic 
metabolizing enzyme, was previously suggested as an ABCA1 interacting protein. In this 
work it was shown that knock-down of AOX1 by siRNA significantly reduced ABCA1-
dependent lipid-efflux and enhanced phagocytic uptake in HepG2 cells. ABCA1 and AOX1 
were found coexpressed in certain human cell types, namely hepatocytes, kidney proximal 
tubular epithelial cells, Leydig cells and cells of the adrenal cortex. Deregulation of ABCA1 
and AOX1 in hepatocellular- and renal cell-carcinomas was observed, suggesting that AOX1, 
perhaps in context with ABCA1, might be used as tumor marker. The involvement of AOX1 in 
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metabolism of ethanol and xenobiotics is of particular interest, as it might link ABCA1 to 
detoxification, a process in which many ABC-transporters are involved. 
Finally, as ABCA1 through its interaction with Fas-associated via death domain (FADD) 
might influence apoptosis, we searched for apoptotic genes regulated by modified 
lipoproteins in a similar manner as ABCA1. Uptake of modified lipoproteins by macrophages 
causes foam cell formation and promotes the development of atherosclerotic lesions. 
Atherogenic lipoproteins exert cytotoxic effects and induce necrosis or apoptosis under 
certain conditions but may also enhance macrophage survival. GeneChip experiments were 
performed to identify genes that are regulated in macrophages treated with enzymatically 
modified low-density lipoprotein (E-LDL). Expression of TOSO, protecting cells against 
CD95- or tumor necrosis factor-mediated apoptosis, was found induced by E-LDL. 
Concomitantly, reduced apoptosis was detected in E-LDL loaded macrophages compared to 
oxidized LDL incubated cells or controls. Abundance of the caspase inhibitor FLICE-like 
inhibitory protein long form (FLIPL) was suggested to mediate the antiapoptotic properties of 
TOSO; however, FLIPL expression is induced neither in E-LDL laden macrophages nor in 
COS-7 cells overexpressing TOSO. E-LDL represents coreless liposome like particles and 
may be taken up by Fc- and complement-receptor dependent phagocytosis. Internalization of 
phagobeads by monocytes and macrophages upregulates TOSO but phagocytosis was not 
altered by TOSO in COS-7 cells. These data indicate that E-LDL-generated foam cells are 
protected from cell death most likely through the expression of TOSO by a mechanism 
independent of FLIPL. 
ABCA1 and ABCA7 may be related but exert distinct functions in the lipid-
efflux/apoptosis/autophagy complex. While the function of ABCA1 is highly modulated by 
protein interactions, ABCA7 might be more affected by transcriptional regulation.
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